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Abstract
The retinoblastoma tumor suppressor protein (pRB) functions to maintain
proliferative control and act as a barrier to tumorigenesis. pRB is capable of regulating E2F
transcription factors to mediate control of proliferation through transcriptional regulation of
S-phase target gene expression. In addition, pRB can stabilize the CDK inhibitor p27 through
an interaction with two ubiquitin ligase complexes. Further, pRB is capable of forming a
unique interaction with E2F1 termed the ‘specific’ interaction that is capable of blocking
E2F1 induced apoptosis. These functions of pRB are mediated by distinct binding interfaces
and their contributions to the overall functionality of pRB are not well defined. In this thesis
multiple experimental approaches are employed to study the function of the distinct binding
sites in isolation to better define their functional roles. As described in chapter 2 the E2F1
‘specific site’ is capable of maintaining and interaction with hyperphosphorylated pRB while
the E2F ‘general site’ is disrupted by phosphorylation. This suggests that pRB can function
beyond the G1 phase of the cell cycle to regulate E2F1 through the ‘specific site’. Using a
series of novel synthetic mutations of pRB we found that multiple binding sites contribute in
a redundant manner to the overall cell cycle arrest ability of pRB. While, the ‘general site’
appears to play a critical role in the regulation of cell cycle arrest through the regulation of
E2F transcription factors, the LXCXE binding cleft and the ‘specific site’ can function
redundantly to control proliferation. A gene-targeted mouse model was developed that
disrupted the ‘general site’ while leaving other binding sites on pRB intact. Strikingly, these
mice are unable to regulate E2F target gene expression yet they maintain appropriate
proliferative control in multiple cellular contexts. The maintained proliferative control by
pRB appears to be largely due to the activity of p27 as disruption of E2F regulation and p27
deficiency results in loss of proliferative control and subsequent tumorigenesis. Taken
together, this work defines the contribution of the distinct binding sites to the overall
functionality of pRB and provides insight into the disruption of pRB in human cancer.
Keywords
pRB, E2F, E2F1, p27, retinoblastoma, cancer, apoptosis, Rb1
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1

Introduction
1.1

Identification of the retinoblastoma tumor

suppressor as a critical element of cell cycle control
1.1.1

Cell proliferation in cancer
Proliferative control is an essential process in multicellular organisms that ensures

cells only replicate at appropriate times. Evasion of these control mechanisms is one of
the hallmarks of cancer and is essential for initiation and sustained growth of tumors (1).
Many of the critical elements that regulate proliferation have been elucidated through the
study of human cancers. Adult tumors are typically caused by multiple genetic
alterations that disrupt many distinct cellular pathways in a heterogeneous manner across
the tumor. This heterogeneity has limited the efficacy of treatment and hindered the
identification of causative elements in the initiation of the cancer. In contrast, childhood
tumors have been found to have 5-10 fold fewer mutations than their adult counterparts
(2). Further, many childhood cancers arise from the inheritance of mutant proteins that
result in a rapid loss of proliferative control and subsequent tumor formation. The more
homogenous nature of childhood tumors has made the treatment of these cancers often
much more efficacious and facilitated the identification of critical tumor suppressor
pathways. The retinoblastoma tumor suppressor protein (pRB) was found to be an
essential element of retinoblastoma formation. Later this was extended to show that
1
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disruption of the pRB pathway was a central hallmark of all human cancers (3). However,
the specific mechanisms by which pRB functions to block tumorigenesis remains in
question. For this reason this thesis uses multiple approaches to investigate the tumor
suppressive mechanisms of pRB.

1.1.2

Retinoblastoma
Retinoblastoma, a rare childhood cancer, occurs with an incidence between

1:15,000 and 1:20,000 live births (4, 5) with an average of 25 new cases identified each
year in Canada (6). This tumor arises from the retina and typically presents in individuals
before 5 years of age (6). Retinoblastoma typically presents in two forms: unilaterally,
where only one eye is affected, and bilaterally, where both eyes are affected. In 1971,
Alfred Knudsen published a pioneering study that utilized clinical data from
retinoblastoma patients with either unilateral or bilateral retinoblastoma to propose a
genetic basis for retinoblastoma occurrence (7). He suggested that the generation of
retinoblastoma required two mutational events and termed this the ‘two hit hypothesis’
(7). Patients with the familial form of retinoblastoma inherited the first mutational event,
making it much more likely to develop bilateral retinoblastoma after a second mutational
event or ‘hit’. Patients without a genetic basis required two mutational events, which
made it much more likely for these patients to present with unilateral disease. This report
postulated the existence of a key tumor suppressor protein whose disruption was a critical
event in retinoblastoma formation.

2
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1.1.3

Mutation of RB1 in retinoblastoma patients
Retinoblastoma was initially associated with disruption of chromosome 13(8, 9)

and in 1986 the retinoblastoma tumor suppressor (RB1) cDNA was cloned (10, 11).
Patients with the heritable form of retinoblastoma were found to carry one mutant allele
of RB1. The second ‘hit’ was shown to be the loss of heterozygosity (LOH) of the
remaining wild-type RB1 allele (12, 13). Shortly after the discovery of RB1, it was shown
that proteins from DNA tumor viruses, specifically HPV-E7, SV-40 T antigen and
Adenovirus E1A, could all interact with the protein product of the RB1 gene pRB (1419). These proteins are all described as oncoproteins as they have the ability to disrupt
normal proliferative control mechanisms to induce cells to undergo oncogenic
transformation. Further these proteins all contained a similar sequence that was required
for transformation and interaction with pRB (20, 21). The direct interaction between the
retinoblastoma tumor suppressor protein and the viral oncogenes raised the possibility
that these proteins competed to regulate the same cellular pathways.

1.1.4

pRB regulates proliferation
pRB was found to be phosphorylated in a cell cycle-dependent manner at the

transition between the G1 and S phase of the cell cycle (22). This suggested that pRB
might have a role in the regulation of the G1-S phase transition of the cell (22). This is a
critical decision making step for a cell, as once cells proceed into S-phase, DNA
replication will begin and the cell will be committed to complete the cell cycle. pRB was
found to attenuate the activity of transcription factors known as E2Fs in the G1 phase of
the cell cycle and this inhibition was relieved upon S-phase entry (23-25). E2Fs induce a
3
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transcriptional program at the G1-S transition that functions to drive the entry into Sphase and initiate DNA synthesis (26). The importance of E2Fs in transcriptional control
of the cell cycle control is highlighted by the ability of E2F1 to drive the entry of cells
into S-phase from quiescence (27). This described a functional network of the G1
checkpoint with pRB negatively regulating the ability of E2Fs to activate the
transcription of key S-phase target genes to control S-phase entry.

1.1.5

Summary

The study of human tumors has led to the identification of pRB as a central regulator
of the G1-S transition of the cell cycle. This regulation appears to be imparted upon E2F
transcription factors and has highlighted a transcriptional mechanism of cell cycle
control. While, the RB1 gene is disrupted in retinoblastoma the majority of human
cancers contain functional pRB that is inactivated through deregulation of upstream
regulators of pRB activity (28). Small cell lung cancer is a notable exception as 90% of
cancers have inactivation of the RB1 gene (28-30). Interestingly, inactivation of RB1 is a
rare event in non-small cell lung cancer with only 10% of cancers having inactivation of
pRB (28, 29, 31, 32). The apparent selection for inactivation of RB1 in a subset of
cancers suggests a complex role for pRB in tumorigenesis that extends beyond the simple
negative regulation of E2Fs at the G1-S transition. However, current models of pRB
function suggest that E2F regulation is a central element of pRB function and is critical
for maintaining proliferative control.

4
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1.2
1.2.1

Pocket protein family
The pocket domain

pRB is a member of the pocket protein family that also includes p107 and p130
(33, 34). The pocket protein name is derived from the fact that all members share a wellconserved pocket domain (33). The pocket domain can be further seperated into the small
and large pocket domains (Fig. 1.1). The large pocket is required for full growth
suppression activity and is sufficient to complement the tumor suppressive properties of
pRB when expressed in place of the full-length protein (35, 36). The small pocket, in
contrast, is defined as the minimal domain required for interaction with the viral
oncogenes (37). The crystal structure of the small pocket has been determined (Fig. 1.2),
and the domain consists of two halves defined as A and B, which both adopt cyclin-like
folds (38, 39). These two halves interact with one another to form a dumbbell shaped
globular domain (38, 39). This small pocket domain is well conserved between the
pocket proteins, though there are some subtle differences. Specifically, p107 and p130
both contain relatively large insertions in the B region of the small pocket (Fig. 1.1).
Furthermore, the flexible linker that connects the two halves of the pocket is significantly
longer in the p107 and p130 proteins. The functional implications of these alterations are
not well understood, however, there are some reports that suggest that these regions allow
for distinct regulation and functionality of p107 and p130 (33).

5
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pRB

A

B

C

Large Pocket
Small Pocket
C-terminus

p107

A

B

p130

A

B

C

B

B

C

Domain structure of pRB, p107 and p130. The relative size and location of the A and B regions of pocket are
defined along with the C-terminus of the pocket proteins. The large pocket is denoted in orange, the small pocket
in red and the C-terminus is shown in green. .

Figure 1-1 Domain Structure of the pocket protein family

6

7

The pocket proteins are highly conserved as the majority of multicellular
organisms contain a close homologue to the pocket protein family of proteins (40).
While, mammals contain a complement of three pocket proteins lower organisms contain
fewer pocket proteins. Drosophila has only two proteins termed RBF1 and RBF2 and
Caenorhabditis elegans contains only a single homologous protein lin35. These proteins
appear to share similar roles as disruption of these proteins contribute to ectopic
proliferation in Drosophila and C. elegans (40). Multi-component complexes have been
identified that contain pocket protein homologues that are thought to be critical to
transcriptional regulation in Drosophila and C. elegans. These complexes termed
dREAM/MMB in Drosophila (41, 42) and DRM in Caenorhabditis (43) contain pRB
homologues, E2F/DP proteins, orthologues of the histone binding RbAp46/RbAp48,
MYB and a series of MYB interacting proteins (40). These large protein complexes are
thought to function as a critical element of transcriptional control in Drosophila and
Caenorhabditis. In mammals these protein complexes are also conserved but they do not
contain pRB but rather multi-subunit complexes have been identified with p107 and p130
that contain MYB proteins and other associated proteins (44-46). Interestingly, pRB has
not been associated with these complexes in mammalian cells. This suggests that
p107/p130 appear to have maintained the more evolutionary conserved roles of the
pocket proteins. Further, p107 and p130 share more homology to Drosophila and
Caenorhabditis pocket proteins than pRB (40). The pocket proteins are an evolutionary
conserved group of proteins of which p107 and p130 appear to share similar functionality
to the ancestral protein while pRB has diverged such that it does not appear to participate
in the same evolutionary conserved complexes.

7
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1.2.2

The pocket proteins regulate the activity of E2F transcription
factors
The large pocket domain has the ability to interact with E2F transcription factors

and regulate their transcriptional activity. This is mediated by an interaction between the
transactivation domain of E2Fs with the pocket domain of pRB (47). The direct
interaction of pRB with the transactivation domain blocks the ability of E2Fs to activate
transcription (48). The complex of pRB and E2F has been crystallized and defines the
molecular contacts between pRB and E2Fs (47, 49). Short peptides derived from the
transactivation domain of E2Fs were found to interact with the pocket domain at the
interface between the A and B halves of the pocket domain (Fig. 1.2c). Figure 1.2
displays the small pocket domain of pRB colored by the relative conservation. The
interface between the A and B halves in figure 1.2a is one of the most conserved surfaces
of pRB and mediates the interaction with E2F transcription factors. The contacts between
E2F and pRB occur primarily through interaction with the A region of the pocket and are
mediated in part by a series of well-conserved basic residues that contact the largely
acidic E2F transactivation domain shown in figure 1.3. Taken together the pocket
proteins have a well conserved cleft that is formed by the A and B halves of the pocket
domain that uses a series of electrostatic contacts to interact with the acidic
transactivation domain of E2F transcription factors.
The small pocket is not sufficient to interact with E2Fs in vivo, as the C-terminal
domain is also required. The C-terminal domain is thought to be largely unstructured but
appears to have the capacity to form defined structures when complexed with other
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interacting proteins (50). It has been shown that the C-terminal region contains multiple
contact sites that stabilize the interaction between pRB and E2Fs (50, 51). Furthermore,
while the C-terminal domain is not as highly conserved as the small pocket domain the
essential contact regions with E2Fs appear to be conserved (50). The pocket domain is a
conserved feature of this family of proteins and it functions in part to mediate the
interaction with E2Fs through a series of distinct contact sites found throughout the large
pocket region of pRB.

1.2.3

Interaction with chromatin remodeling factors through the
LXCXE binding cleft
The other highly conserved binding interface is the LXCXE binding cleft (Fig

1.2b,d). This binding site is located on the B-half of the pocket domain on the opposite
face from the E2F binding site. This region was initially found to interact with the viral
oncoproteins and co-crystallization studies have confirmed that multiple viral oncogenes
including E1A, HPV-E7 (Fig. 1.2d) and T antigen interact at this binding site (39, 52). A
shallow hydrophobic binding cleft is found in this region that interacts with a host of
cellular proteins in addition to the viral oncoproteins (39). To date there are over 25
confirmed proteins that interact with the LXCXE binding cleft of pocket proteins (53).
The majority of these proteins are involved in modifying chromatin structure. Notable
examples of these proteins are HDAC 1 (54) and Suv39h1 (55), both of which function to
produce repressive chromatin environments. HDAC1 is a histone de-acetylase that
functions to remove acetyl groups from lysine residues on histone tails. This promotes the
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The E2F binding site and LxCxE binding cleft are conserved elements of the pocket proteins. (A-D) The RB
crystal structures (A,C PDB:1N4M) (B,D PDB:1GUX) were colored based upon residue similarity across the
pRB homologues from human, newt, chicken, fruit fly, maize, human p107 and human p130. As shown in (E) the
darkest shade of blue indicates residues with similar properties are conserved in all pRB homologues and white
indicates that less than 60% of the aligned residues are similar at that position. (C) Depicts the co-crystallized
E2F2 peptide bound at the interface of the A and B regions of the small pocket. Depicted in (D) is the cocrystallized HPV-E7 derived peptide bound to the LXCXE binding cleft on the opposite face of the small pocket
domain in the B region!"

Figure 1-2 Conservation of the E2F and LXCXE binding sites
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A

B
Basic residue
Acidic residue
Polar residue
Non-polar residue

The cleft between the A and B regions of the small pocket domain of pRB is highly basic and interacts with
a series of conserved acidic residues in the transactivation domain of E2Fs. (A) The crystal structure of pRB
(PDB:1N4M) with co-crystallized E2F2 peptide is colored based upon the charges of individual residues. As
shown in (B) basic residues are colored blue, acidic residues red, polar residues grey and non-polar residues
white.

Figure 1-3 Electrostatic interface between pRB and the E2F transactivation domain
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formation of a closed heterochromatin conformation that blocks gene expression (56).
Suv39h1, in contrast, is capable of methylating lysine 9 on histone H3. This modification
recruits HP1 that promotes the formation of heterochromatin that is not accessible for
transcription (55). Pocket proteins are proposed to utilize this binding cleft to recruit
chromatin-remodeling factors (CRFs) to actively repress E2F target genes through the
formation of a closed chromatin environment.
In addition to the interaction with CRFs to actively suppress the expression of
E2F target genes the LXCXE binding cleft has been implicated in the maintenance of
genomic stability. pRB has the ability to interact with components of the condensin
complex which have a critical role in maintaining correct genomic architecture and
stability (57). Mice with targeted disruption of the LXCXE cleft in pRB were defective in
forming complexes between pRB and condensin II and were observed to have
chromosome stability defects akin to those observed in condensin II depleted cells (58).
Thereby, the well-conserved LXCXE binding cleft has the ability to interact with distinct
signaling elements to affect not only E2F target gene regulation but also the maintenance
of genomic stability through the interaction with condensin complexes.

1.2.4

Current model of proliferative control by the pocket proteins
A model for pocket protein function has been derived that is shown in figure 1.4.

This model integrates the ability of pocket proteins to interact with both E2F and
chromatin remodeling factors. The pocket proteins are unable to interact with DNA,
however, upon interaction with E2Fs the proteins are capable of interacting with E2F
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Model of pRB function in the regulation of the G1-S phase transition. In G1 pRB interacts with the
transactivation domain of E2F/DP heterodimer and blocks their activation of E2F target genes. pRB-E2F-DP
complexes bound to E2F target genes are capable of recruiting chromatin remodeling factors (CRFs) to further
repress the activation of these genes through the generation of a repressive chromatin environment. As cells
transition through G1 into S phase cyclin dependent kinases are activated including CDK4 (K4) with Cyclin D
(D) and CDK2 (K2) with Cyclin E (E). These kinases extensively phosphorylate pRB and mediate the release of
E2F/DP complexes. The free E2Fs activate the transcription of E2F target genes to drive the progression into Sphase and through the remainder of the cell cycle.

Figure 1-4 Transcriptional control of proliferation by pRB
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target sequences (25, 59). In turn, the pocket proteins can act as adapter proteins to recruit
distinct chromatin remodeling factors to these E2F target genes (59). Thereby, pRB and
other pocket proteins function by not only regulating the activity of E2F transcription
factors, but also by actively repressing E2F target genes through the recruitment of CRFs
to produce repressive heterochromatin states that further repress expression of these
genes.

1.3
1.3.1

Regulation of pocket protein activity
Differential expression mediates distinct roles of the pocket
proteins

The pocket proteins share a similar mechanism of regulating the transcription of
E2F target genes, however, they appear to have distinct cellular roles. This differential
activity is due in large part to their differential expression (33). As depicted in figure 1.5
pRB is a highly stable protein that is expressed at similar levels throughout the cell cycle
and its activity is primarily regulated by phosphorylation (60). In contrast, p107 is an E2F
target gene, and as such, its expression correlates with E2F transcriptional activity (61,
62). The expression of p107 is low in quiescent cells but increases sharply in S-phase
after activation of E2Fs. p130 is expressed primarily in quiescent and differentiated cells
with correspondingly low levels in proliferative cells (63). The low levels of p130 are due
in part to its degradation in proliferative cells (33). Specifically the E2F target gene Skp2
is capable of interacting with and targeting phosphorylated p130 for degradation (64). In
cultured cells the pocket proteins p107 and p130 have an inverse relationship with the
expression limited to proliferating and non-cycling cells respectively. In contrast pRB is
14
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maintained throughout the cell cycle and is expressed in both proliferating and noncycling cells.

Post-translational modifications of the pocket proteins

1.3.2

The pocket proteins are relatively stable with considerable half-lives that extend
beyond 10h for pRB (65). This stability results in proteins that persist through multiple
stages of the cell cycle. Thereby, the activity of pocket proteins is governed largely
through post-translational modifications, specifically, phosphorylation. In the G1-phase of
the cell cycle, pocket proteins exist in a hypophosphorylated state. Mitogenic signaling
results in the activation of cyclin-dependent kinases (CDKs) that phosphorylate pRB and
other pocket proteins to maintain the proteins in a hyperphosphorylated state through the
remainder of the cell cycle (60, 66). Initially, cyclin D CDK4 complexes are activated
and utilize a docking site found in the C-terminus of pRB to phosphorylate it (67).
Complete phosphorylation of pRB requires cyclin E CDK2 activity, which
phosphorylates the remaining sites on pRB (68). While p107 and p130 are
phosphorylated in a similar manner the differences in their structures allows for activities
that are not observed in pRB. Specifically, the large spacer region between the A and B
halves of the pocket domain along with the insertion in the B domain contain high
affinity sites for cyclins that allow p107 and p130 to act as inhibitors of the cyclindependent kinases and potentially provide an additional mechanism of cell cycle control
(69, 70).
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p130
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S

Model of relative protein levels for the three pocket proteins throughout the cell cycle adapted from Classon
and Dyson, 2001. pRB shown in blue is expressed at relatively constant levels throughout the cell cycle,
p107 shown in black is expressed predominately in proliferating cells in late G1 and S-phase, while p130 is
expressed at highest levels in non-proliferating cells and at very low levels in proliferating cells.

Figure 1-5 Levels of the pocket proteins throughout the cell cycle
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1.3.3

Disruption of E2F binding by phosphorylation
pRB contains 14 putative consensus CDK phosphorylation sites distributed

throughout the protein and at least 10 distinct phosphopeptides of pRB have been
identified (71, 72). These sites are shown in figure 1.6 and localize predominantly to
regions of the pRB that are thought to lack intrinsic structure (39, 50). The
phosphorylation sites localize primarily to the flexible linker between the A and B halves
of the pocket domain, the disordered C-terminal domain, and the N-terminal domain of
pRB as shown in figure 1.6 (39, 50, 73). Interestingly, the majority of the predicted sites
are distributed in pairs with two phosphorylation sties found in close proximity to one
another. Phosphorylation of pRB results in conformational changes in these flexible
domains that are enriched with CDK consensus sites (74). These conformational changes
function in part to obscure the E2F binding site that is mediated by the cleft between the
A and B halves of the pocket domain (74). Specifically, phosphorylation of the linker
between the A and B region results in a conformational change that leads to an
interaction between the phosphorylated linker and the cleft formed by the A and B halves
of the pocket domain (74). This obstructs the E2F binding site and blocks the interaction
between pRB and the transactivation domain of E2Fs (74). pRB is extensively
phosphorylated in regions that flank the well-structured pocket domain to cause a
concerted change in structure that obscures the E2F binding site and frees E2Fs from the
negative repression by pRB.
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Relative locations of CDK phosphorylation sites on pRB. The majority of CDK sites are found in pairs outside of
the structured regions of the small pocket domain in the N-terminal domain, the linker between the A and B
regions and in the C-terminal region of pRB.

Figure 1-6 CDK phosphorylation sites on pRB

18

19

1.3.4

Protein phosphatases are capable of reactivating
phosphorylated pRB
At the transition between metaphase and anaphase, there is a sharp decrease in the

activity of CDKs that results from the degradation of cyclin B by the anaphase-promoting
complex (APC) (75). At this time pRB must be returned to a hypophosphorylated state in
the G1 phase of the cell cycle. This is largely mediated by the active dephosphorylation of
pRB by phosphatases including protein phosphatase 1 (PP1), which dephosphorylates
pRB beginning in anaphase (76, 77). When environmental conditions are unfavorable for
cell division the cell is capable of inducing an acute arrest of proliferation that also results
in the reactivation of pRB to a hypophosphorylated state. Once again, PP1 has been
shown to play a major role in the dephosphorylation of pRB in response to cell cycle
arrests induced by DNA damage or hypoxia (78, 79). Upon DNA damage PP1 is
activated to promote the dephosphorylation of pRB to a hypophosphorylated state that
can maintain the interaction with E2Fs and block their transcriptional activity to mediate
an acute arrest of the cell cycle (80). In addition protein phosphatase 2 also interacts with
and dephosphorylates pRB in some cellular contexts (81). The relative contribution of
PP1 and PP2 mediated effects on pRB phosphorylation are not well described and
warrant further investigation. It is apparent that a robust regulatory network exists
whereby pRB activity is modulated by its phosphorylation state that is controlled by the
opposing activity of both kinases and phosphatases.
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1.3.5

Regulating the activity of CDKs
The progression through the cell cycle is largely governed by the activity of

CDKs that function to phosphorylate specific targets including pRB in a timely fashion to
mediate the ordered progression through the cell cycle. Mammalian cells contain at least
11 distinct CDKs that are all activated by regulatory cyclin subunits (82). In addition to
requiring a cyclin subunit for activity CDKs are regulated by multiple mechanisms that
include, phosphorylation on activating or inhibiting sites and the interaction with cyclin
dependent kinase inhibitors (CKIs) (83). The CKIs have a critical role in regulating cell
cycle progression as they represent a means by which the activity of CDKs can be
blocked abruptly in response to cellular cues such as DNA damage or developmental
signals. The CKIs can be grouped into two distinct classes, the Cip/Kip proteins include
p21Cip1, p27Kip1, p57Kip2 and the INK4 family includes p16INK4A, p15INK4B, p18INK4C and
p19INK4D (84). The INK4 class of inhibitors function to inactive CDK4 and CDK6
complexes by blocking the association of the kinases with the regulatory cyclin D
subunit. The Cip/Kip family interacts with both the cyclin and CDK subunits to regulate
the activity of a broad class of cyclin CDK complexes (83)
The INK4 family of inhibitors requires the activity of Cip/Kip proteins to induce a
cell cycle arrest (85). This is due to the fact that these proteins function by inhibiting
CDK4/6 cyclin D complexes and releasing the sequestered Cip/Kip proteins bound to
CDK4/6 to inactivate CDK2 complexes. (85) The Cip/Kip proteins are potent antiproliferative factors that are capable of restraining proliferation in multiple contexts
including development, differentiation and in response to cellular stresses. These distinct
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contexts of cell cycle arrest typically induce only a single Cip/Kip factor. p21 is a critical
target of p53 and induces a cell cycle arrest in response to cellular and genotoxic stresses
(86). p27 in contrast is activated in response to lack of mitogens or in the induction of a
quiescent state (87) and p57 typically mediates developmentally mediated cell cycle
arrest paradigms (88). These proteins act to integrate distinct signals to induce a cell
cycle arrest through the inhibition of CDK complexes.

1.4

Unique and overlapping functions of the pocket

proteins
1.4.1

Disruption of Rb1 in mice
Discerning the functional role of the distinct pocket proteins has been greatly

aided by the use of gene-targeted mouse models to specifically disrupt individual pocket
proteins. Genetic disruption of the mouse Rb1 gene to produce Rb1-/- mice results in
embryonic lethality between embryonic day (E) 13.5 and E15 (89). The Rb1 -/- embryos
have increased proliferation and apoptosis in the central nervous system (CNS) and the
peripheral nervous system (PNS) (89). These mice also have defects in hematopoiesis
and altered development and proliferation of the lens (89-92). The inappropriate
proliferation observed in Rb1-/- mice can be partially rescued by combined disruption of
E2F1 or E2F3, which suggests that E2F regulation is a critical function of pRB (93-95).
The ectopic proliferation and apoptosis observed was thought to highlight a critical role
for pRB in maintaining appropriate growth control in distinct developmental contexts.
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However, many of the defects in Rb1-/- mice were later found to be secondary to
proliferative defects that occur in the placenta of these mice (96).
Specifically, the trophoblast cells found within the labyrinth layer of the placenta
were found to be hyperproliferative in Rb1-/- embryos (97). This over-proliferation results
in a decrease in the space between the maternal and fetal blood supply (96). This in turn
was found to result in decreased nutrient transport to the embryos (96). To investigate
phenotypes of Rb1-/- mice that are independent of the placental defect Rb1-/- mice were
produced with normal placenta using tetraploid aggregation (97). The provision of the
normal placenta was found to rescue many of the phenotypes associated with loss of Rb1
(97). Most notably the mice were no longer embryonic lethal between E13.5-E15.5 but
rather could survive until birth (96). The defects in hematopoiesis and apoptosis in the
CNS were not observed in the rescued Rb1-/- animals (96). However, the excess
proliferation in the CNS and the lens was observed in the rescued animals suggesting that
these defects occurred independently of the placental defects (96). The mice, however,
died shortly after birth due to defects in skeletal muscle formation (96). This defect
results in significant disruption of the diaphragm that prevents the lungs of newborn Rb1/-

animals from inflating and resulted in an inability for the mice to respire. Experiments

using conditional deletion of pRB in myoblasts suggest that the defect in skeletal muscle
results from an inability of the Rb1-/- cells to terminally differentiate into multinucleated
myotubes (98). Fibroblasts generated form Rb1-/- embryos also display significant defects
in proliferative control. Specifically the fibroblasts have a shorter G1 phase of the cell
cycle, with a coincident reduction in cell size (99). While the cells remain sensitive to
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serum starvation they are unable to respond to ectopic arrests induced by p16 (100) and
TGF! (101).
Taken together mouse models of pRB have defined an essential role for pRB in
mammalian development. Specifically pRB function is required for proper proliferative
control, placental development and muscle differentiation. Many cell types are able to
proliferate and respond normally in distinct developmental contexts, as Rb1-/- animals are
viable until birth if supplied with a normal placenta. Given the essential role for pRB in
tumorigenesis and the postulated role in the regulation of the G1-S transition the
development of these mice suggests that in some contexts other pathways can function in
the absence of pRB to maintain cell cycle control.

1.4.2

Redundancy in the pocket protein family
pRB appears to have a clear role in regulating a distinct set of developmental

processes as observed from the Rb1-/- mice. However, proliferative control is maintained
in many tissues and death in animals with a normal placenta is the result of defective
differentiation of muscle cells. The maintenance of proliferative control in Rb1-/- mice
appears to be due in part to the activity of the other pocket proteins p107 and p130. Loss
of pRB results in a deregulation of E2F target gene expression that induces the expression
of p107 which is itself an E2F target gene (102). The increased levels of p107 can allow
for compensation for loss of pRB in many contexts. Combined disruption of pRB and
p107 or pRB and p130 results in more severe apoptotic and proliferative defects that
result in earlier embryonic lethality between E11 and E13 (103, 104). Importantly loss of
p107 or p130 alone does not alter the viability of mice in a mixed genetic background
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(105). Combined disruption of both p107 and p130 results in neonatal lethality with
severe defects in bone development that results in shorter bones (105, 106). This suggests
that the pocket proteins control partially overlapping pathways and in some
circumstances function to compensate for the loss of other pocket proteins.
To further test the compensation between pocket proteins, fibroblasts were
generated that disrupted pRB, p107 and p130, called TKO cells (107, 108). These
fibroblasts were generated from the differentiation of directly targeted ES into TKO
fibroblasts (107, 108). The TKO cells are defective for proliferative control and do not
arrest in the G1 under a variety of conditions (107, 108). However, more recently TKO
embryos have been generated and survive until days 9-11 of gestation (109). Further the
embryos and cultured TKO cells are capable of exiting the cell cycle in G1 and
differentiating into multiple epithelial and neural lineages (109). This suggests that in
some contexts cell cycle exit can occur in the absence of pocket protein activity however,
the mechanism by which this may occur is still unclear.

1.4.3

A unique role for pRB in cancer
Loss of pRB in the retina results in the generation of retinoblastoma early in life.

Initial efforts using the mouse model of Rb1 disruption investigated whether a similar
effect would be observed in pRB null mice. In contrast to humans the Rb1+/- mice do not
develop retinoblastoma but rather develop pituitary tumors that arise from the
intermediate lobe of this gland. (89) Rb1+/- mice typically develop tumors by one year of
age in either the intermediate lobe of the pituitary gland or less frequently in the thyroid
gland (110). These tumors display loss of heterozygosity (LOH) of the remaining wild
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type allele of Rb1 to produce a tumor that is nullizygous. Interestingly disruption of other
cell cycle regulators such p27 or p18 also results in pituitary tumors in the intermediate
lobe (111-114). This suggests that this region may be uniquely susceptible to loss of
proliferative control that gives rise to the observed tumors. Furthermore, the intermediate
lobe is rudimentary and likely non-functional in humans which may explain the fact that
pRB loss in humans does not induce pituitary tumors (115).
In contrast, the induction of retinoblastoma in mice requires disruption of both pRB
and p107 as Rb1-/- Rbl1-/- chimeras or mice with deletion of pRB and p107 in the retina
develop spontaneous retinoblastomas (116, 117). This further supports the compensatory
role of p107 in the absence of pRB. p107 and p130 themselves are rarely disrupted in
human cancers and mice lacking p107 gene Rbl1 or the p130 gene Rbl2 are not prone to
tumors (118). Further, Rbl1+/- Rbl2-/- and Rbl1-/- Rbl2+/- mice are not tumor prone
suggesting a unique role for the remaining pRB in tumor suppression (34). Taken
together this suggests that pRB has a unique role in tumorigenesis but the other pocket
proteins can function in the absence of pRB in certain contexts to maintain proliferative
control. Given the ability of all pocket proteins to interact with E2F transcription factors
the mechanistic basis for the unique role of pRB in tumorigenesis is not clearly defined.

1.5
1.5.1

E2F family of transcription factors
Division of labor in the E2F family

In a similar manner to the pocket proteins, E2Fs consist of a family of proteins
that share many common features but also have unique functions that differentiate the
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individual E2Fs. There is a division of labor in pocket protein E2F interactions as specific
pocket proteins preferentially interact with individual E2Fs. pRB is capable of interacting
with E2F1, E2F2, E2F3 and E2F4 while E2F4 and E2F5 interact with p107 and p130.
E2F6, E2F7 and E2F8 in contrast do not interact with any pocket proteins (119). The E2F
transcription factors can also be divided into two distinct functional classes based upon
their observed ability to either activate or repress E2F dependent transcription. E2F1,
E2F2 and E2F3 are all classified as activator E2Fs due to their ability to strongly activate
E2F transcriptional targets while E2F4, E2F5, E2F6, E2F7 and E2F8 are defined as
repressor E2Fs due to their ability to block E2F dependent transcription (120).

1.5.2

Structural features of the E2F transcription factor
All eight E2F transcription factors share a high degree of similarity in their DNA

binding domains (Fig. 1.7). E2F1-6 all contain a dimerization domain that is required for
the interaction with DP proteins (121-123). The dimerization with DP is critical for the
function of E2Fs as E2F1-6 are not capable of interacting with DNA without DP
heterodimerization. Both E2F and DP contain a DNA binding domain, that recognizes a
E2F recognition sequence through a winged-helix DNA binding motif (124). DP proteins
share a limited homology with E2F factors, specifically the fold of the DNA binding
domain and the sequences that contact DNA are conserved (124). While there are three
distinct DP proteins (DP1, DP2/3, DP4) the roles of these factors are not well understood
and the specificity of the E2F/DP complex is thought to be imparted mainly by the E2F
subunit (119). E2F7 and E2F8 have two DNA binding domains that allow for the
interaction with the E2F recognition sequence independently of DP (125, 126).
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The recognition sequence in E2F responsive promoters has been characterized
largely from in vitro experiments (127). Further, the consensus sequence was found to
differ slightly for individual E2F/DP complexes and for tri-molecular pRB-E2F/DP
complexes (127). However, in vivo studies have suggested that other mechanisms
contribute to the specificity of E2F factors as the majority of identified binding sites do
not contain a E2F consensus site (128-130). E2F1, E2F4 and E2F6 were identified in an
overlapping manner at the majority of binding sites in vivo suggesting that there is little
specificity for individual E2F/DP complexes (129). These data suggest that a functional
redundancy exists between E2F factors and the association with E2F responsive
promoters is mediated by multiple factors that extend beyond a consensus site.

1.5.3

Activator E2Fs
The activator E2Fs, E2F1-3 are highly homologous to one another sharing many

of the same domains including the transactivation domain which can activate E2F target
gene expression. The C-terminal transactivation domain is capable of recruiting the basal
transcription machinery including TFIID as well as co-activating proteins that include,
p300, TRAPP and GCN5 to E2F target promoters (131-134). It is this domain
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Domain structure of the E2F family of transcription factors. The nuclear localization signal (NLS), the nuclear
export signal (NES), the DNA binding domain (DBD), the dimerization domain (DMZ), the marked box domain
(MB) and the transactivation domain (TA) are shown. (A) The activator class of E2Fs that require dimerization
with DP and interact primarily with pRB. (B) The repressor class of E2Fs that also require DP dimerization and
do not primarily interact with pRB. (C) The second class of repressor E2Fs that dimerize independently of DP and
do not interact with pocket proteins.

Figure 1-7 The E2F family of transcription factors
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that pocket proteins interact with and function to block the ability of E2Fs to recruit the
transcriptional machinery to E2F target promoters. The activator E2Fs are expressed in a
cell cycle dependent manner due in large part to the fact that they are themselves E2F
target genes (135, 136). Therefore, increased E2F activity creates a positive feedback
loop that promotes the expression of more E2F transcription factors. Coupled with the
strong nuclear localization signal (137) the activating E2Fs represent potent inducers of
S-phase target gene expression at the G1-S transition to drive the cell through the
remainder of the cell cycle.

1.5.4

Repressor E2Fs
The repressor class of E2Fs consisting of E2F4 through E2F8 are expressed at

constant levels throughout the cell cycle and are thought to primarily act to repress E2F
target gene expression. This repressive activity is mediated in part by their lack of a
nuclear localization signal that is found on E2F1-3 (138). E2F4 and E2F5 also contain a
nuclear export signal that limits their accumulation in the nucleus (139). The transport of
E2F4 and E2F5 to the nucleus requires the formation of complexes with p107 or p130
(140). This limits the nuclear pool of E2F4 and E2F5 to E2F-pocket protein complexes
which can block proliferation through the recruitment of chromatin remodeling factors to
E2F target genes. E2F6-8 do not contain nuclear export signals but lack the
transactivation domain (120). As such these proteins do not interact with pocket proteins
to regulate E2F dependent transcription. E2F6 in contrast interacts with the polycomb
repressive complex to mediate the silencing of E2F target genes (141, 142). E2F7 and
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E2F8 can also function to block transcriptional activation but a co-repressor complex has
yet to be defined.

1.5.5

Disruption of E2Fs highlight overlapping and unique roles for
E2F family members
A series of gene targeted mouse models have furthered the understanding of the

roles of the individual E2F transcription factors. To assess unique roles of individual
E2Fs in developmental processes each E2F has been genetically disrupted in the mouse.
No one E2F is required for development as all single knockouts are viable in mixed
genetic backgrounds. However, each E2F knockout appears to have defects in distinct
tissues, which suggests that the individual E2Fs may have tissue specific roles (120).
Specifically, E2F4-/- mice have craniofacial defects and maturation defects in
hematopoietic lineages, which results in increased susceptibility to infections (143).
E2F2-/- mice were found to develop autoimmune disease due to enhanced T-Cell receptor
signaling induced proliferation leading to low concentrations of self-ligand triggering
autoimmune reactions (144). This suggests that E2F2 may play largely a repressive role
through the recruitment of pRB-E2F2 complexes to block the proliferation of naïve Tcells. In contrast, disruption of E2F3 in mice results in reduced viability with a defect in
proliferation in cells derived from E2F3-/- mice (145). This work has suggested that the
individual E2Fs may have tissue specific function and E2F3 may have a larger role in
driving the progression into S-phase of the cell cycle.
Recent data has shown that E2F3 is expressed as two distinct isoforms, E2F3a and
an N-terminally truncated E2F3b. Gene knockout studies suggest that the two isoforms
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have similar functional properties with differences in expression (146). A recent study
suggests that mammalian development requires only a single activator E2F as disruption
of E2F1, E2F2 and E2F3b results in viable mice and disruption of E2F1, E2F2 and
E2F3a results in neonatal death at day 19.5 (147). Furthermore, E2F1 or E2F3b were
found to be sufficient for development if they were expressed from the E2F3a locus
(147). This suggests that the activator E2Fs are functionally redundant in terms of
proliferative control and many of the differences observed may be attributed to
differential expression of the E2Fs.

1.5.6

Cycling without E2F transcription factors
Disruption of all activating E2Fs was initially shown to be incompatible with the

proliferation of fibroblasts as E2f1-/- E2f2-/- E2f3fl/fl cells infected with Cre recombinase
to remove the remaining E2F3 allele, failed to proliferate in culture (148). E2F target
genes were severely downregulated and these cells failed to enter S-phase. This fits with
the critical role for activating E2Fs in the expression of the genes required for S-phase
entry. However, more recent experiments have shown that cells are capable of cycling in
the absence of activating E2F transcription factors (149, 150). Genetic disruption of
E2F1, E2F2 and E2F3 results in embryonic lethality by embryonic day 11.5 (149).
However, at embryonic day 9.5 embryos with disruption of all activating E2Fs can be
recovered that appear histologically normal with only subtle defects in proliferation of the
myocardium (149). The ability of embryos to develop to this stage suggests that E2Fs are
not essential for cell division, as a vast amount of division has occurred in the first 9 days
of development. An analogous study disrupted all of the E2Fs in the retina of mice and
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found that retinal cells could also proliferate in the absence of activating E2Fs (150).
This proliferation was dependent on the activity of N-myc, which functioned to block the
buildup of CDK inhibitors that resulted from the disruption of the activating E2Fs (150).
These studies suggest that activating E2F activity is not essential for S-phase entry but
rather the E2Fs have important contributions to cell cycle advancement that can be
compensated by other factors in many cellular contexts.

1.5.7

A unique role for E2F1 in the induction of apoptosis
In many contexts the activating E2Fs have redundant roles in proliferative control.

E2F1, however, appears to be uniquely linked to apoptosis. This linkage is highlighted by
the fact that loss of E2F1 in mice results in defective apoptosis in thymocytes that leads
to a defect in negative selection (151). E2f1-/- mice also develop a broad spectrum of
tumors between 8 and 18 months of age that includes lymphoma (152). This suggests that
E2F1 induced apoptosis has a critical role in eliminating pre-neoplastic cells.
Importantly, apoptotic defects have not been reported after the disruption of other E2Fs
(144-146, 153-156), suggesting that this is a unique feature of E2F1.
As described previously Rb1-/- animals have a significant increase in apoptosis
that was thought to be a direct result of deregulated E2F signaling. In support of this
model disruption of E2F1 or E2F3 along in Rb1-/- animals attenuates the observed
apoptosis and extends the viable development of the embryos (94, 157). However, the
apoptosis was found to be secondary to a proliferative placental defect that is
significantly improved by genetic disruption of E2f3 (95). This suggests that the
reduction in apoptosis observed may be a non-cell autonomous event.
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Ectopic expression of E2Fs in both cell culture and in transgenic mice has been
shown to induce apoptosis (158-162). This observation is complicated as the majority of
E2Fs are themselves E2F targets and ectopic expression of individual E2Fs results in
coincident activation of other E2Fs (135, 136). To further investigate this possibility
conditional E2F3 transgenic mice were crossed with E2f1-/- animals (163). Strikingly,
E2F3 expression can induce ectopic S-phase entry in the absence of E2F1 but requires
E2F1 to actively induce apoptosis (163). Thus E2F1 has a unique role in the active
induction of apoptosis and other E2Fs appear to drive apoptosis through the activation of
E2F1 expression.
Under normal cellular conditions E2F1 does not appear to significantly induce
apoptosis, however upon ectopic expression of E2F1 or during DNA damage E2F1 can
effectively activate an apoptotic program. E2F1 can induce apoptosis through activation
of p53 or its homologue p73 (164-166). E2F1 has been shown to activate a series of
apoptotic targets including p19-ARF, which functions to inhibit the mdm2-induced
degradation of p53 (167). E2F1 can also activate p73 directly to induce apoptosis
independently of p53 (168). The ability of E2F1 to induce apoptosis through p73 is
important as the majority of human cancers lack p53 function (169). Therefore, the
apoptotic response in many tumors is largely mediated by the activity of p73 which is
itself primarily activated by E2F1 (170). Furthermore, E2F1 can directly activate proapoptotic molecules such as Apaf-1 caspases and bid (171-173). This suggests that E2F1
has a unique ability to activate both proliferative and apoptotic genes and this may play a
functional role in human cancers.
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1.5.8

Independent regulation of E2F1 induced proliferation and
apoptosis
This dual function of E2F1 raises the question of how E2F1 can under some

circumstances, induce proliferation and under other conditions induce apoptosis. One
proposed mechanism is the linkage of E2F1 with DNA damage signaling. In response to
DNA damage E2F1 undergoes a series of post-translational modifications. E2F1 is
phosphorylated by the DNA damage kinases ATM (174) and Chk2 (175), acetylated by
PCAF (176) and demethylated by LSD1 (177). The modified E2F1 is stabilized and
increases the affinity for apoptotic promoters (168). In addition pRB is itself modified
following DNA damage by Chk1/2 phosphorylation at S612 (178), acetylated at
K873/874 (179) and methylated by Set7/9 and SMYD2 (180, 181). The DNA damage
modifications of E2F1 and pRB may provide a means to impart a selective induction of
E2F1’s apoptotic potential. The lack of these modifications under a normal cell cycle
could restrict the activity of E2F1 to proliferative promoters. However, the structural
basis for the ability of these modifications to direct the activation of E2F1 to specific
promoters is poorly understood.
Current understanding of pRB suggests the phosphorylation by CDK complexes
in cycling cells results in the release of E2F transcription factors to drive cell
proliferation. This has been challenged by work that suggests that E2F1 complexes may
persist with phosphorylated pRB under some cellular contexts (182, 183). Furthermore,
during S-phase in which the majority of pRB is phosphorylated pRB-E2F complexes
have been identified bound to specific genomic loci that are not observed in cells in G1
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(184). Following DNA damage complexes between phosphorylated pRB and E2F1 have
also been identified and correlated with the presence of E2F1-pRB complexes at proapoptotic genes including TP73 (182). These complexes are proposed to recruit and
activate the histone acetyltransferase PCAF to promote the activation of this gene (182,
185). These reports suggest that pRB may be able to maintain the interaction with E2F
proteins in its phosphorylated state, however, the mechanism by which phosphorylation
can disrupt a subset of E2F complexes but maintain others has yet to be described.

1.6

pRB can regulate E2F1 through two distinct

binding sites
1.6.1

Dissecting the distinct E2F binding sites by mutagenesis
In efforts to abrogate E2F binding to pRB it was found that pRB is capable of

interacting with E2F1 through two distinct binding conformations (186). In addition to
the E2F binding site mediated by the large pocket of pRB there is an E2F binding site in
the C-terminal region of pRB (186). This binding site forms a unique interaction with the
marked box domain of E2F1 (187). To differentiate between the two binding sites a
nomenclature has been developed. The large pocket site that is capable of interacting with
E2F1, E2F2, E2F3 and E2F4 is referred to as the ‘general site’ while the C-terminal E2F1
site is described as the ‘specific site’ as shown in figure 1.8. As shown in figure 1.8b pRB
is capable of forming two distinct interaction types mediated by distinct binding
interfaces with E2F1 to form the ‘general’ or ‘specific’ complexes. To dissect the
function of these individual binding sites synthetic mutants of pRB have been generated
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to selectively disrupt the individual interactions (186-188). A mutant termed "G was
generated to disrupt the ‘general site’ and the "S mutant was generated to selectively
disrupt the ‘specific site’ (186, 187). The "G mutant consists of 11 mutations that span
both the A and B halves of the pocket domain. All of the mutations are alanine
substitutions that act to disrupt contacts between pRB and E2F complexes across the
pocket domain. The large number of mutations required to disrupt E2F binding suggests
that the contacts between pRB and E2F extend beyond the binding cleft defined by cocrystallization studies with the E2F transactivation domain (47, 49). The "S mutation
consists of substitutions of M851A and V852A which are found in the C-terminal domain
(187). These residues are part of the crystal structure recently determined between the Cterminus of pRB with the marked box domain of E2F1 (50). These residues are observed
to interact with both E2F1 and DP1 in the crystal structure (50). The substitutions
remove critical contacts at the site to disrupt the ‘specific’ interaction with E2F1 in
isolation.
These mutants have been used to investigate the functional roles of these two
distinct binding sites. The ‘general site’ appears to function to control proliferation while
the ‘specific site’ has been shown to be dispensable for proliferative control (186-188).
The ‘specific site’ has been linked to regulation of E2F1 induced apoptosis. Furthermore,
forcing the interaction of E2F1 through the ‘specific site’ in the "G mutant results in an
increased ability of pRB to block E2F1 induced apoptosis (186). Disruption of the
‘specific site’ in the "S mutant in turn blocks the ability of pRB to regulate E2F1 induced
apoptosis (187). This suggests that the ‘specific site’ has an active role in E2F1 induced
apoptosis. However, the mechanism by which this occurs is not well understood. pRB36
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pRB can form two distinct interactions with E2F transcription factors. The C-terminal region of pRB
interacts selectively with the marked box domain of E2F1 to mediate the ‘specific’ interaction. The large
pocket of pRB interacts with the transactivation domain of E2F1-4 to mediate the ‘general’ interaction.

Figure 1-8 pRB contains two distinct E2F binding sites
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E2F1 complexes in the ‘specific’ conformation were observed to have low affinity for the
canonical E2F DNA recognition sequence (186). This suggests that complexes between
E2F1 and the pRB in the specific conformation do not function in the traditional manner
to repress E2F target genes but rather raises the possibility that they function at a subset
of genes and warrants further investigation.
This data suggests that pRB has the ability to regulate the contrasting ability of E2F1
to induce proliferation and apoptosis through the ‘general’ and ‘specific sites’. The
mechanisms by which these complexes selectively regulate proliferative or apoptotic
targets are not well understood. The E2F1 specific complex is resistant to disruption by
E1A as pRB-E2F1 complexes are maintained during adenovirus infection suggesting that
the two complexes are regulated through distinct mechanisms (189). A recent report has
suggested that complexes between pRB-E2F1 can function in response to DNA damage
to promote the activation of pro-apoptotic genes (182). However, it is not clear which
binding site regulates this activity. Other studies have also shown that DNA damage
disrupts the interaction with pRB (190). To reconcile these contrasting observations there
is a need to selectively study the ‘general’ and the ‘specific’ sites in isolation at
endogenous conditions to investigate the role of these distinct binding sites.
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1.7

E2F independent functions of pRB
E2F independent regulation of differentiation

1.7.1

The current model typically describes the activity of pRB in terms of interaction
with E2F transcription factors and the recruitment of chromatin remodeling factors to
E2F target genes!(3, 191). However, data from a synthetic pRB mutant "663 that does
not interact with E2F or with LXCXE interactors is defective for proliferative control but
maintains the ability to regulate differentiation (192). This mutant along with other
mutations that are defective for E2F binding maintain the ability to activate the
expression of muscle or bone specific genes and promote the differentiation of pRB null
cells (192).

Multiple mechanisms have been shown to influence E2F independent

differentiation mediated by pRB. In the case of bone differentiation pRB is capable of
interacting with and stabilizing complexes between HES1 and RUNX2 which function to
activate osteoblast specific genes (193). This suggests that pRB can influence the
transcription of E2F independent pathways to regulate differentiation.

1.7.2

Regulation of p27 through an E2F independent mechanism
by pRB
In addition to the control of differentiation there are reports that suggest pRB can

also control proliferation independently of E2F transcription factors. pRB can stabilize
p27 through post translational mechanisms that are independent of E2Fs and do not occur
in other pocket proteins (194). This work was first described in a study published by Ji et
al. where expression of pRB in the RB-null osteosarcoma cell line Saos-2 was studied.
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When pRB expression was activated in a tetracycline inducible cell line the authors noted
that the levels of p27 were upregulated before downregulation of E2F target gene
expression occurred (195). This further suggested that p27 could be regulated
independently of E2F activity. Specifically, pRB was found to regulate the stability of
p27 through interacting with the ubiquitin ligase complex containing Skp2 and blocking
its ability to target p27 for degradation (195). Importantly, mutants that are defective for
E2F regulation are still capable of p27 regulation and this has been shown to be a critical
aspect of senescence (194, 195). pRB is also capable of interacting with components of
the anaphase promoting complex (APC) containing the Cdh1 targeting subunit (196).
Importantly this complex functions in the G1 phase of the cell cycle to promote the
degradation of key proteins including Skp2 to maintain cells in the G1 phase of the cell
cycle. pRB binds to Cdh1 through a LXCXE dependent binding site in the pocket domain
and with Skp2 through the C-terminal domain (195, 196). By interacting with both of
these proteins pRB is capable of promoting the degradation of Skp2. This degradation
prevents SCFSkp2 complexes from targeting p27 for degradation and results in the
stabilization of p27(196).

1.7.3

Proliferative control mediated by p27
The critical role for p27 in proliferation is highlighted in Cdkn1b-/- animals which

display hyperplasia with all organs observed to be at least 20% larger (112-114). Loss of
p27 results in the development of pituitary tumors in a similar manner to Rb1+/- mice
(112-114). Furthermore, combined disruption of p27 and Rb1 results in an acceleration of
pituitary tumors, a shift to more aggressive tumors and an increase in incidence of thyroid
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tumors (197). The ability of p27 loss to enhance tumorigenesis of Rb1+/- animals suggests
that p27 may have pRB independent functions. Notably tumors observed in Rb1+/- mice
have significant downregulation of p27, which supports the importance of the
stabilization of p27 by pRB.
Current models of p27 activity describe a function upstream of pRB to inactivate
the CDKs that results in the activation of pRB. Active pRB then is able to repress the
transcription of E2F target genes. Importantly, expression of p27 into RB1 null cell lines
induces at least a partial cell cycle arrest (198). This in turn suggests that p27 can
function downstream of pRB to induce a cell cycle arrest independently of pRB. The
mechanism by which this occurs may be dependent upon the inhibition of CDKs by p27.
Notably, Rb1-/- cells are capable of partially arresting in response to expression of a
dominant negative CDK2 protein (199). This suggests that down regulation of kinase
activity can block the proliferation of cells in the absence of pRB (199). As such both
pRB and p27 appear to have a partially overlapping role in proliferative control, however,
the contribution of these proteins to a given cell cycle arrest is not well described.

1.8

Structure function analysis of the retinoblastoma

tumor suppressor protein
1.8.1

A context dependent role for LXCXE interactions
The development of a gene-targeted mouse model that selectively disrupts the

interaction with proteins at the LXCXE binding cleft has allowed for a functional role for
LXCXE interactions to be defined in multiple cellular contexts (200). Fibroblasts
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homozygous for this mutation termed !L are able to maintain proliferative control in
asynchronous growing cultures, in response to serum deprivation and confluence arrest
(200). Furthermore, the mice are viable and do not develop spontaneous tumors (58).
However, the cells and mice were found to be defective in their response to other cell
cycle arrest stimuli. Specifically, female Rb1!L/!L animals had a reduced ability to nurse
their pups resulting in the neonatal lethality of animals raised by Rb1!L/!L mothers (201).
This correlated with an observed hyperplasia in the ducts of the mammary glands of these
animals and an inability of fibroblasts to respond to TGF-! growth arrest
(201). However, differentiation and cell cycle exit was observed to occur in other
developmental contexts in an appropriate manner in the Rb1!L/!L mice (202). This work
suggested a specific role for LXCXE interactions in cell cycle regulation in a limited set
of developmental contexts. Specifically Rb1!L/!L cells treated with TGF-! were found to
express elevated levels of E2F target genes suggesting that the recruitment of chromatin
remodeling factors was necessary in some cellular contexts to fully repress E2F target
gene expression (201).
Recent work has highlighted a critical role for pRB in cellular senescence (107,
202, 203). Senescence is a permanent form of cell cycle arrest and is thought to have a
critical role in blocking the proliferation of pre-malignant cells (204). Depletion of pRB
in primary human cells induced to undergo senescence results in a failure to appropriately
silence the expression of E2F target genes that is required to maintain the senescent state
(203). This is mediated by the inability of other pocket proteins to localize to these target
promoters in the absence of pRB. Furthermore, disruption of the LXCXE binding cleft in
Rb1!L/!L fibroblasts also disrupts the ability of pRB to maintain a stable repression of E2F
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target genes in senescence (202). The LXCXE binding cleft appears to be necessary to
sustain the stable repression of E2F target genes to maintain a senescent arrest.

1.8.2

Dissecting the contribution of E2F dependent mechanisms to
overall cell cycle arrest
To dissect the contribution of E2F dependent and independent mechanisms to the

function of pRB the R661W mutation has been utilized. This mutant is a tumor-derived
mutation that is defective for E2F binding. R661 faces the interior of pRB at the interface
between the A and B halves of the pocket domain. The substitution of R661W disrupts a
hydrogen bond network that abrogates the interface between the A and B regions of the
small pocket domain (39). This mutant is defective for transcriptional control of E2F but
it also disrupts other activities of pRB, as the R661W-pRB is partially defective for
LXCXE interactions (205). This mutation results in an increase in the interaction with
E2F4, which may result from an altered nuclear localization of pRB as E2F4 is normally
localized to the cytoplasm (206). A gene targeted mouse model has been generated from
this mutation by introducing the analogous R654W substitution in the mouse Rb1 gene.
Homozygous mice carrying this mutation are embryonic lethal due to placental defects.
However, the placental defects are less severe than in Rb1-/- embryos. This allows for
better nutrient transport from the placenta to the embryo proper and the mice typically
survive 1-2 days longer than the Rb1-/- mice (206). Mice heterozygous for the R654W
substitution are also tumor prone with a similar prevalence of pituitary and thyroid
tumors as the Rb1+/- mice (207). This suggests that E2F binding is required for growth
control by pRB. This however, does not fit with the cell culture experiments that have
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shown that the R661W mutant when transfected into RB deficient cancer cell lines is
capable of inducing an arrest to a similar extent as WT-pRB (195). It is possible that the
contrasting results are partially mediated by differences in expression of pRB between the
endogenous levels in the R654W mice and the levels expressed from the tetracycline
inducible cell lines. It is conceivable that the R654W mutation reduces the stability of
pRB and alters the nuclear localization such that the levels of R654W-pRB are reduced to
levels insufficient to maintain growth control in the absence of E2F binding. Therefore,
there is a need to develop new mouse strains that cause defined change in structure that
disrupts E2F binding of endogenous pRB without interfering with other binding sites or
expression. The generation of this reagent would allow for the study of the functional role
of E2F-independent mechanisms of cell cycle control.

1.9

Objectives

As described in this introductory chapter, pRB can utilize multiple mechanisms to
regulate proliferation and function as a barrier to tumorigenesis. While pRB has the
ability to regulate E2F transcription factors and stabilize p27, the relative importance of
these pathways to a given cell cycle arrest is poorly understood. Furthermore, the
mechanism by which pRB is capable of independently regulating the proliferative and
apoptotic potential of E2F1 has yet to be defined. The overall aim of this thesis is to
utilize multiple experimental systems to better define the molecular role of pRB in cell
cycle control and E2F1 regulation.
First I examined the structural basis for the existence of E2F1-pRB complexes
that were resistant to disruption by CDK phosphorylation. I hypothesized that the
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‘specific site’ may function to regulate the interaction between E2F1 and
hyperphosphorylated pRB. Using a cell culture approach in which the phosphorylation
state and composition of pRB-E2F complexes could be effectively modulated I
characterized the structural basis for these interactions. Further, using site directed
mutagenesis the structural basis of the ‘specific site’ was further defined to elucidate
some of the molecular contacts that mediate the unique ability of E2F1 to interact with
this region of pRB. These results are discussed in detail in chapter 2 of this thesis.
The complexes identified in chapter 2 between hyperphosphorylated pRB and
E2F1 likely exist in cycling cells. Proliferating cultures of primary cells exposed to DNA
damage rapidly activate a cellular program that returns pRB to a hypophosphorylated
state. While PP1 has been implicated in this process the structural basis for this process
was unclear. Our collaborator Dr. Seth Rubin at the University of California, Santa Cruz
produced !"#$%&''()"&*+,! and functional data suggesting that the docking site for CDK
complexes overlapped with the binding site for PP1. We hypothesized that this shared
docking site would produce a competitive binding, in which PP1 could exclude the
docking of CDK complexes to hypophosphorylated pRB species and thus block
phosphorylation. Using a cell culture approach and in vitro binding assays we describe a
functional role for the competition between the overlapping PP1 and CDK docking sites
in the C-terminal domain of pRB to more rapidly activate it. This work published with
the crystallographic and functional data from the Rubin lab (208) is presented in
appendix 1.
Active pRB can arrest cells in the G1 phase of the cell cycle. However, the
contribution of the distinct interaction surfaces to the overall ability to arrest in G1 has yet
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to be elucidated. To advance our understanding of this process, chapter 3 describes the
generation of a series of synthetic mutants that separate distinct elements of cell cycle
control mediated by pRB. I hypothesized that each of these binding sites would
contribute to the overall ability of pRB regulate proliferative. Using the well-studied
ability of ectopic pRB to arrest Saos-2 cells we studied the contribution of these sites in
an acute G1 arrest.
In chapter 3 I suggest that overlapping interaction surfaces function to mediate
proliferative control by pRB. As described in chapter 4 I sought to extend this work using
a series of mouse models to understand the contribution of the distinct elements of pRB
function to cell cycle control. To separate the role of E2F binding from other pathways of
cell cycle control I generated a gene-targeted mouse model in which the ability of pRB to
regulate E2Fs through the ‘general site’ was disrupted. I hypothesized that these mice
would maintain the ability to control proliferation through other mechanisms that occur
independently of the ‘general site’. To further investigate these other pathways we
crossed our animals with mice lacking p27 and E2F1 to assess the role of p27
stabilization and the ‘specific site’ in proliferative control and tumorigenesis.
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2

The biochemical basis of CDK phosphorylationindependent regulation of E2F1 by the retinoblastoma
protein
2.1

Abstract

The pRB (retinoblastoma protein) has a central role in the control of the G1–S phase
transition of the cell cycle that is mediated in part through the regulation of E2F
transcription factors. Upon S-phase entry pRB is phosphorylated extensively, which in
turn releases bound E2Fs to drive the expression of the genes required for S-phase
progression. In the present study, we demonstrate that E2F1-maintains the ability to
interact with ppRB (hyperphosphorylated pRB). This interaction is dependent upon the
‘specific’ E2F1-binding site located in the C-terminal domain of pRB. A unique region of
the marked box domain of E2F1 contacts the ‘specific’ site to mediate the interaction
with ppRB. The mechanistic basis of the interaction between E2F1 and ppRB is subtle. A
single substitution between valine and proline residues in the marked box distinguishes
E2F1’s ability to interact with ppRB from the inability of E2F3 to bind to the ‘specific’
site in ppRB. The E2F1–pRB interaction at the ‘specific’ site also maintains the ability to
regulate the transcriptional activation of E2F1 target genes. These data reveal a
mechanism by which E2F1 regulation by pRB can persist, when pRB is
hyperphosphorylated and presumed to be inactive.
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2.2

Introduction

Disruption of the G1 checkpoint of the cell cycle is a ubiquitous event in essentially
all forms of cancer that allows for inappropriate entry into the cell cycle (1). The
retinoblastoma tumor suppressor protein (pRB) has a central role in the regulation of Sphase entry through its ability to repress the activity of E2Fs (2). E2Fs are potent
transcription factors that function to activate genes required to progress into S-phase.
Mitogenic signaling results in the activation of cyclin-dependent kinase (CDK)
complexes, which phosphorylate pRB, and free E2F transcription factors to drive cell
cycle progression. The RB1 gene is mutated only in a small subset of cancers that include
retinoblastoma and small cell lung cancer (3). Instead, the majority of human cancers
express wild-type pRB that exists predominately in an inactive phosphorylated state due
to deregulation of CDKs (4). Thereby, most human cancers disrupt G1 checkpoint control
upstream of pRB through the deregulation of CDK activity.
Inactivation of pRB by phosphorylation requires the activity of both Cyclin DCDK4/6 and Cyclin E-CDK2 complexes (5). This inactivated form of pRB has often
been defined by its slower migration in SDS-PAGE and is commonly referred to as
hyperphosphorylated, and abbreviated as ‘ppRB’. Hyperphosphorylated pRB has been
shown to contain at least 10 distinct phosphopeptides, indicating that it is extensively
phosphorylated (6, 7), while the faster migrating hypophosphorylated form appears to
have limited phosphorylation of some of the same sites (7, 8). These observations,
combined with mutational analysis of the 16 predicted CDK phosphorylation sites, has
lead to a model in which many phosphorylation sites contribute in a redundant manner to
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the displacement of E2F binding to ppRB (9, 10). The CDK phosphorylation sites are
localized to disordered regions of pRB that flank the well-structured pocket domain (Fig.
2.1a) (11). The small pocket domain consists of two halves termed A and B (Fig. 2.1a)
that each adopt a cyclin-like fold to form a large globular domain that is capable of
interacting with E2F transcription factors (11). Co-crystallization studies have revealed
an interaction between the transactivation domain of E2Fs and the cleft that forms
between the two cyclin-like folds of the pocket domain defined as the ‘general’
interaction (Fig. 2.1b) (12, 13). CDK phosphorylation of pRB results in conformational
changes of the unstructured regions containing the CDK phosphorylation sites that block
the interaction with the transactivation domain of E2Fs (14). In this regard, a relatively
detailed picture of how phosphorylation regulates pRB-E2F interactions has emerged.
However, pRB contains an additional E2F binding site that is utilized exclusively by
E2F1 called the ‘specific’ site (Fig. 2.1b) (15). This interaction is mediated by the marked
box region of E2F1 and the C-terminus of pRB (Fig. 2.1b) (16). The regulatory effects of
CDK phosphorylation on this unique pRB-E2F1 interaction are unknown.
There are eight E2F proteins in mammals that share the ability to regulate E2F
target genes through a conserved DNA binding domain (17). E2F1, E2F2 and E2F3 are
defined as activator E2Fs as they contain strong nuclear localization signals and
transactivation domains that allow them to induce the expression of S-phase targets (17).
pRB exclusively regulates the activity of the activator class of E2Fs indicating that they
have an intimate relationship in cell cycle control (18). Gene-targeting experiments have
demonstrated that a single activator E2F can support development in mice, indicating
considerable redundancy (19). E2F1, however, appears to have a unique role in the
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Figure 2-1 Domain structure of pRB
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induction of apoptosis that is distinct from its role in proliferation. The functional
significance of this is emphasized by the apoptotic defects that occur in the thymus of
E2f1-/- mice and the susceptibility of these mice to multiple tumors including lymphoma
(20, 21). E2F1 has the unique ability to activate the transcription of pro-apoptotic
molecules including ARF, Apaf-1, Caspase 7, Caspase 8, Bid, and p73 (22-26). The
ability of E2F1 to induce both cell proliferation and cell death necessitates a mechanism
by which these contrasting activities can be controlled. Surprisingly, there is little data
available to suggest a mechanism by which E2F1-induced apoptosis is controlled
independently of proliferation. Using experiments that interchange domains from E2F1
and E2F3, the marked box region of E2F1 has been demonstrated to function in the
activation of p73 and p53 induced apoptosis (27). The marked box region is a proteinprotein interaction domain that has been shown to interact with cellular factors, such as
Jab-1 to induce transcription of ARF and apoptosis (28), as well as the ‘specific’ site in
the C-terminus of pRB (Fig. 2.1b), which is capable of attenuating E2F1-induced
apoptosis (15, 16). Based on our current understanding of the regulation of pRB-E2F
interactions by CDK phosphorylation at the G1 to S-phase transition, it is difficult to
reconcile how E2F1’s pro-apoptotic activity is restrained in normal cells as they enter Sphase and E2Fs are released from pRB’s regulation.
Surprisingly, a number of studies suggest the existence of pRB-E2F1 complexes
under circumstances where CDK phosphorylation is expected to disrupt their interaction.
First, ectopic expression of G1 Cyclin-CDKs has been shown to have differential effects
on E2F1 release from pRB, suggesting that this complex may have altered sensitivity to
the kinases relative to other pRB-E2F complexes (29). Second, pRB and E2F1 have been
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found at the same E2F-responsive promoters and CpG islands in S-phase by chromatin
immunoprecipitation (30). Third, following DNA damage, pRB-E2F1 complexes have
been reported to assemble while at least some phosphorylation sites on pRB remain
phosphorylated (31). Unfortunately, none of these reports offer a mechanistic explanation
that accommodates both the release of E2Fs from hyperphosphorylated pRB and the
maintenance of pRB-E2F interactions under the same circumstances.
This study describes a mechanism whereby E2F1 can be bound and regulated by
hyperphosphorylated pRB. This interaction is mediated by the C-terminal ‘specific’
binding site in pRB and the marked box domain of E2F1 (Fig. 2.1b). Despite high
conservation of the marked box region of E2Fs, subtle but important sequence
differences render only E2F1 capable of interacting with the C-terminus of pRB.
Substitution of a single proline to valine in E2F3, to resemble E2F1, is sufficient to create
an interaction with phosphorylated pRB. E2F1 interaction with the ‘specific’ site of pRB
is also capable of regulating the activation of a pro-apoptotic gene promoter, whereas this
interaction has little ability to regulate other E2F1-dependent transcription. Taken
together, this data provides a biochemical basis for the ability of proliferative and
apoptotic functions to be differentially regulated by pRB during cell cycle advancement.

2.3
2.3.1

Methods
Plasmid constructions

Site-directed mutagenesis of a pRB cDNA was carried out by PCR as previously
described (32, 33). Mutants were introduced into the bacterial GST-RBLP (Large Pocket
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Domain) or the GST-RBC (C-terminal domain only) cloned into the pscodon vector
(Delphi Genetics). Mutagenesis of E2Fs was carried out in a similar manner using an E2F
cDNA cloned into pBluescript and later subcloned into the CMV-HA expression vector.
All subclones of PCR products were sequenced to ensure that they only contained the
desired mutations. CMV-HA-E2F1, -E2F2, E2F3, -DP1, and their sources have been
described previously (15). CMV-CDK2, -CDK4 and -DN-CDK2, were reported initially
by van den Heuvel and Harlow, 1993 (34). CMV-Cyclin D and –Cyclin E were reported
initially by Hinds et al., 1992 (35). p73-Luc plasmid was reported initially by Urist et al.,
2004 (36). The myc-PP1 construct was reported by Traweger et al., 2008 (37).

2.3.2

Cell Culture
C33A and T98G cell lines were obtained from ATCC and cultured according to

standard methods. Cell culture was carried out in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum, 2mM L-glutamine, penicillin (50U/mL) and
streptomycin (50µg/mL). The C33A cells were used to generate extracts for GST-pulldown and co-transfection immunoprecipitation experiments. The C33A cells were
transfected using calcium phosphate with the precipitates left on the cells for 16h before
fresh growth medium was added. The T98G cells were used to characterize endogenous
complexes between pRB and E2Fs synchronized by serum starvation for 72 hours in
media with 0.1% fetal bovine serum. The cells were stimulated to re-enter the cell cycle
with media containing 20% fetal bovine serum.
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2.3.3

Immunoprecipitations and Western blotting
GST-pull-down and co-immunoprecipitation assays were performed as previously

described (33). To generate extracts for these experiments C33A cells were plated at a
density of 6 X 106 cells in a 15cm dishes and transfected with a total of 60µg of DNA
using calcium phosphate. 48 hours after transfection the cells were harvested. To generate
extracts for GST pull-down assays the cells were washed twice with phosphate buffered
saline (PBS) and collected into 1mL of Gel Shift Extract (GSE) buffer (20mM Tris pH
7.5, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25% glycerol, 5µg/mL leupeptin,
5µg/mL aprotinin, 0.1mM Na3VO4, 0.5mM NaF and 1mM DTT). Extracts were frozen at
-80°C. To generate extracts for co-immunoprecipitation of pRB-E2F complexes nuclear
extracts were prepared. Briefly, cells were washed twice and collected in 1mL of PBS.
Cells were resuspended in three times the cell volume of hypotonic lysis buffer (20mM
Tris pH 7.5, 10mM KCl, 3mM MgCl2, 1mM EDTA, 1mM PMSF, 1mM DTT, 5µg/mL
leupeptin, 5µg/mL aprotinin, 5mM NaF, 0.1mM Na3VO4 1mM DTT). Extracts were
incubated on ice for 5 min before 0.05% NP-40 was added to the hypotonic lysis buffer
and the extracts were incubated on ice for a further 5 min. Nuclei were pelleted by
centrifugation at 4°C at 4000rpm for 6 min and washed two times with hypotonic lysis
buffer containing 0.05% NP40. Nuclei were resuspended in GSE buffer and frozen at 80°C
Extracts were thawed and cellular debris was removed by centrifugation at 14,000
rpm. For co-transfection immunoprecipitations C33A extract was diluted in IP wash
buffer (20mM Tris pH 7.5, 200mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25mM DTT
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and 0.1% NP-40). pRB complexes were immunoprecipitated with 12CA5 for HA-tagged
E2Fs, C-20 (Santa Cruz) for E2F1 and C-18 (Santa Cruz) for E2F3, bound to protein Gsepharose (GE healthcare). Immunoprecipitations were incubated with rocking for 1
hour at 4°C. The protein G-sepharose beads were washed twice with IP wash buffer then
eluted in 1X-SDS-PAGE sample buffer and resolved by electrophoresis on a sodium
dodecyl sulfate 8% polyacrylamide gel electrophoresis (SDS-8% PAGE) gel. Proteins
were transferred to a nitrocellulose membrane by standard techniques. HA-tagged E2Fs
were detected using 3F10 (Roche), E2F1 by KH20 (Santa Cruz), E2F3 by PG37
(Upstate), Myc-tagged PP1 by 9E10 and pRB by G3-245 (BD Pharmingen).

2.3.4

GST pulldown binding experiments
GST-fusion proteins were expressed in BL21-DE3-Gold E.coli (Stratagene) in

500mL cultures. Briefly, cells were grown for 2 hours at room temperature after which
100µM Isopropyl "-D-1-thiogalactopyranoside (IPTG) was added to the cultures and the
cultures were grown overnight at 16°C. The following morning the cells were harvested
and GST-fusion proteins were purified using glutathione sepharose according to standard
protocols. Purified GST-fusion protein (2µg) was diluted in low salt GSE buffer (20mM
Tris pH 7.5, 200mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 1mM DTT and 0.1% NP-40)
and incubated with 100mL of whole cell C33A extract expressing HA-E2Fs or myc-PP1.
GST-pRB complexes were precipitated with glutathione sepharose and washed twice
with low salt GSE buffer and eluted with 1X-SDS-PAGE sample buffer. Samples were
electrophoresed on an SDS-8% PAGE gel and blotted using the same antibodies outlined
for the immunoprecipitation experiments.
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Luciferase reporter assays

2.3.5

Transcriptional reporter assays were carried out as reported previously (33). Saos-2
cells were plated in 6 well plates at a density of 5 X 105 cells per well. Cells were
transfected with 100ng of the E2F4B-luciferase reporter or 200ng of the p73-Luc reporter
plasmid along with 15ng of CMV-HA-E2F, 15ng CMV-HA-DP1 and 200ng of CMV-!Gal. Increasing concentrations of CMV-pRB expression plasmid were transfected to
block the activity of the transfected E2Fs. Total plasmid DNA was normalized with the
addition of CMV-CD20. Cells were harvested 36 hours after transfection with 1X
Reporter Lysis Buffer (Promega). The luciferase activity was determined with the
Luciferase assay system (Promega) and normalized to !-gal activity. The !-gal activity
was determined using standard techniques to measure the hydrolysis of 2-Nitrophenyl-!-D-galactopyranoside (ONPG) at 405nm. The average of three independent transfections
is shown and the error bars indicate one standard deviation from the mean.

2.4
2.4.1

Results
A unique interaction between E2F1 and
hyperphosphorylated pRB

The disruption of pRB-E2F complexes by phosphorylation is thought to be a
critical event of the G1-S phase transition of the cell cycle. Gel shift experiments have
described the release of E2Fs from pRB upon S-phase entry (38, 39). These experiments
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have often utilized a double-stranded DNA probes from the adenovirus E2 promoter that
contain a canonical E2F site and is bound by E2Fs and pRB-E2F complexes (38, 39).
Complexes formed between pRB and E2F1 using the C-terminal ‘specific’ site have low
affinity for this type of probe (15), and as such pRB-E2F1 ‘specific’ complexes are not
observed in gel shift experiments. Thereby, previous work that has described the release
of E2Fs following cell cycle entry only pertains to the ‘general’ E2F interaction that is
common among E2Fs that interact with pRB. To explore other binding sites that may be
regulated independently of phosphorylation at the G1-S transition we utilized coimmunoprecipitation to directly assess the ability of E2Fs to interact with all binding sites
in ppRB.
T98G cells, which have an intact G1 checkpoint (40), were synchronized by serum
starvation for 72 hours, then induced to re-enter the cell cycle with media containing 20%
serum. Initially, pRB exists primarily in a hypophosphorylated state and further culture of
cells in high serum results in a significant enrichment for ppRB (Fig 2.2a). Extracts from
cells synchronized to enrich for ppRB were immunoprecipitated with E2F1 and E2F3
antibodies. Both E2F1 and E2F3 are capable of interacting with and coimmunoprecipitating pRB (Fig 2.2b). E2F3 only interacts with the hypophosphorylated
form of pRB (Fig. 2.2b) suggesting that phosphorylation disrupts the interaction between
ppRB and E2F3. In contrast, E2F1 can immunoprecipitate both pRB and ppRB as
determined by the electrophoretic mobility of the precipitated proteins (Fig 2.2b). The use
of the shift in apparent molecular weight to detect ppRB ensures that it is extensively
phosphorylated. This provides experimental evidence for complexes between
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phospho-specific antibodies.

Figure 2-2 E2F1 forms a unique complex with ppRB in T98G cells

77

78

endogenous ppRB and E2F1 and suggests there is functional relevance to E2F1
regulation after S-phase entry.
To further characterize the interaction between E2Fs and ppRB, the RB1-null cell
line C33A was utilized. These cells do arrest in response to the ectopic re-expression of
pRB, which allows for its phosphorylation state to be modulated independently of the cell
cycle phase. To produce hypophosphorylated pRB, a dominant negative CDK2 (CDK2DN) was expressed to block the activity of endogenous CDK complexes. Alternatively,
hyperphosphorylated ppRB was produced by expression of CyclinD/CDK4 and
CyclinE/CDK2 complexes (denoted as E2/D4 in Fig. 2.2c). As shown in figure 2.2c,
modulation of the kinase activity is sufficient to shift the ectopically expressed pRB from
a hypophosphorylated to hyperphosphorylated state as determined by the electrophoretic
mobility shift, as well as with phospho-specific antibodies raised against phosphorylated
S807/S811. HA-tagged E2F and DP1 constructs were co-transfected and
immunoprecipitated with a HA-specific antibody. The use of a HA-antibody excludes
potential differences in the E2F1 and E2F3 antibodies to recognize E2F-ppRB
complexes. This provides a system in which the phosphorylation state of pRB can be
modulated to investigate the interaction of ppRB with different E2F transcription factors.
In cells expressing CDK2-DN, both HA-E2F1 and HA-E2F3 are capable of
interacting with pRB, confirming that either can immunoprecipitate pRB in its
hypophosphorylated state (Fig 2.2c,d.). In cells expressing CDKs to produce
predominately ppRB, HA-E2F3 is only capable of interacting with and
immunoprecipitating the small amount of residual hypophosphorylated pRB that remains
(Fig. 2.2d). In contrast, HA-E2F1 is capable of immunoprecipitating ppRB as determined
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by both the electrophoretic mobility shift and with phospho-specific antibodies shown in
figure 2.2c. This suggests that E2F1 has a significant affinity for ppRB that allows for the
formation of stable complexes between these proteins. In contrast, hyperphosphorylation
of pRB is sufficient to abrogate the binding of E2F3, revealing differential regulation of
E2F1 and E2F3 by pRB.
Our experiments demonstrate that complexes between ppRB-E2F1 can be
detected at endogenous levels, suggesting that this interaction occurs as part of normal
cell cycle progression. While both E2F1 and E2F3 are capable of efficiently interacting
with hypophosphorylated pRB, only E2F1 is capable of forming an interaction with
hyperphosphorylated pRB. This demonstrates that the interaction with ppRB is a unique
feature of E2F1 that allows for its independent regulation.

2.4.2

The ‘specific’ interaction is a unique feature of pRB and
E2F1 that mediates the E2F1-ppRB complex
Detailed reports have described the structural mechanisms by which

phosphorylation of pRB results in the release of bound E2F transcription factors. These
studies report that phosphorylation induces multiple conformational changes in pRB that
function to abrogate interaction with E2Fs (10, 14, 41, 42). The interaction between
ppRB and E2F1 observed in this study is an apparent contradiction to the structural
models of pRB phosphorylation. However, many of these previous studies predate the
identification of the ‘specific’ E2F1 binding site found in the C-terminus of pRB (Fig.
2.1b). Therefore, we next sought to determine if the ‘specific’ site mediates the
interaction between ppRB and E2F1.
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The two distinct E2F binding sites on pRB can be studied through the use of
recombinant proteins that contain the entire large pocket of pRB (RBLP) or the Cterminus (RB-C). Recombinant proteins were incubated with extract from C33A cells
expressing HA-E2F and HA-DP1 proteins. As shown in figure 2.3a RBLP is capable of
precipitating complexes with HA-E2F1, HA-E2F2, HA-E2F3 and HA-E2F4. In contrast,
RB-C only precipitated HA-E2F1 in appreciable amounts (Fig. 2.3a.). Taken together this
confirms that RBLP contains both the ‘general’ and the ‘specific’ E2F binding sites while
RB-C essentially contains only the ‘specific’ site. Furthermore, the availability of two
distinct E2F1 binding sites allows E2F1 to adopt both interaction types interchangeably
as shown in figure 2.3b. However, the mechanism by which E2F1 contacts the ‘specific’
site has not been extensively studied and raises the possibility that it may mediate the
observed interaction between ppRB and E2F1.
To assess the interaction of E2F1 at the ‘general’ and ‘specific’ binding sites of
ppRB, mutants of pRB were utilized that disrupt the individual E2F binding sites in
isolation. Previously a mutant termed "G was reported to disrupt the interaction between
pRB and E2Fs at the ‘general’ site (15). This mutant contains substitutions in the A, B
and C-terminal regions, including K873 and K874, which are important contact sites of
CDK2 associated cyclins and is necessary for efficient phosphorylation (43). As a result,
this mutant, defined as Old-"G for this study, is not phosphorylated to the same extent as
the WT protein (Fig. 2.3c). For this reason a new "G mutant was created that selectively
disrupts the ‘general’ E2F binding site while other binding sites remain intact. This
mutant contains R467E and K548E substitutions and is phosphorylated to a similar extent
as WT-pRB when transfected into C33A cells (Fig. 2.3c). In a similar manner to the old80
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(top panels) were detected by western blotting. (B) Schematic diagram outlining the ability of E2F1 to
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Figure 2-3 Differentiating between 'specific' and 'general' E2F interactions with
pRB
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"G mutant, the new "G mutant disrupts the ability of E2Fs to bind to the ‘general’ site
but maintains the ability to interact with E2F1 through the ‘specific’ site. This is
highlighted by the inability of recombinant "G-pRB to interact with HA-E2F2, HA-E2F3
or HA-E2F4 but maintain an interaction with HA-E2F1 (Fig. 2.3d).
As depicted in figure 2.4a the novel "G-pRB mutant and the previously reported
"S mutant (16) provide a means to study the two distinct E2F binding sites. The "G
mutant selectively disrupts the ‘general’ site in order to study the ‘specific’ site, while the
"S mutant disrupts the ‘specific’ site allowing the ‘general’ site to be studied in isolation.
This allows us to determine the binding site that mediates the observed complex between
ppRB and E2F1. In a similar manner to our previous experiments, C33A cells were
transfected with combinations of CDK complexes to modulate the phosphorylation state
of the "G and "S pRB mutants. As shown in figure 2.4b and c both the "G and "S pRB
proteins are extensively phosphorylated by expression of CDK complexes. As shown in
figure 2.4b, E2F1 is capable of immunoprecipitating both the "G-pRB and "G-ppRB
species, suggesting that the ‘specific’ site is sufficient to mediate the observed ppRBE2F1 complex. To investigate this further the "S mutation was employed to selectively
disrupt the ‘specific’ site, thus directing E2F1 to the ‘general’ site. As is shown in figure
2.4c, the "S mutant is also extensively phosphorylated when CDKs are expressed,
however, HA-E2F1 is only capable of interacting with and immunoprecipitating the
hypophosphorylated "S-pRB. The small amount of residual pRB that is precipitated
migrates at the hypophosphorylated size and has almost no detectable phosphorylation at
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(A) Schematic outlining the ability of the !G and !S mutants to selectively block the ‘general’ or ‘specific’
sites in order to study distinct E2F interactions in isolation. (B,C) pRB mutants and HA-E2Fs were
transfected into C33A cells and the phosphorylation state was modulated by the expression of DN-CDK2 or
active Cyclin E/CDK2 and Cyclin D/CDK4 (designated E2/D4). Input levels of transfected proteins are
shown in the left most panels. pRB and ppRB were co-immunoprecipitated with HA-E2F1 and detected by
western blotting. The phosphorylation state of pRB was determined by the electrophoretic mobility shift and
with phospho-specific antibodies raised against phosphorylated S807/S811.

Figure 2-4 The 'specific site' is required for the interaction between E2F1 and
hyperphosphorylated pRB
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S807/S811 (Fig. 2.4c). This reveals a critical role for the ‘specific’ site in ppRB-E2F1
complex formation.
This provides a biochemical basis for the observed ability of E2F1 to maintain an
interaction with ppRB while other E2Fs are released. The ‘specific’ site is necessary and
sufficient to mediate the interaction with ppRB. Furthermore, it reveals that the ‘general’
and ‘specific’ sites are regulated independently from one another, as the ‘general’ binding
site is regulated by CDK phosphorylation while the ‘specific’ binding site is resistant.
Therefore, the ‘specific’ site provides a means for regulating E2F1 independently of cell
cycle position.

2.4.3

Unique structural elements of pRB and E2F1 mediate the
‘specific’ interaction and ppRB-E2F1 complexes
The ‘specific’ site has been previously localized to the C-terminal domain of pRB

and the marked box domain of E2F1 (16), however, there is still little understanding of
the structural basis for E2F1’s unique interaction with pRB at this site. The critical role of
the ‘specific’ site in mediating the complex between hyperphosphorylated pRB and E2F1
underscores the importance of understanding the structural basis for the interaction
between the C-terminus of pRB and E2F1 and motivated us to investigate it in more
detail.
pRB is a member of a family of proteins termed the pocket proteins, which share
a well conserved pocket domain. Interestingly, while the C-terminal region contributes to
E2F binding by all pocket proteins, there is little conservation between the C-terminal
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domains of pRB and its other family members (Fig. 2.5a). Furthermore, p107 and p130
share common sequence elements that are distinct from pRB suggesting that this region
differentiates pRB from its two closest relatives (Fig. 2.5a). To investigate the role of the
C-terminus of pocket proteins in E2F1 binding, we generated GST-C-terminal constructs
of p107 and p130 termed p107-C and p130-C. These constructs consist of the
polypeptides that are aligned in figure 2.5a. They are sequences from p107 and p130 that
begin immediately C-terminal to the small pocket domain and extend to the C-terminus.
These recombinant proteins were incubated with extracts containing HA-E2F1 and HADP1, and complexes were precipitated with glutathione sepharose. Only GST-RB-C is
capable of precipitating HA-E2F1 complexes as shown in figure 2.5b. This suggests that
the ‘specific’ site is a unique feature of pRB that differentiates its interaction with E2F1
from other pocket protein-E2F1 interactions.
Crystallographic data has described the interaction between a fragment of the Cterminus of pRB and the marked box domain of E2F1 and DP1 (42). Since these regions
have previously been mapped as the site of interaction for the ‘specific’ site (16), we
designed experiments to investigate if its structural features contribute to the ‘specific’
E2F1-pRB interaction. This crystal structure shows how a small pRB fragment interacts
with a hydrophobic cleft that is formed by the marked box domain of E2F1 and DP1 (Fig.
2.5c). We used a computational alanine scanning mutagenesis approach to identify
critical interaction sites between pRB and E2F1. The residues identified were largely
hydrophobic and include I831, L832, V833, I835, F839, F845, I848, N849, M851 and
V852 of pRB. Most of these amino acids form contacts found on the #-helix, the loop,
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(A) The ‘specific’ site is a unique feature of RB-C. The C-terminus of the other pocket proteins, p107 and
p130 was determined as the terminal region that extended past the conserved small pocket. The C-termini of
pRB (NP_000312) p107 (NP_002886) and p130 (NP_005602) were aligned using ClustalW and shaded
based on their conservation. Dark shading indicates complete conservation of a specific residue, light
shading represents conservative changes and no shading denotes the absence of conservation. (B)
Recombinant GST fusion proteins with the C-terminal regions of pRB, p107 and p130 were incubated with
extracts expressing HA-E2F1. Complexes were precipitated with glutathione sepharose and bound HA-E2F1
was detected by western blotting. Input levels of the recombinant proteins are shown in the coomassie
stained gel. (C) Hydrophobic contacts of RB-C interact with a hydrophobic cleft formed by E2F1/DP1
heterodimers. The amino acid side chains that contact RB-C are colored in blue. E2F1/DP1 are shaded based
on their hydrophobicity. Crystal coordinates are from PDB:2AZE. (D) Recombinant GST-RB-C proteins
were generated in which the indicated hydrophobic amino acids were changed to alanine. These proteins
were incubated with extracts expressing HA-E2F1/HA-DP1 or Myc-tagged PP1 and precipitated using
glutathione sepharose. The amount of bound HA-E2F1/HA-DP1 or Myc-PP1 was detected by western
blotting and the input levels of the recombinant RB-C proteins were determined by coomassie staining.

Figure 2-5 Characterization of critical structural contacts that define the 'specific
site'
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and !-strand portions of pRB in this structure (Fig. 2.5c). They contact a patch of
hydrophobic residues at the E2F1-DP1 interface (Fig. 2.5c). To test the importance of
these residues in maintaining the interaction between pRB and the marked box domain of
E2F1, RB-C constructs were generated with substitution of the predicted contacts to
alanine. As is shown in figure 2.5d, these amino acids appear to have a critical role in
maintaining the interaction with E2F1 as mutation of any of them is sufficient to disrupt
interaction with E2F1/DP1 in GST-pulldown experiments. To ensure the integrity of the
RB-C proteins, their interaction with Myc-PP1 was characterized. The recombinant RB-C
mutants were incubated with PP1 which is known to interact with this region of pRB
(44), and the ability of the mutants to precipitate PP1 suggests that these are specifically
defective for binding to E2F1 (Fig. 2.5d). This indicates that these residues are essential
components of the ‘specific’ E2F1 binding site in the C-terminus of pRB.
The ‘specific’ site of pRB interacts with a region of E2F1 known as the marked
box. This region is the site of multiple protein-protein interactions and is well conserved
between distinct E2F family members (Fig. 2.6a). The conservation of this region does
not correlate with the selective interaction between the marked box domain of E2F1 and
the ‘specific’ site. This region, shown in figure 2.6a, is largely conserved between E2F1,
E2F2, and E2F3 with a few exceptions. Of particular interest is V276 (denoted by *) in
E2F1. The valine at position 276 of E2F1 is conserved in closely related mammals such
as human, mice and rats but in E2F2 and 3 this residue is strictly conserved as a proline
(Fig. 2.6a). V276 localizes to the distal end of the !-sheet of E2F1 that is in closest
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(A) Alignment of E2F1, E2F2, and E2F3 proteins using ClustalW and shaded to reflect the conservation with
darkly shaded blocks indicating complete conservation of a specific residue, light shaded blocks indicated
partial conservation, and no shading represents residues that have non-conserved substitutions. V276 of
E2F1 is denoted (*). (B) Crystal structure of RB-C (Blue) bound to E2F1 (Red) and DP1 (Green) with V276
of E2F1 highlighted in yellow (PDB: 2AZE). (C) HA-E2F1 mutants V276P and V276A along with HA-E2F3
mutants P329V and P329A were transfected into C33A cells and incubated with recombinant GST-RBLP or
GST-RB-C. Proteins precipitated with glutathione sepharose were detected by western blotting (upper
panels). Input levels of the transfected proteins are shown in the bottom panel. (D) C33A cells were cotransfected with expression plasmids for pRB and HA-tagged forms of E2F1 and E2F3 mutants, along with
DP1. The lower western blots represent the input expression levels of the proteins in these extracts. The
amount of pRB that co-precipitates with HA-E2F is shown in the upper panels. (E) The phosphorylation
status of pRB was modulated using either expression of DN-CDK2 to produce hypophosphorylated pRB or
expression of CDK complexes to produce hyperphosphorylated ppRB. Input expression levels of E2F and
pRB proteins are shown on the left. The interaction of WT-E2F3 and P329V-E2F3 with ppRB was
determined using western blotting to detect the electrophoretic mobility shift of ppRB and with
phosphorylation specific antibodies.

Figure 2-6 Identification of a structural element in E2F1 that defines selectivity for
the 'specific site'
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proximity to the co-crystallized pRB fragment shown in figure 2.6b. The marked box
domain in E2F2 or E2F3, which contains the conformationally restricted proline at this
site, likely adopts a distinct structural conformation compared to E2F1 in this region. For
this reason we expect it to be incompatible for interacting with the ‘specific’ site of pRB
as depicted by this crystal structure.
To investigate the effects of a V276P substitution on the interaction with the
‘specific’ site of pRB, an HA-tagged E2F1-V276P was expressed in C33A cells. Figure
2.6c, shows that the V276P mutant maintains the interaction with RBLP, presumably
through the ‘general’ site. However, this mutant is unable to interact with RB-C, which
measures interactions at the ‘specific’ site. This suggests that the substitution does not
disrupt the overall fold of E2F1 or the interaction with DP1 but selectively disrupts the
interaction with the ‘specific’ site of pRB. Furthermore, substitution of V276A does not
disrupt the interaction with RB-C, suggesting an important role for proline in determining
compatibility for binding to the ‘specific’ site. The V276P-E2F1 mutant was transfected
into C33A cells along with full-length WT-pRB or "G-pRB to further characterize the
interaction of V276P-E2F1 with the ‘general’ and ‘specific’ binding sites. As shown in
figure 2.6d the V276P substitution does not disrupt the interaction with WT-pRB
suggesting that the overall integrity of E2F1 is maintained. The V276P substitution,
however, leads to a partial disruption in the interaction with "G-pRB, which only
contains the ‘specific site’ (Fig. 2.6d). The remaining binding to full length "G-pRB is
likely mediated by contact sites or structural features that exist outside of the C-terminal
domain of pRB. Taken together this suggests that the introduction of the proline in the
marked box domain of E2F1 is sufficient to disrupt the interaction with the ‘specific site’.
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As shown previously, E2F3 is unable to interact with the ‘specific’ site found in
the C-terminal domain of pRB (Fig. 2.3a). Strikingly, substitution of the analogous
proline (P329) to a valine in E2F3 results in a gain of interaction with RB-C (Fig. 2.6c).
Substitution of P329 to alanine in E2F3 is also sufficient to allow E2F3 to interact with
RB-C. This suggests that the inability of E2F3 to interact with the ‘specific’ site is due in
part to P329 and its effect on this region of the marked box domain. To further validate
the ability of the proline in the marked box domain of E2Fs to prevent interactions with
the ‘specific’ site, the "G mutant was employed to selectively disrupt the ‘general’ site in
order to study the interaction with the ‘specific’ site in isolation. As is shown in figure
2.6d, transfected HA-E2F3 is unable to interact with "G-pRB as it is unable to bind to the
‘specific’ site. Once again, substitution of P329V is sufficient to mediate the interaction
with the ‘specific’ site of pRB, as the mutant protein is able to interact with both WT and
"G-pRB. This further confirms that the presence of a proline in the marked box domain
creates a distinct conformation in E2F3 that prevents the interaction with the ‘specific’
site in pRB.
Given the requirement of the ‘specific’ site for the complex between ppRB and
E2F1, the possibility that the P329 in E2F3 functioned to block the interaction with ppRB
was investigated. In a similar manner to previous experiments, WT-E2F3 is unable to
interact with ppRB and only the residual hypophosphorylated species is precipitated by
HA-E2F3 (Fig. 2.6e). However, substitution of P329V in E2F3 results in an enhanced
interaction with ppRB as it is capable of immunoprecipitating pRB phosphorylated at
S807/S811 that is partially shifted in migration (Fig. 2.6e). This further confirms that the
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interaction with ppRB requires the ability to bind to the ‘specific’ site of pRB and this is
blocked by the presence of a proline in the marked box domain of E2F3.
Taken together this provides novel insight into the mechanism by which E2F1 is
capable of forming a unique interaction with the C-terminus of pRB. The ‘specific’ site
contains hydrophobic contact sites that interact with a cleft that is formed by both E2F1
and DP1. The specificity of this site for E2F1 is imparted by V276, since this amino acid
is a proline in other E2Fs. The proline may create a conformation in the marked box in
these E2Fs that does not interact with the ‘specific’ site. This proline in E2F3 also
prevents the interaction with ppRB, thus supporting the importance of the ‘specific’ site
in forming the E2F1-ppRB complex.

2.4.4

The ‘specific’ site maintains the ability to regulate the
transcriptional activity of E2F1
The ‘specific’ site is resistant to disruption by phosphorylation and provides a

means for pRB to selectively interact with E2F1 beyond the G1 phase of the cell cycle.
We sought to investigate the function of these complexes by testing the ability of the
‘specific’ site to regulate E2F dependent transcription. Saos-2 cells were transfected with
HA-E2Fs (and DP1) and a plasmid encoding luciferase under the control of a canonical
E2F response element (pE2F4B-Luc). As shown in figure 2.7a and 2.7b, HA-E2F2 and
HA-E2F3 can both function as potent activators to stimulate transcription of luciferase
from a reporter containing an E2F response element. Co-transfection of increasing
amounts of WT-pRB results in a dose-dependent decrease in this activity (Fig. 2.7a,b).
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(A) The ability of the pRB mutants to control E2F transcriptional activity was measured by luciferase
reporter assays. Saos-2 cells were transfected with luciferase reporter plasmids, a CMV-b-gal plasmid and
the indicated CMV-RB and –E2F expression plasmids. Extracts were prepared two days later and luciferase
activity was normalized to b-gal activity. The E2F4B-Luciferase construct was co-transfected with E2F2 (A),
E2F3 (B) or E2F1(C) to assess the ability of pRB to control transcription of individual E2Fs. (D) A reporter
construct containing the p73 promoter termed p73-Luc was transfected with E2F1 and the pRB mutants to
assess the ability of pRB to regulate a relevant target of E2F1. Each data point represents three independent
transfections with error bars indicating one standard deviation from the mean

Figure 2-7 Transcriptional regulation of E2Fs by pRB through the 'general' and
'specific' E2F binding sites
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This indicates that the WT-pRB is capable of repressing the transcriptional activity of
E2F2 and E2F3. In contrast, the "G mutant is unable to repress the transcription of E2F2
or E2F3 even at the highest level of expression (Fig. 2.7a,b), which is consistent with the
inability of "G to interact with E2F2 or E2F3 (Fig. 2.3d).
In a similar experiment, WT-pRB was shown to regulate the transcriptional
activity of E2F1 (Fig. 2.7c). However, "G-pRB is also capable of regulating the activity
of E2F1, albeit to a lesser extent than the WT-pRB as only the highest expression levels
of "G-pRB affect transcription (Fig. 2.7c). This agrees with the ability of the ‘specific’
site to maintain the interaction with E2F1 in "G-pRB (Fig. 2.3d). To test the possibility
that the ‘specific’ complex between pRB and E2F1 may regulate selective target genes, a
luciferase construct containing the p73 promoter was utilized (p73-Luc). p73 is a wellstudied target of E2F1 and activation of E2F1 by DNA damage has been shown to
enhance the interaction of E2F1 with this promoter (25, 31). Strikingly, "G-pRB was
found to regulate the activation of the p73 promoter to a similar extent as WT-pRB (Fig.
2.7d). This suggests that pRB-E2F1 complexes formed through the ‘specific’ site have
the ability to regulate the expression of particular E2F1 target genes. This implies that
ppRB-E2F1 complexes present in S-phase, or later in the cell cycle, are capable of
negatively regulating E2F1-specific transcriptional targets.

2.5

Discussion

Contrary to current understanding of pRB-E2F regulation, this study suggests that
ppRB can maintain an interaction with E2F1. Our data indicates that E2F1, but not E2F3,
is capable of forming an interaction with ppRB, and that this interaction is dependent on
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the ‘specific’ site of pRB. This suggests a potential mechanism by which phosphorylation
can independently regulate the interaction between pRB and distinct E2F proteins (shown
in Fig. 2.8). In its hypophosphorylated state, depicted in figure 2.8a, pRB is capable of
interacting with E2Fs using the ‘general’ site or the ‘specific’ site. Phosphorylation of
pRB by CDK complexes results in well described structural changes that disrupt E2F
binding to the ‘general’ site (9, 10, 14, 42, 45). Our data, however, indicates that CDK
phosphorylation does not disrupt the ‘specific’ site found in the C-terminus of pRB, and
as a result, ppRB is capable of maintaining an interaction with E2F1. While previous
studies have suggested the existence of E2F1 complexes with phosphorylated pRB, the
mechanism by which phosphorylation of pRB could both disrupt interactions with some
E2Fs and maintain interactions with E2F1 has been unknown. Our data provides a
mechanism that explains the ability of pRB to be phosphorylated on most CDK directed
sites while disrupting only a portion of pRB-E2F complexes.
This study describes the mechanistic basis for the unique ability of E2F1 to interact
with ppRB. The ‘specific’ site of pRB, which is required for the interaction between
ppRB and E2F1, provides the observed selectivity for E2F1 complexes. The selectivity of
the ‘specific’ site is mediated in part by a valine at position 276 in E2F1. All other
mammalian E2Fs, and E2Fs from multiple lower organisms, contain a proline at the
analogous position to V276 in E2F1. This suggests that the ancestral E2F protein
contained a proline at this position. During the divergence of E2F1 from the ancestral
E2F proteins it is likely that the P276V substitution occurred and this was key to
introducing a new interaction site between E2F1 and pRB. This sequence difference
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(A) E2F1, E2F2, E2F3 and E2F4 utilize the ‘general’ or ‘G’ interaction to bind to hypophosphorylated pRB.
This interaction inhibits E2Fs and decreases E2F dependent transcription. In addition to the ‘general’
interaction, E2F1 can interact with the ‘specific’ site (abbreviated as ‘S’) of pRB and this interaction is also
capable of blocking activation of E2F1 targets. (B) Phosphorylation of pRB by Cyclin/CDK complexes
results in a series of conformational changes that prevents the ‘general’ site from interacting with E2F
transcription factors resulting in an increase in cell cycle gene expression. In contrast, the ‘specific’ site is not
disrupted in ppRB and allows it to interact with E2F1 to regulate transcription.

Figure 2-8 Regulation of pRB-E2F interactions by phosphorylation
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provides the means by which E2F1 can be regulated distinctly from other E2Fs and may
have further promoted the divergence of E2F1 function from other E2Fs. E2F1 has a
unique role in the induction of apoptosis that is not observed in other E2F transcription
factors. This ability has raised the question as to how E2F1-induced apoptosis is
attenuated in normal proliferating cells. Traditional models of pRB-E2F regulation
suggest that all E2Fs are released from pRB following its phosphorylation at the G1-S
transition. The ability of cells to maintain viability as they proceed through the cell cycle
suggests that additional mechanisms exist to inhibit the pro-apoptotic potential of E2F1.
Our work has refined this model such that the roles of the two distinct E2F binding sites
are included. As shown in figure 2.8 the ‘general’ site is disrupted by CDK
phosphorylation but ppRB maintains the ability to interact with E2F1 through the
‘specific’ site. Thereby, phosphorylation of pRB results in the release of E2Fs from the
‘general’ site, which drive the expression of cell cycle genes, but maintains the
interaction of E2F1 with the ‘specific’ site, which is capable of regulating E2F1 target
genes.
While the ‘specific’ site is capable of regulating the transcriptional activity of E2F1, this
complex has a relatively low affinity for the canonical E2F DNA response element (15).
The ability of the ‘specific’ site to effectively control the activity of the p73-Luc
promoter suggests that the ‘specific’ site may target pRB-E2F1 complexes to distinct
regions of the genome. This is supported by work that identified targets for pRB and
E2F1 in S-phase of the cell cycle (30). Cells synchronized in S-phase in that report
contained largely ppRB that could be immunoprecipitated on DNA with phospho-specific
antibodies. Taken with the results from our study, it suggests that the observed complexes
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consisted of E2F1 bound to the ‘specific’ site of ppRB. Interestingly the targets of pRB in
S-phase were not observed in other stages of the cell cycle suggesting that ppRB was
capable of localizing to a distinct set of cellular genes (30). Thereby, phosphorylation of
pRB results in complex formation between ppRB and E2F1 through the ‘specific’ site
that may impart an altered DNA binding specificity and the regulation of distinct cellular
targets.
Given that phosphorylation of pRB largely abrogates E2F binding and blocks the
formation of pRB complexes at E2F-target genes few studies have investigated the ability
of ppRB to maintain interaction with chromatin-remodeling factors. The ability of ppRB
to maintain the interaction with E2F1 described in this study raises important questions
regarding the ability of ppRB-E2F1 complexes to recruit chromatin remodeling factors to
E2F1-target genes. Recent work has shown phosphorylated pRB at apoptotic promoters
including p73 in response to DNA damage along with E2F1 and the histone acetyl
transferase P/CAF (31). Interestingly the histone deacetylase HDAC1, which is
commonly found associated with pRB on cell cycle promoters, is absent from the p73
promoter (31). This suggests that the phosphorylation state of pRB may allow for the
recruitment of distinct chromatin remodeling complexes to E2F target genes.
Furthermore, given the distinct interaction surfaces used in the ‘general’ and ‘specific’
complexes it is possible that these two complexes are capable of associating with
different chromatin remodeling factors to give rise to the observed selectivity. Lastly, the
‘specific’ complex containing ppRB and E2F1 may serve as a platform on which to
assemble activating or repressive complexes depending on growth status or other cell
signals.
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The majority of human cancers express functional but inactivated pRB that is
maintained in a hyperphosphorylated state. The ability of ppRB to interact with E2F1
suggests that tumorigenesis may select for cells that maintain pRB in a
hyperphosphorylated state as a means to attenuate E2F1-induced apoptosis while
simultaneously deregulating proliferation. In some cases depletion of pRB in cells that
express predominantly ppRB results in cell death (46), suggesting that the therapeutic
disruption of the ‘specific’ site may provide a means to induce apoptosis in cancer cells
expressing predominately ppRB. In contrast to the retention of wild type pRB, the
majority of human tumors directly inactivate p53 to block the induction of apoptosis (3).
The ability of p53-deficient cancer cells to undergo apoptosis is largely mediated by the
p53 homologue p73, which is strongly activated by E2F1 (47). This further highlights the
therapeutic potential of the ‘specific’ site as it could be utilized as a robust means to
sensitize cancer cells to p73-dependent apoptosis. Taken together this work advances our
understanding of the regulation of pRB-E2F interactions by CDK phosphorylation and
suggests a selective advantage for retention of wild type pRB during tumorigenesis.
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3

The retinoblastoma tumor Suppressor Protein Engages
Multiple Overlapping Pathways to Regulate Cell Cycle
Entry.
3.1

Abstract

The retinoblastoma tumor suppressor protein (pRB) regulates the activity of E2F
transcription factors to control entry into S-phase. Recent work has identified pRB
regulation of p27 as an E2F independent mechanism of growth control. A second E2F
binding site that is unique to E2F1, has also been identified in pRB that may also regulate
proliferation. However, the contribution of these distinct interactions to the overall
activity of pRB is not well understood because they have yet to be compared in a single
study. We report the development of two pRB mutants that selectively disrupt individual
protein interactions with pRB. One mutant substitutes R467E and K548E to disrupt E2F
interactions with the small pocket region of pRB. The other substitutes Y756W to disrupt
LXCXE type interactions with Cdh1 and HDACs. These mutants were utilized in
combination with other mutations to systematically disrupt the known binding sites in
pRB. Importantly the disruption of all E2F binding along with LXCXE interactions was
sufficient to completely abrogate the ability of pRB to regulate cell cycle. When
examining individual interactions, only loss of the ‘general’ E2F binding site results in
even a partial decrease in the ability of pRB to arrest Saos-2 cells. Surprisingly, this
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suggests redundant roles for the regulation of E2Fs and p27 in proliferative control.
Taken together, pRB can engage multiple mechanisms through distinct binding interfaces
to induce a cell cycle arrest.

3.2

Introduction

The retinoblastoma tumor suppressor gene (RB1) was the first identified tumor
suppressor, and inactivation of the RB pathway is a common feature of essentially all
types of cancer (1, 2). The RB protein product (pRB) is a key regulator of entry into the
cell cycle and can control proliferation through the regulation of E2F target gene
expression (3). pRB directly interacts with E2F transcription factors and blocks their
ability to activate the genes required to progress into S-phase of the cell cycle. The
interaction is mediated by a well-conserved region of the pocket domain of pRB that
binds to the C-terminal transactivation domain of E2Fs (4, 5). The complex between pRB
and E2Fs remains capable of binding to DNA and allows pRB to recruit chromatin
remodeling factors through LXCXE binding cleft dependent interactions to participate in
transcriptional repression of E2F target genes (6-8). The distinct binding sites are
outlined in figure 3.1a.
In addition to controlling E2Fs, pRB is capable of regulating the G1-S transition
through the regulation of p27 levels. This regulation is mediated by the ability of pRB to
bind to both Cdh1 and Skp2 to target Skp2 for degradation (9). Degradation of Skp2
prevents it from targeting p27 for destruction that in turn leads to increased p27 levels to
block cyclin dependent kinase activity. Furthermore, pRB’s ability to interact with Skp2
competitively inhibits Skp2-p27 interactions (10). The interaction with Cdh1 is mediated
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(A) Diagram of the pocket domain structure of the pRB protein is shown at the top. The location of the A, B,
and C regions is shown. The minimal fragments of pRB that mediate the indicated binding interactions are
highlighted. (B) The structure of pRB (blue) in complex with E2F1 (red) (PDB:1O9K). Surface exposed
residues of pRB that contact conserved residues in the E2F1 derived peptide are highlighted in yellow. (C)
Conservation of the co-crystallized E2F1 peptide sequence amongst other E2F transcription factors.
Conserved interactions between K548, K530, and R467 and acidic amino acids in E2Fs are indicated by
lines.

Figure 3-1 Rationale and design for a novel !G-pRB mutant
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in part by the LXCXE binding cleft contained within the B region of pRB. Mutants of
pRB that disrupt other functions of pRB including the partially penetrant R661W allele
remain capable of regulating proliferation through the Cdh1-Skp2-p27 axis (9, 10),
suggesting that this regulation has a crucial role in cell cycle regulation.
In addition to regulating proliferation, pRB has the ability to negatively control
E2F1 induced apoptosis. E2F1 is unique amongst the E2F transcription factors as it has
the ability to induce both proliferation and apoptosis. This necessitates a mechanism by
which E2F1-induced apoptosis can be restrained in normal proliferating cells. Recently it
has been shown that pRB contains two distinct E2F binding sites that can control these
contrasting functions (11-13). The first binding site termed the ‘general’ site is capable of
interacting with E2F1-4 and is described above to have a critical role in controlling E2F
induced proliferation. The second binding site forms a unique interaction with E2F1 near
the C-terminus of pRB and it is known as the ‘specific’ site. While the ‘specific’ E2F1
interaction can potently block E2F1 induced apoptosis, disruption of this interaction in
combination with other mutations in pRB suggests it can affect proliferative control
under certain circumstances (13).
Much of our understanding of pRB’s mechanism of action in G1 regulation has
come from studying its re-expression in the RB1 deficient osteosarcoma cell line, Saos-2
(9, 10, 14-22). From studies using re-expression of pRB we have come to appreciate that
it represses E2F transcription coincident with a G1 arrest (23). Interestingly, experiments
that demonstrate the cell cycle regulatory properties of Cdh1 and Skp2 in proliferation
use Saos-2 based cell lines with tetracycline inducible pRB expression. This raises the
question of whether pRB uses different arrest mechanisms (E2F vs. Cdh1-Skp2) based on
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an unknown difference in cellular context of these experiments, or if both mechanisms
co-exist in a single cell cycle arrest event. Furthermore, pRB has been shown to form
mutually exclusive complexes with E2F1 and Cdh1 (24) suggesting that there may be
some level of competition between these mechanisms of cell cycle arrest. Taken together
it is unclear how these pathways co-exist in proliferative control.
In this report we sought to investigate the relative contributions of E2F and Cdh1Skp2 regulation in cell cycle control. We describe the development of a number of pRB
mutants with discrete defects in interacting with E2Fs or chromatin regulators and Cdh1.
This has allowed us to establish a map of the protein interactions necessary for pRBinduced arrest of Saos-2 cells. Surprisingly, no single contact site on pRB is absolutely
essential for proliferative control. Instead, our work suggests that cell cycle control by
pRB is carried out through a redundant mechanism that incorporates E2F regulation of
transcription and Cdh1-Skp2 control of cyclin/cdk activity simultaneously.

3.3
3.3.1

Methods
Plasmid constructions

Site-directed mutagenesis of a pRB cDNA was carried out by PCR as previously
described (17, 25). Mutants were introduced into the bacterial GST-RBLP (Large Pocket
Domain) expression vector pscodon (Delphi Genetics). All subclones of PCR products
were sequenced to ensure that they only contained the desired mutations. Mutants were
cloned as an AccI/NheI fragment into the CMV-pRB expression construct. CMV-HAE2F1, -E2F2, E2F3 and E2F4, CMV-HA-DP1, CMV-TAg, CMV-!-Gal, CMV-CD20,
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pE2F4B-Luc p107(-280)-Luc and pBB14 and their sources have been described
previously (12). The CMV-Myc-Cdh1 expression plasmid was a generous gift from Nick
Dyson (MGH, Boston, MA, USA).

3.3.2

Cell Culture
Saos-2, C33A and HeLa cell lines were obtained from ATCC and cultured

according to standard methods (17). Cell culture was carried out in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum, 2mM L-glutamine, penicillin
(50U/mL) and streptomycin (50µg/mL). The C33A cells were used to study protein
interaction to generate extracts for GST-pulldown and co-transfection
immunoprecipitation experiments as well as for the E2F1 induced apoptosis assay. C33A
cells were transfected using calcium phosphate with the precipitates left on the cells for
16h before fresh growth medium was added. The Saos-2 cells were transfected with
Fugene 6 (Roche) as recommended by the manufacturer. These cells were used for the
luciferase reporter and the cell cycle arrest assays.

3.3.3

Immunoprecipitations and western blotting
GST-pull-down and co-immunoprecipitation assays were performed as previously

described (17) except figure 3.5b where HeLa nuclear extracts were used as described in
Isaac, et. al. (26) and figure 3.6a which used the methods published in Binné et. al. (9).
To generate extracts for these experiments C33A cells were seeded at 6 x 106 cells in
15cm dishes and transfected with a total of 60µg of DNA using calcium phosphate. 48
hours after transfection the cells were washed twice with phosphate buffered saline (PBS)
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and collected into 1mL of Gel Shift Extract (GSE) buffer (20mM Tris pH7.5, 420mM
NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25% glycerol, 5µg/mL leupeptin, 5µg/mL
aprotinin, 0.1mM Na3VO4, 0.5mM NaF and 1mM DTT). Extracts were freeze-thawed at
-80 C and cellular debris was removed by centrifugation at 14,000 rpm. For cotransfection immunoprecipitations C33A extract was diluted in IP Wash buffer (20mM
Tris pH 7.5, 200mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25mM DTT and 0.1% NP40). pRB complexes were immunoprecipitated with 12CA5 (#-HA) for HA-tagged E2Fs
or PAB419 (#-TAg), bound to protein G-sepharose (GE healthcare).
Immunoprecipitations were incubated with rocking for 1 hour at 4°C. The protein Gsepharose beads were washed twice with IP wash buffer then resuspended in 1X-SDSPAGE sample buffer and boiled at 95 C for 5 min to elute the bound proteins. The eluted
material was resolved by electrophoresis on sodium dodecyl sulfate-8% polyacrylamide
gels (SDS-8%PAGE) gel. Proteins were transferred to a nitrocellulose membrane by
standard techniques. HA-tagged E2Fs were detected by the 12CA5 monoclonal
antibody, Myc-tagged Cdh1 by 9E10, TAg by PAb419, pRB by C36 or G3245 (BD
Bioscience), Skp2 by sc-7164 (Santa Cruz), HDAC by sc-6298 (Santa Cruz), RbAp46 sc8272 (Santa Cruz) and RBP1 by LY11.

3.3.4

GST pulldown binding experiments
GST-fusion proteins were expressed in BL21-DE3-Gold E.coli in 500mL

cultures. Briefly, a 25mL culture of cells containing the GST-fusion protein cloned into
either pscodon (Delphi Genetics) or pGEX 4T-2 were grown overnight at room
temperature with ampicillin. The following day the 25mL culture was used to inoculate
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500mL of LB media in a 2L flask. The cells were grown for 2 hours at room temperature
after which 100µM Isopropyl "-D-1-thiogalactopyranoside (IPTG) was added to the
cultures for overnight growth and protein induction at 16°C. The following morning the
cells were harvested and GST-fusion proteins were purified using glutathione sepharose
according to standard protocols. Extracts for GST-pulldowns were prepared in a similar
manner to the co-transfection immunoprecipitation experiments with transfected C33A
cells. Purified GST-fusion proteins (2µg) were diluted in low salt GSE buffer (20mM
Tris pH 7.5, 200mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 1mM DTT and 0.1% NP-40)
and incubated with 100µL of C33A extract expressing E2Fs or other pRB interacting
proteins. For Cdh1 interaction studies 100ng of GST-RBLP was used with 10µL of
extract expressing myc-Cdh1. GST-pRB complexes were precipitated with glutathione
sepharose and washed twice with low salt GSE buffer and eluted with 1X-SDS-PAGE
sample buffer. Samples were subjected to western blot using the same antibodies outlined
for the immunoprecipitation experiments. For interaction with CRFs in figure 3.5b HeLa
nuclear extract was utilized. For GST-E7 pulldown experiments 2µg of recombinant
GST-E7 was used to pulldown pRB from C33A cell extracts. The GST-E7 was a
generous gift from Biljana Todorovic and Joe Mymryk (University of Western Ontario,
London, Ontario)

3.3.5

Luciferase reporter assays
Transcriptional reporter assays were carried out as reported previously (17).

Saos-2 cells were plated in 6 well plates at a density of 5 X 105 cells per well. Cells were
transfected with 100ng of the E2F4B-luciferase reporter or 200ng of the p107-Luc
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reporter plasmid along with 15ng of CMV-HA-E2F, 15ng CMV-HA-DP1 and 200ng of
CMV-!-Gal. Increasing concentrations of CMV-pRB expression plasmid were
transfected to block the activity of the transfected E2Fs. Total plasmid DNA was
normalized with the addition of CMV-CD20. Cells were harvested 36 hours after
transfection with 1X Reporter Lysis Buffer (Promega). The luciferase activity was
determined and normalized to !-gal activity. The !-gal activity was determined using
standard techniques to measure the hydrolysis of 2-Nitrophenyl !$D-galactopyranoside
(ONPG) at 405nm. The average of three independent transfections is shown and the error
bars indicate one standard deviation from the mean.

Flow cytometry assays

3.3.6
3.3.6.1

Cell Cycle

Saos-2 cells were transfected and harvested as previously described (17). Briefly
1 X 106 cells were plated in 6cm dishes and transfected with 0.75µg of CMV-pRB 1µg of
CMV-CD20 and 3.25µg of CMV-!-gal or 1µg of CMV-CD20 and 4µg of CMV-!-gal
using Fugene 6 (Roche). Cells were re-plated in 10cm dishes 24 hours after transfection
and harvested 72 hours after transfection. Cells were stained with propidium iodide (PI)
and fluorescein conjugated anti-CD20 antibody prior to flow cytometric analysis. The
percentage of CD20 positive cells with 2N DNA content was quantified. The graph
displays the average of three independent transfections and error bars represent one
standard deviation from the mean.
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3.3.6.2

Apoptosis

E2F1-dependent apoptosis was measured in transfected C33A cells as previously
reported (12). One million cells were plated in 6cm dishes and transfected using calcium
phosphate. 0.25µg of CMV-HA-E2F1 and CMV-HA-DP1 or 0.5µg CMV-!-gal was
transfected along with 1µg of pBB14 (membrane bound GFP expression vector) and
8.5µg CMV-HA-pRB or CMV-HA-!-gal. Adherent and floating cells were harvested and
stained with PI prior to analysis by flow cytometry. The population of GFP positive cells
with less than 2N DNA content was quantified. All graphs display the average of three
independent transfections and error bars represent one standard deviation from the mean.

3.3.7

Determination of protein stability
C33A cells were transfected with CMV-pRB mutant constructs using calcium

phosphate in 15cm dishes at a density of 6 million cells per plate. The following morning
the plates were washed twice with PBS and split onto 6, 6cm dishes. 24 hours later,
100µg/mL cycloheximide was added to each plate and plates were harvested at 0, 3, 6, 9,
12 and 15 hour time points. Extracts were prepared from the cells and 25µg of total
protein was loaded in each lane of the gel. The relative levels of pRB were determined
by western blotting using the pRB antibody G3-245 (BD Pharmingen).
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3.4
3.4.1

Results
Disruption of the ‘general’ E2F binding site

The interaction of Cdh1 and Skp2 with pRB offers a relatively new and largely
unexplored means by which pRB can control cell cycle advancement. Recent work by
Binné et al. has revealed that the previously generated pRB mutant that is defective for
E2F binding (called "G because it disrupts the ‘general’ E2F interaction), is also partially
defective for Cdh1 binding (9). Because the precise interaction site of Skp2 on pRB is
unknown, and the overlapping nature of all of these interactions with pRB, it is difficult
to define how they each contribute to pRB’s ability to control proliferation (Fig. 3.1a). To
better understand the relative contribution of E2F and Cdh1 binding to overall growth
control by pRB, we sought to develop a new mutant allele that selectively disrupts E2F
binding to the pRB pocket domain.
We were aided by two crystal structures that define the interface between pRB
and E2Fs at the ‘general’ E2F binding site (Fig. 3.1b)(4, 5). This binding site is formed in
part by a cleft that is shaped by the A and B regions of the pocket domain of pRB (Fig.
3.1b). The co-crystallized E2F peptide contacts predominantly the A box of pRB through
the ends of the bound peptide (4, 5). The amino acids in the E2F peptide that mediate this
interaction with pRB are conserved among E2Fs that are known to bind to pRB (Fig.
3.1c). This suggests that these are key sites of contact between pRB and E2Fs. In an
effort to minimize the number of mutations required to disrupt this interaction, and take
advantage of the electrostatic nature of these conserved contacts, we introduced acidic
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amino acids in place of well conserved basic residues in pRB. Specifically the following
substitutions were generated; K530D, K548E and R467E.
Mutation of R467E, K548E, or K530D individually were insufficient to abrogate
binding of E2Fs at the ‘general site’ as determined by GST-pull down experiments
summarized in Table 3.1. The R467E and K548E combination was sufficient to disrupt
binding of E2F2 and E2F3 in immunoprecipitation-western blotting or GST-pulldown
experiments (Fig. 3.2a). We define this set of mutations as "Gn throughout the
remainder of this study and use it to disrupt the ‘general’ E2F binding site. As outlined in
figure 3.2b, E2F1 can bind to pRB through either of two distinct interaction sites.
Disruption of the ‘general’ E2F binding site is insufficient to disrupt E2F1 binding to
pRB (12), as E2F1 simply uses the ‘specific’ binding site instead (Fig. 3.2b) (13). In a
similar manner the "Gn mutant retained the ability to interact with E2F1 (Fig. 3.2c and
Table 3.1). However, combining the "Gn mutant with the previously reported mutant that
disrupts the ‘specific’ site ("S) drastically reduces E2F1 binding (Fig. 3.2c). This
indicates that the "Gn mutation allows for the disruption of E2F1-4 binding to the
‘general’ E2F binding site on pRB, while leaving other distinct binding sites intact.
Taken together, these experiments reveal that the "Gn mutant is ideal for studying
E2F regulation, as this mutant has discrete defects in E2F interaction.
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3.4.2

The "Gn mutant is defective in controlling E2F dependent
transcription.
In addition to disrupting the interaction of E2Fs with pRB the "Gn mutant is

defective in regulating the transcriptional activity of E2F transcription factors. A p107Luciferase reporter construct was used because pRB regulates its transcription in an E2F
dependent manner (27). In figure 3.3a WT-pRB is able to repress the p107-Luciferase
construct in a dose dependent manner by blocking the ability of endogenous E2F
transcription factors to activate the p107-luciferase reporter. Conversely, the "G and the
"Gn mutant did not repress p107-Luc construct activity, suggesting that the ability to
control E2F dependent transcription is abrogated in the "Gn mutant.
In order to dissect the ability of the pRB mutants to regulate the activity of
specific activator E2Fs, the individual E2Fs were expressed and the ability of the pRB
mutants to block their transcriptional activation of the E2F4B-Luciferase reporter was
measured. The E2F4B-luciferase construct has been shown previously to measure E2Factivated transcription from 4 tandem E2F binding sites (17, 28). Figures 3.3b and c show
that WT-pRB is able to repress E2F2 and E2F3 activity, but the "Gn mutant is again
unable to repress the transcription of either E2F2 or E2F3. Taken together, these data
indicate that the "Gn mutant and the "G mutant function similarly in that they do not
repress endogenous E2F activity and that of ectopically expressed E2F2 or E2F3. We
also investigated the transcriptional regulation of E2F1 by the "Gn mutant (Fig. 3.3d). In
this case, increasing levels of the pRB "Gn mutant resulted in distinct repression of E2F1
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(A,C) C33A cells were co-transfected with expression plasmids for pRB and HA-tagged forms of E2F1,
E2F2 or E2F3 with DP1. The lower western blots represent the input expression levels of the proteins in
these extracts. The amount of pRB that co-precipitates with HA-E2F is shown in the upper panel. (B)
Diagram outlining the two mechanisms by which E2F1 can interact with pRB through the ‘general’ or the
‘specific’ sites. The pRB DG mutant blocks the interaction at the ‘general’ while allowing E2F1 to bind to
the ‘specific’ site. Combination of the DG and DS mutants disrupts all E2F1 binding to pRB. To study pRB
binding to E2F1 through the ‘general’ site, the !S mutant was used to disrupt binding at only the ‘specific’
site. (C) This approach was used to characterize the effects of the R467E, K548E mutations in pRB on E2F1
binding.

Figure 3-2 The !Gn mutant disrupts the 'general' interaction in the pRB pocket
domain
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Table 3-1 Summary of binding characteristics of new !G mutants

Summarized data obtained from both GST-pulldowns and co-transfection immunoprecipitation experiments
with the pRB mutants. All binding is relative to WT-pRB. ++ Indicates binding equal to WT, + indicates
reduced binding compared to WT, - indicates little to no detectable binding. ND: Not Determined.
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(A) The ability of the pRB mutants to control E2F transcriptional activity was measured by luciferase
reporter assays. Saos-2 cells were transfected with luciferase reporter plasmids, a CMV-b-gal plasmid and
the indicated CMV-RB plasmids. Extracts were prepared two days later and luciferase activity was
normalized to b-gal activity. (A) The ability of the pRB mutants to utilize endogenous E2Fs and repress a
p107-Luc reporter was determined (B-D) The E2F4B-Luciferase construct was co-transfected with E2F1,
E2F2, or E2F3 and CMV-pRB constructs to assess the ability of pRB to control transcription of individual
E2Fs. Each data point represents three independent transfections with error bars indicating one standard
deviation from the mean.

Figure 3-3 The !Gn is defective in controlling E2F dependent transcription
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activity in a dose-dependent manner. This effect is consistent with regulation occurring
through the ‘specific’ E2F1 interaction site that remains in the "Gn mutant. This effect
was also observed with the "G mutant and its ability to regulate E2F1 separately from
other E2Fs has been previously published (16). These experiments show that "Gn pRB
exhibits a discrete defect in regulating E2F transcription factors demonstrated by
transcription reporter assays, as well as protein-protein interaction assays.

3.4.3

The pRB "Gn mutant is stably expressed and other binding
sites are maintained
We measured the stability of the "Gn mutant because other pRB mutations have

been found to disrupt overall protein stability. CMV expression vectors encoding WTpRB or "Gn-pRB were transfected into C33A and relative stability was monitored by
blocking protein synthesis with cycloheximide. Levels of pRB were assessed by western
blotting over a 15 hour time course (Fig. 3.4a) and the "Gn mutant was found to be as
stable as WT-pRB with an approximate half-life of 12 hours.
Previous studies have shown that the ‘specific’ site is required for pRB to block
apoptosis induced by E2F1-(13, 16). Furthermore, disruption of the ‘general’ site
enhances the ability of pRB to block apoptosis suggesting that when E2F1 is forced to
bind to the ‘specific’ site there is an active role for this complex in repressing apoptosis.
To further validate the activity of the ‘specific’ site we investigated its ability to regulate
E2F1 induced apoptosis. As is shown in figure 3.4b the "Gn mutant can repress E2F1induced apoptosis equivalently to "G.
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(A) CMV-pRB expression constructs were transfected into pRB deficient C33A cells and the stability of the
transfected proteins was determined by inhibiting protein synthesis with cycloheximide. The level of
transfected pRB was determined every three hours over a 15 hour time course by western blotting. (B) The
ability of the E2F1 binding site in the "Gn mutant to block E2F1 induced apoptosis was tested. C33A cells
were transfected with pRB and E2F1/DP1 expression plasmids and a GFP reporter. Two days later the
percentage of GFP positive cells with less than 2N DNA was measured using propidium iodide staining and
flow cytometry. Each measurement is an average of three experiments and error bars indicate one standard
deviation. (C) Plasmids expressing pRB-mutants and TAg were transfected into C33A cells and pRB was
co-immunoprecipitated with TAg. Input levels of expressed proteins are shown in the lower panels and
relative levels of bound protein are shown in the upper panel

Figure 3-4 Stability and apoptotic regulation by the !Gn mutant
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Lastly, to ensure that the LXCXE cleft is maintained in the "Gn mutant, we also
investigated the ability of TAg to bind to this pRB mutant in an immunoprecipitation and
western blotting experiment (Fig. 3.4c). TAg is capable of forming a complex with the
"Gn mutant in an analogous manner to WT pRB and the "G mutant. Together, these
experiments suggest that both the LXCXE binding cleft and the E2F1 ‘specific’ site are
maintained in the "Gn mutant. Furthermore, the similar stability of the "Gn mutant to
wild type indicates it can selectively disrupt E2F binding without altering other aspects of
pRB’s function.

3.4.4

Selective disruption of LXCXE binding cleft dependent
interactions with chromatin remodeling factors.
In order to create a pRB mutant that is functionless in cell cycle control, it is

necessary to demonstrate that it is stable and capable of at least one type of protein
interaction to rule-out a non-specific loss of function. To this end we generated a mutant
that substitutes Y756 for tryptophan, termed "CRF. Y756 is found in the LXCXE
binding cleft in the B region of the small pocket of pRB. It is found on the same helix as
the M761, N757 and I753 residues that were substituted in the previously reported pRB
"L allele that is defective for binding to chromatin regulators, such as HDACs, and viral
proteins that use an LXCXE motif (17, 25). Figure 3.5a depicts a peptide containing the
LXCXE sequence derived from the viral oncoprotein E7 bound to pRB (29). The "L
substitutions shown in orange directly contact the E7 peptide while the Y756 residue fills
part of the cleft that defines this binding site and does not directly contact the E7 peptide.
The substitution of Y756W in the "CRF mutant is sufficient to disrupt the interaction
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Figure 3-5 The !CRF mutant selectively disrupts the interaction with chromatin
remodeling factors
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with chromatin remodeling factors including HDAC1, HDAC2, RbAp46 and RBP1 in a
GST-pulldown assay (Fig. 3.5b). However, the interaction with viral oncoproteins is
maintained in the "CRF mutant (Fig. 3.5c). The interaction with GST-E7 ensures that
when combined with other mutations that disrupt protein-protein interactions with pRB, a
single remaining interaction can be used to characterize the overall integrity of the pocket
domain of pRB. As shown in figure 3.5c the "Gn+"CRF+"S mutant retains the ability to
interact with GST-E7 suggesting that the pocket domain is intact in this mutant.
Furthermore, the stability of the "Gn+"CRF+"S is not affected given that it has a
similar half-life to WT-pRB when transfected into C33A cells (Fig. 3.5d). Taken
together, the "CRF mutant selectively disrupts the interaction with chromatin remodeling
factors while maintaining overall stability and structural integrity. These properties are
critical to the interpretation of cell cycle arrest experiments using these mutants.

3.4.5

Selective abrogation of Cdh1 and pRB interactions using the
"CRF mutant.
The retinoblastoma protein acts as a scaffold to bring together APC-Cdh1 and

Skp2 leading to Skp2 ubiquitylation and degradation. Loss of interaction through the
LXCXE binding cleft on pRB prevents APC-Cdh1 dependent degradation of Skp2 and is
reported to cripple pRB dependent cell cycle arrest (9). In addition to disrupting the
interaction with chromatin remodeling factors, the "CRF mutant greatly reduces the
interaction with Cdh1. A GST-pulldown assay is shown in figure 3.6a examining the
interaction properties of our pRB mutants with Cdh1 that demonstrates this property and
also confirms that "Gn is not deficient for this interaction. Since Cdh1 uses pRB to
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Figure 3-6 The !CRF mutant selectively disrupts the interaction with Cdh1
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capture Skp2 it is also important to confirm that Skp2 binds to pRB normally. Since the
precise binding site for Skp2 in the C-terminus of pRB is unknown and the "S
substitutions that we are using are found within this part of pRB, we tested the ability of
C-terminal fragments of pRB to interact with Skp2. Figure 3.6b shows that a C-terminal
fragment of pRB (RBC) that contains the "S mutation interacts with Skp2 to a similar
extent as the WT protein. In this way, the pRB "CRF mutant creates a discrete loss of
Cdh1 binding, but pRB’s ability to recruit Skp2 is retained in this C-terminal mutant.
Therefore this mutation allows us to disrupt this aspect of growth control by pRB at the
level of Cdh1 recruitment. This collection of mutants permits examination of the relative
contributions of E2Fs through their two types of interaction with pRB as well Cdh1
targeting of Skp2 to cell cycle control.

3.4.6

Separating the relative contributions of E2F and Cdh1
interactions in cell cycle control by pRB.
The "Gn mutant allows separation of E2F binding to the ‘general site’ from other

functions of pRB including interaction with Cdh1. To investigate the contribution of
these various binding sites to overall cell cycle control by pRB, we generated mutants
that contained combinations of our "Gn, "S and "CRF substitutions. The amino acid
substitutions and properties of the mutant combinations are summarized in Table 3.2. The
relative activity of these mutants to arrest proliferation was characterized using the wellstudied Saos-2 cell cycle arrest assay. CMV-pRB was expressed at the minimum level
needed to achieve maximal growth suppression; the CMV-pRB mutants were then
expressed using the same conditions to assess their ability to control proliferation.
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(A-C) Saos-2 cells were transfected with CMV-CD20 and CMV-pRB constructs and replated at low density
to give the cells the ability to proliferate. Two days later cells were stained with an anti-CD20 flourescein
conjugated antibody and propidium iodide. The percentage of cells with G1 DNA content, that were CD20
positive, was determined by flow cytometry. (A) Cell cycle distribution of CD20 positive cells transfected
with b-gal, WT-pRB or !Gn+!CRF+!S-pRB. (B-D) Graphical representation of the mean percentage of
cells with G1 DNA content from at least three independent transfections. (E) Data from all experiments was
compiled and compared directly by scaling pRB’s relative cell cycle arrest ability to the change in the
percentage of G1 cells. Error bars represent one standard deviation from the mean. * denotes a statistically
significant difference between the indicated measurements using a t-test (P<0.05).

Figure 3-7 Multiple protein interactions are necessary for a G1 arrest
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Table 3-2 Disruption of distinct binding sites by pRB mutants

++ denotes binding site is intact, + indicates the binding site is partially disrupted and – indicates that the
binding is undetectable. ND: Not Determined.
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Combined disruption of both types of E2F interaction and the LXCXE binding cleft in
the "Gn+"CRF+"S mutant completely disrupts the ability of pRB to regulate
proliferation given that it is not statistically different from the !-gal negative control (Fig.
3.7a and b). This suggests that the E2F and LXCXE binding sites mediate the cell cycle
control activity of pRB dectectable by this assay. Surprisingly, disruption of the
‘general’ E2F binding site in the "Gn mutant is sufficient on its own to reduce pRB’s
ability to block proliferation (Fig. 3.7c and d). Combined disruption of the ‘general’ site
along with disruption of the LXCXE binding cleft ("CRF) or disruption of the E2F1
‘specific’ site ("S) resulted in a further decrease in the ability of pRB to induce a cell
cycle arrest (Fig. 3.7d). Interestingly, neither the "CRF nor the "S mutations alone
compromise pRB’s ability to control cell cycle advancement. Each of these experiments
were assessed side-by-side to facilitate t-test analyses (Fig. 3.7e). All of the above
mentioned differences are statistically significant (P<0.05).
These results reveal a surprising degree of flexibility by pRB in growth control
whereby it can engage multiple growth suppressive pathways as needed. In particular,
some of these pathways are only required when others are compromised.

3.5

Discussion

pRB acts as an adapter protein to interact with various cellular proteins through
distinct binding surfaces to control cell proliferation. In this report we describe the
generation and combination of mutants that allow us to discretely and quantitatively
account for pRB’s growth suppression activity. To quantify the activity of pRB we
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‘general’ E2F site the interaction with Skp2 and Cdh1 or the interaction with E2F1 through the ‘specific site’
can act to maintain proliferative control by pRB.

Figure 3-8 Model of pRB proliferative control

129

130

expressed the pRB mutants into Saos-2 and measured the percentage of cells arrested in
G1. We find that disruption of both types of E2F interactions and p27 regulation is
required to fully abrogate cell cycle control by pRB. This suggests that pRB utilizes a
number of distinct mechanisms to control cell cycle arrest as depicted in figure 3.8. The
regulation of E2Fs through the pRB ‘general’ site appears to have a dominant role in cell
cycle control because the "Gn mutant was the only single mutant that altered
proliferative control by pRB. The ‘general’ E2F binding site of pRB functions by
interacting with and blocking the transactivation region of E2F1-4. The dominant nature
of E2F regulation fits with the essential role for activator E2Fs in proliferation, as
fibroblasts lacking E2F1-3 are unable to enter into S-Phase (30) and E2Fs are required for
proper development in mice (31). The mechanism by which E2F regulation has a
dominant role may involve the mutually exclusive nature of E2F and Cdh1 complexes
with pRB that was recently described (24).
While the ‘general’ E2F binding site appears to have the most prominent role in
controlling proliferation, its loss in isolation still leaves pRB with greater than 50%
activity in our assays. For this reason, the LXCXE binding site and the ‘specific’ E2F1
binding site also have important roles in cell cycle regulation even though they appear
redundant with other growth arresting mechanisms. This is consistent with the fact that
fibroblasts derived from mice carrying a mutation in the Rb1 gene that disrupts the
LXCXE binding cleft have normal cell cycle entry control (26). Chromatin remodeling
factors, such as HDACs, interact with the LXCXE binding cleft and are recruited to
promoters through pRB in an E2F dependent manner. Disruption of E2F binding in "Gn
pRB will leave the interaction with CRFs intact but prevent their recruitment to E2F
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target genes. Since disruption of the LXCXE binding cleft by the "CRF mutant in
conjunction with the "Gn substitution acts to further reduce the activity of pRB, it is
unlikely that the added effect of LXCXE disruption is mediated by CRFs. pRB can
however, regulate the levels of p27 independently of E2F activity through the interaction
with Cdh1 and Skp2. The interaction with Cdh1 is greatly reduced in the "CRF mutant of
pRB, which in turn disrupts the ability of pRB to regulate the levels of Skp2, and in turn
p27 levels (9). Since functions associated with the LXCXE binding cleft occur
independently of E2F binding we suggest that LXCXE motif interactions are critical to
control cell cycle in the absence of E2F binding in our assays.
However, disruption of these two distinct pathways is insufficient to completely
abrogate the activity of pRB, as the "Gn+"CRF is still capable of inducing a partial
arrest of Saos-2 cells. The remaining activity has been attributed to the E2F1 ‘specific’
site found in the C-terminus of pRB. This site forms a unique interaction with the
marked box region of E2F1. The complex between pRB and E2F1 bound through the
‘specific’ site was found to have a low affinity for DNA (12) and relatively weak
regulation of E2F1 dependent transcription (Fig. 3.3d). This suggests that the site may
function by sequestering E2F1 from E2F target genes to block cell cycle advancement or
it may use a mechanism that is currently unappreciated.
The ability of pRB to engage multiple independent mechanisms of cell cycle
arrest has important implications for why it is a barrier to oncogenic transformation. Our
model predicts that disruption of proliferative control requires inactivation of three
distinct binding interfaces on pRB. For this reason it is noteworthy that pRB is most often
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inactivated in cancer by large deletions or the introduction of nonsense mutations that
inactivate the entire protein (32). These types of mutations are the only way to
simultaneously disrupt all elements of cell cycle control by pRB.
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4

E2F regulation by the retinoblastoma tumor suppressor
protein is dispensable for proliferative control and tumor
suppression

4.1 Abstract
The retinoblastoma tumor suppressor protein (pRb) has a well-described role in the
regulation of the G1-S phase transition of the cell cycle. In the G1 phase of the cell cycle,
pRb interacts with E2F transcription factors to attenuate the activation of S-phase target
genes. To investigate the role of E2F regulation by pRb in proliferative control we
generated a gene-targeted mouse model that introduced R461E and K542E substitutions
into the endogenous Rb1 gene. This allele, termed !G, disrupts the interaction between
the large pocket domain of pRb and E2Fs. Fibroblasts derived from the Rb1!G/!G embryos
have deregulated E2F target gene expression, and pRb-!G is defective in forming
complexes with E2F response elements in gel shift assays. E2F target gene expression is
deregulated in Rb1!G/!G fibroblasts to a similar extent, as observed in Rb1-/- cells, further
suggesting that pRb-!G is unable to effectively regulate E2Fs. Strikingly, proliferative
control is largely maintained in the Rb1!G/!G fibroblasts. Viable Rb1!G/!G mice have been
obtained that do not display other overt phenotypes and do not appear to develop tumors.
While Rb1-/- animals do not survive past E15 due to placental defects, Rb1!G/!G mice are
born at the expected Mendelian ratios. Cell cycle regulation by pRB mutants deficient for
E2F regulation was found to be dependent upon the LXCXE binding cleft, which can
regulate p27 stability through the interaction with the Cdh1 subunit of the APC ubiquitin
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ligase complex. To explore the maintained proliferative control, Rb1!G/!G Cdkn1b-/fibroblasts were generated and appear to have distinct defects in maintaining
proliferation. Furthermore, mice containing the !G mutation along with p27 deficiency
rapidly develop pituitary tumors with a similar incidence to Rb1+/- Cdkn1b-/- animals.
This suggests that deregulated E2F activity is not sufficient to induce ectopic
proliferation, as pRb can regulate other pathways that include p27 stabilization to
maintain cell cycle control and block tumorigenesis. These findings extend the molecular
understanding of the tumor suppressive properties of pRb and suggest that direct
regulation of E2F transcriptional activity by pRb is one aspect of its for cell cycle control
and tumor suppression function.

4.2

Introduction

The retinoblastoma tumor suppressor protein (pRb) has a central role in the
regulation of the G1 checkpoint and inactivation of this control is a hallmark of cancer
(1). pRb is thought to regulate the entry into S-phase largely through its ability to repress
E2F transcription factors (2). E2Fs are potent transcription factors, which activate a
transcriptional program to drive S-phase progression. In the G1 phase of the cell cycle, a
direct interaction mediated by the large pocket domain of pRb with the transactivation
domain of E2Fs blocks the expression of S-phase target genes and is thought to maintain
the cell in the G1 phase of the cell cycle (3). Activation of cyclin-dependent kinases
(CDK) results in the phosphorylation of pRb, which releases bound E2F transcription
factors. The free E2Fs activate a transcriptional program, which drives the progression
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into S phase and through the remainder of the cell cycle. This model of pRb function
suggests that E2F regulation is a central element of proliferative control. This predicts
that mutations that disrupt the binding to E2Fs should be tumorigenic. However, no
mutations of pRb in cancer that have been shown to lead to discrete interaction defects
(4). The mutations found in human cancers are typically complete loss of function
alterations that completely inactive the pRb protein (5). The paucity of E2F-binding
deficient mutants in human cancer suggests that other mechanisms may contribute to the
tumor suppressive properties of pRb. However, the basis by which this may occur
remains unclear.
In addition to the large pocket E2F-binding site defined as the ‘general site’, a
second E2F-binding site (the ‘specific site’) has been identified in the C-terminus of pRb
that forms a unique interaction with E2F1 (6). This site has been shown to function in the
absence of the ‘general site’ to regulate proliferation to a small extent, but is thought to
primarily function in the regulation of E2F1-induced apoptosis (7). Furthermore, E2F1
bound to the ‘specific site’ has a low affinity for the canonical E2F response element, yet
retains the ability to regulate p73 transcription (6, 8). The ‘specific site’ is resistant to
disruption by CDK phosphorylation suggesting that this site is regulated independently of
the ‘general site’ to control the unique ability of E2F1 to induce apoptosis (8). However,
the function of the ‘general site’ and ‘specific site’ at endogenous levels in nontransformed cells has yet to be characterized and development of a reagent to study these
sites in isolation is needed to understand their contribution to proliferation and apoptosis.
In addition to the regulation of E2Fs, pRb is also capable of increasing the
stability of the CDK inhibitor p27 (9). Specifically, pRb interacts with components of the
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anaphase promoting complex (APC) when bound with the Cdh1 targeting subunit (9).
This complex functions to promote the degradation of Skp2, and maintain cells in the G1
phase of the cell cycle. pRb binds to Cdh1 through a binding site in the pocket domain
and with Skp2 through the C-terminal domain (9, 10). By interacting with both of these
proteins, pRb is capable of promoting the degradation of Skp2. This degradation prevents
SCFSkp2 complexes from targeting p27 for degradation and results in the stabilization of
p27(9). Cdh1 and E2F have been shown to form mutually exclusive complexes with pRb
suggesting that there may be a complex interplay between growth suppressive pRb
complexes in G1 (11). While there is clear evidence that suggests pRb can regulate cell
cycle advancement through both E2F and p27 regulation, the contribution of these
pathways to a given cell cycle arrest is poorly understood.
Much of the molecular understanding of pRb function has been obtained through
the use of gene-targeted mouse models to selectively disrupt elements of the G1
checkpoint. Genetic disruption of the mouse Rb1 gene results in embryonic lethality
between embryonic day (E) 13.5 and E15 (12) with severe defects in multiple organ
systems. However, the major defects were found to be secondary to ectopic proliferation
in the trophoblast cells of the placenta that limits the nutrient transport to the developing
embryo (13). Rb1-/- animals rescued with a wild-type placenta were viable until birth at
which time all animals died from a severe defect in skeletal muscle differentiation that
prevented the neonatal animals from respiring (13, 14). Rb1+/- mice are viable but
develop pituitary tumors at approximately one year of age (15, 16). Fibroblasts generated
from Rb1-/- embryos have a shorter G1 phase of the cell cycle, with a coincident
reduction in cell size (17), and are unable to respond to ectopic arrests induced by p16
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(18) and TGF! (19). Genetic disruption of p27 in Cdkn1b-/- mice results in hyperplasia in
multiple organs, female sterility and a late onset of partially penetrant pituitary tumors
after 1 year of age (20). Compound mutant Rb1+/- Cdkn1b-/- mice are viable but rapidly
succumb to pituitary and thyroid tumors at an average of 178 days (21). Taken together
the genetic disruption of Rb1 has revealed a context dependent role for pRb in cell cycle
regulation and tumor suppression. Furthermore, pRb and p27 appear to play an
overlapping role in tumor suppression, however the basis by which this occurs is not well
defined.
To investigate the relative contribution of E2F regulation to cell cycle control
mediated by pRb, we generated a gene-targeted mouse model that selectively disrupts the
interaction between pRb and E2F transcription factors. We find that fibroblasts generated
from Rb1!G/!G embryos have deregulation of E2F activity yet maintain the ability to
regulate proliferation in multiple cellular contexts. To investigate pathways that might
compensate for loss of E2F binding in the !G-mice we inter-crossed our mice with E2f1/-

and Cdkn1b-/- mice. Combination of E2F1 loss with the !G mutation does not alter

proliferative control. In contrast, combined disruption of the p27 gene Cdkn1b with the
!G mutation results in proliferative defects in cell culture and the compound mutant mice
develop a high incidence of pituitary tumors. Taken together this work suggests that E2F
regulation by pRb is dispensable for cell cycle control as p27 accumulation can function
to maintain appropriate cell cycle control in multiple contexts and function as a barrier
for tumorigenesis.
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4.3
4.3.1

Methods
Gene targeting and cell culture

ES cell culture, transfection and selection was preformed by the Van Andel
Institute Germline modification facility (Grand Rapids, MI). ES cells correctly targeted
by the "G-pRb targeting vector shown in figure 4.1a were indentified by Southern Blot
using probes outside the 5’ and 3’ ends of homology to ensure proper integration at the
Rb1 locus. A probe specific to the Neomycin resistance gene was also used to ensure that
targeted clones only contained a single site of integration of the targeting vector. ES
clones were then injected into blastocysts to generate chimeric mice. Male chimeras were
mated with EIIa-cre transgenic mice to remove the PGK-Neo selectable marker that was
flanked by Loxp sites. Progeny were then intercrossed to generate mice that had excised
the selectable maker and did not express the Cre-recombinase. The mice were genotyped
by amplification of a short sequence that surrounds the remaining LoxP site. Using L-F
(ctgcaatctgcgcattttta) and L-R (cgatgctgcaggcctataat) a 250 bp and a 330 bp fragment was
produced that corresponds to the mutant and wild-type allele respectively. Wild-type and
Rb1!G/!G fibroblasts were derived from matched littermates and experiments were carried
out using passage 3-5 MEFs. Asynchronous cell populations were cultured according to
standard methods. Cell culture was carried out in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum, 2mM L-glutamine, penicillin (50U/mL) and
streptomycin (50µg/mL). Cells deprived of serum were cultured for 72 hours in media
with 0.1% FBS. Confluence arrested cells were cultured for 7 days after reaching
confluence in 10% FBS. All animals were housed and handled as approved by the
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Canadian Council on Animal Care. Mice were monitored throughout their lives and
animals were euthanized after the development of signs of tumor burden. Euthanized
animals were subjected to a necropsy with abnormal tissues and tumors fixed in formalin
and processed for histological assessment. Sections of tumors and tissues fixed in
formalin for at least 72 hours were washed for 3 days in PBS then transferred to 70%
ethanol. The tissues were embedded in paraffin and five µm sections were cut from
superficial and deep sections of the blocks. Sections were subsequently stained with
Hematoxylin and eosin and images were captured on a Zeiss Axioskop40 microscope and
Spot Flex camera using EyeImage software (Empix Imaging, Mississauga, Ontario,
Canada).

4.3.2

Retroviral infections
Retroviral infections were performed as described in Pear et al, 1993 (22). The

BOSC packing cells were plated at a density of ten million cells per 15cm plate the day
before the transfections. The following the day the cells were transfected with 60µg of
pBabe plasmid or pBabe containing p16 or p27 using calcium phosphate and the next
morning the media was replaced. The media was removed 48 hours later, filtered through
a 0.45µm filter and supplemented with 4µg/mL of Polybrene. The filtered viral
supernatant was placed directly on MEFs that had been plated the previous day at 8 x 105
cells in a 10cm dish. Fresh media was added to the transfected BOSC cells for another 12
hours. After 12 hours the media from the MEFs was removed and a second round of
infection was preformed by once again adding the filtered viral supernatant with
Polybrene to the MEFs. The viral supernatant was incubated on the MEFS for a further 8-
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12 hours and then replaced with media containing 5µg/mL of puromycin for 4 days. The
infected MEFs were then replated at low density in puromycin containing media and
labeled with BrdU for subsequent flow cytometry analysis.

4.3.3

Protein interaction analysis and western blotting
To generate extracts the cells were washed twice with phosphate buffered saline

(PBS) and collected into 1mL of Gel Shift Extract (GSE) buffer (20mM Tris pH7.5,
420mMNaCl, 1.5mM MgCl2, 0.2mM EDTA, 25% glycerol, 5mg/mL leupeptin, 5mg/mL
aprotinin, 0.1mM Na3VO4, 0.5mM NaF and 1mM DTT). Extracts were frozen at -80°C.
Extracts were thawed and cellular debris were removed by centrifugation at 14,000 rpm.
For immunoprecipitations extract was diluted in IP Wash buffer (20mM Tris pH 7.5,
200mM NaCl, 1.5mMMgCl2, 0.2mM EDTA, 25mM DTT and 0.1% NP-40). pRb
complexes were immunoprecipitated with C-18 (Santa Cruz) for E2F3, bound to protein
G-sepharose (GE healthcare). Immunoprecipitations were incubated with rocking for 1
hour at 4°C. The protein G-sepharose beads were washed twice with IP wash buffer then
resuspended in 1X-SDS-PAGE sample buffer and boiled at 95°C for 5 min to elute the
bound proteins. The eluted material was resolved by electrophoresis on a sodium dodecyl
sulfate-8% polyacrylamide gel electrophoresis (SDS-8%PAGE) gel. Proteins were
transferred to a nitrocellulose membrane by standard techniques. E2F1 was detected by
KH20 (Santa Cruz) and E2F3 by PG37 (Upstate) and pRb by G3-245 (BD Pharmingen).
Purified GST, GST-E7 and GST-E1A were obtained as a kind gift from Biljana
Todorovic and Joe Mymryk. Two micrograms of the GST-fusion proteins was diluted in
low salt GSE buffer (20 mM Tris/HCl, pH 7.5, 200 mM NaCl, 1.5 mM MgCl2, 0.2 mM
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EDTA, 1 mM DTT and 0.1 % Nonidet P40) and incubated with whole cell extract from
Rb1+/+ or Rb1!G/!G fibroblasts. The GST complexes were precipitated with glutathione–
Sepharose and washed twice with low salt GSE buffer and eluted with 1 # SDS/PAGE
sample buffer. Samples were electrophoresed on SDS/PAGE (8% gel) and blotted using
the same antibodies outlined for the immunoprecipitation experiments above and input
levels of recombinant proteins was detected by coomassie stain.

4.3.4

Electromobility shift assays
Electromobility shift assays were performed using DNA probes described in

Hurford et al. (23). These probes were labeled with 50µCi of [#-32P]dCTP with klenow
fragment for 15 min at room temperature. The labeled probes were purified on a G25 spin
column. Extract was prepared from confluent MEFs as described above. Each sample
was diluted in EMSA buffer (20mM Tris pH7.5, 4% Ficoll 400-DL (Sigma), 2.5mM
MgCl2, 40mM KCl, 0.1mM EGTA, 2mM spermine, 0.5mM DTT, 0.25µg salmon sperm
DNA, 10µg bovine serum albumin) and 5µg of nuclear extract. Samples with cold
competitors were first incubated with 40ng of wild-type or mutant unlabelled
oligonucleotides for 10 min on ice. 400pg of labeled probe was then added to each
reaction and incubated on ice for 10 min. For antibody supershifts antibodies were added
and the samples were incubated on ice for a further 25 min. For supershifts 1µg of the
following antibodies were used; pRb 21C9 (a kind gift from Sibylle Mittnacht), CDK2
(Upstate), CDK4 C-22 (Santa Cruz Biotechnology), Cyclin E M-20 (Santa Cruz
Biotechnology), p107 C-18 (Santa Cruz Biotechnology) and p130 C-20 (Santa Cruz
Biotechnology). Samples were loaded onto a 4% polyacrylamide gel (containing 0.25X
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Tris-borate-EDTA and 2.5% glycerol) and electrophoresed at 4°C for 4 h at 180V. Gels
were dried and complexes were detected by autoradiography.

4.3.5

RNA quantification
Expression levels of the E2F target genes, Pcna, Ccne1, Ccna2, Tyms and Rbl1

were determined using the Quantigene Plex 2.0 reagent system from Affymetrix (Santa
Clara, CA) and a BioPlex200 multiplex analysis system according to manufacturers
instructions. Expression levels were quantified were normalized to the expression of
acidic ribosomal phosphoprotein P0 (Rblp0).

4.3.6

Cell Cycle analysis
Cell cycle analysis of MEFs was performed by pulse-labeling cells with

bromodeoxyuridine (BrdU) (Amersham Biosciences) according to manufacturers
instructions 1.5 hours before harvesting cells. The cells were fixed in ethanol and
immunostained with anti-BrdU antibodies (BD Biosciences), along with propidum iodide
as reported in Classon et al. (24). Cell populations were analyzed by flow cytometry on a
Beckman-Coulter EPICS XL-MCL instrument.

4.3.7

Immunohistochemistry

To quantify intestinal proliferation three age-matched Rb1+/+and Rb1!G/!G pairs were
injected with 200µL of 16µg/mL BrdU (sigma) 1 hour before sacrifice. Intestines were
then isolated fixed in formalin, embedded and sectioned according to standard protocols.
To quantify proliferation in the retina of embryos Rb1!G/+Cdkn1b+/- females were
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injected with 200µL of 16µg/mL BrdU on the 15th day of pregnancy 2 hours before
sacrifice. Embryos were then isolated, genotyped and fixed in formalin. The heads of the
embryos were embedded and sectioned until sections of the retina were obtained. BrdU
incorporation was detection was performed on paraffin sections that had been
deparaffinized and rehydrated using a series of xylene and ethanol washes. The sections
were brought to a boil in sodium citrate buffer and then maintained at 95°C for 10 min.
The cooled sections were rinsed in water three times for 5 minutes each time and then
rinsed in PBS for 5 minutes. The sections were blocking solution (Phosphate buffered
saline (PBS) supplemented with 2.5% horse serum and 0.3% Triton X) for 1 hour. The
sections were incubated with anti-BrdU (BD-Biosciences) in blocking buffer overnight at
4°C and then rinsed in PBS three times for 5 minutes each time. The slides were
incubated with horse anti-mouse immunoglobulin G-fluorescein isothiocyanate (Vector)
for 1h and then rinsed in PBS. The slides were mounted with Vectashield plus DAPI
(Vector) and sealed with nail polish. Fluorescent images were captured on a Zeiss
Axioskop40 microscope and Spot Flex camera and colored using EyeImage software
(Empix Imaging, Mississauga, Ontario, Canada).

4.4
4.4.1

Results
Targeted disruption of E2F binding in the mouse Rb1 gene

To disrupt the interaction between pRb and the transactivation domain of E2F
transcription factors, two substitutions (R461E and K542E) were introduced into the
mouse Rb1 gene. These substitutions are the mouse equivalents to R467E and K548E
described in chapter 3 as the !Gn mutant. For simplicity mouse pRb with R461E and
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K542E substitutions is now defined as !G-pRb. As shown in the genomic structure of the
mouse Rb1 gene (Fig 4.1a), R461 and K542 are found in exons 15 and 17 respectively. A
1.5 kb intron is found between exon 16 and 17 that was utilized to insert the selectable
marker. A gene-targeting vector was constructed with 11kb of homologous sequence
containing the PGK-Neo selectable marker cassette inserted 4kb from the end of the 5’
end of homology as depicted in figure 4.1a. The substitutions were introduced into the
exons 15 and 17 along with novel KpnI sites upstream of the R461E substitution and
downstream of the K542E substitution. The PGK-dta cassette was inserted outside the
region of homology to select against clones that contained random integration of the
vector. After selection of embryonic stem cells for G418 resistance, DNA from 471
clones was screened for correct integration of the targeting cassette. As depicted in
figure 4.1a, the WT-Rb1 gene has a single 23kb KpnI fragment that can be detected by
southern blot with either a 5’ or 3’ prime probe. Correct integration of the targeting
vector on the 5’ and 3’ side of the PGK-NEO cassette results in the introduction of two
novel KpnI sites to produce 6kb and 13kb fragments detected by the 5’ and 3’ probes
respectively. As shown in figure 4.1b, two clones were identified to have correctly
targeted the mouse Rb1 gene with the introduced KpnI sites on one of the alleles (Fig.
4.1b). A probe specific to the PGK-Neo cassette was also used to confirm that there was
only a single integration site in the clones used (Fig. 4.1b).
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A) Targeting scheme to introduce the R461E and K542E into exons 15 and 17 of the mouse Rb1. The
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PKG-dta outside of the homology is shown. The targeted allele is also shown with the introduced KpnI sites
that were utilized for screening clones for proper integration. (B) Southern blot analysis of genomic DNA
from ES clones selected for G418 resistance. The correct size of wild-type and targeted !G KpnI fragments
are indicated for both the 3’, 5’ probes and the size of the fragment detected by the neo probe. (C)
Sequencing of DNA from embryos homozygous for the !G allele shows the introduced substituties R461E
and K542E (D) PCR genotyping of the !G-mutation using primers that flank the remaining LoxP site to
produce a 330bp and 250bp band for the !G and WT- alleles respectively.

Figure 4-1 Targeting the mouse Rb1 gene
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The targeted embryonic stem cells were used to generate chimeric animals that
were subsequently bred to mice expressing the Cre recombinase in order to remove the
PGK-Neo cassette and leave only a single LoxP site within the intron downstream of
exon 16. The mice were interbred and the substitutions were confirmed by direct
sequencing of DNA isolated from embryos homozygous for the !G-allele (Fig. 4.1c).
Genotyping of the !G-mice was accomplished by PCR using a pair of primers that flank
the integrated LoxP site to produce an 80bp larger band for the !G allele due to the
integrated LoxP site and surrounding sequence (Fig. 4.1d).
To assess the disruption of pRb-E2F interaction extract was generated from
asynchronously grown Rb1+/+ and Rb1!G/!G fibroblasts. As shown in figure 4.2a, pRb is
expressed at similar levels in both the Rb1+/+ and Rb1!G/!G fibroblasts, indicating that the
substitutions do not disrupt the overall stability or expression of pRb. E2F3 was then
immunoprecipitated from these extracts and immunoblotted for bound pRb. As shown in
figure 4.2a, complexes between pRb and E2F3 are easily detected in the Rb1+/+ cells;
however, no complexes were observed between !G-pRb and E2F3 in the Rb1!G/!G cells.
This suggests that the interaction defect in the gene-targeted mice is consistent with the
initial in vitro studies. To confirm that other structural aspects of pRb were maintained in
the Rb1!G/!G fibroblasts the interaction with the viral oncoproteins was assessed. There is
a well-characterized interaction between the viral oncoproteins E7 and E1A with the
LXCXE binding cleft of pRb. As shown in figure 4.2b, GST-E7 and GST-E1A are able
to form stable complexes with pRb from extract generated from both Rb1+/+ and Rb1!G/!G
fibroblasts, confirming that the LXCXE binding cleft is maintained in !G-pRb. Taken
together the introduction of the R461E and K548E substitutions into the mouse Rb1 gene
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produces a discrete defect in the interaction with E2F transcription factors but preserves
the overall stability and interaction with proteins at the LXCXE binding cleft.
To further characterize the interaction defects in the Rb1!G/!G mice we analyzed
E2F complexes using an electromobility shift assay (EMSA) with a oligonucleotide
derived from the adenovirus E2 promoter (23). In fibroblasts, three distinct types of E2F
complexes are detected bound to the E2F probe. The fastest migrating band corresponds
to free E2F/DP complexes (Fig 4.3). The next band consists of the pocket proteins (pRb,
p107 or p130) bound to E2F/DP, while the shortest migrating complex corresponds to
Cyclin/CDK bound to pocket protein-E2F complexes. Importantly, the complexes with
Cyclin/CDK proteins consist only of p107 and p130 and are mediated by a high affinity
cyclin binding site that is absent in pRb (25). As shown in figure 4.3a, there appears to be
an increase in the relative amount of pocket protein-E2F/DP-Cyclin/CDK complexes in
Rb1!G/!G fibroblasts in contrast to wild-type cells. This suggests that the balance of E2F
complexes is shifted towards binding to p107 and p130 with the corresponding
complexes with CDKs in the Rb1!G/!G cells. To further delineate the composition of
pocket protein complexes a pRb- specific antibody was utilized to shift pRb-E2F
complexes. Addition of the pRb specific antibody to Rb1+/+ fibroblasts produces a new
band that migrates similar to the Pocket-protein-Cyclin/CDK complexes (Fig. 4.3a). In
extracts derived from Rb1!G/!G fibroblasts, addition of the pRb specific antibody does not
alter the distribution of E2F complexes, suggesting that !G-pRb is unable to interact with
E2F proteins. Furthermore, addition of p107 and p130 antibodies was sufficient to alter
the migration of the majority of the pocket protein-E2F complexes in Rb1!G/!G extract
(Fig. 4.3a).
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(A) Immunoprecipitation of E2F3 complexes from Rb1+/+ and Rb1!G/!G fibroblasts. Input levels of pRb,
E2F3, actin and the amount of bound pRb co-precipitaed with E2F3 is shown as detected by western
blotting. (B) Recombinant GST, GST-E7 and GST-E1A were incubated with from Rb1+/+ and Rb1!G/!G
fibroblasts and precipitated using glutathione–Sepharose. The relative amount of input and bound pRB was
detected by Western blotting and the amount of input GST proteins was detected by coomassie.

Figure 4-2 The !G mutation selectively disrupts the interaction with E2F
transcription factors
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Electromobility shift assay (EMSA) were utilized to analyze complexes bound to a radiolabelled fragment
derived from the adenovirus E2 promoter from extract generated from both Rb1+/+ and Rb1!G/!G fibroblasts.
The distinct E2F complexes are indicated as Free-E2F/DP complexes, pocket proteins bound to E2F/DP (PPE2F) and pocket proteins bound to E2F/DP associated with cyclin/CDK complexes (PP-E2F-CDK). The
composition of specific complexes was determined by the additions of antibodies to shift the migration and
these are indicated with the SS-prefix. (A) The addition of antibodies to identify the distinct pocket protein
complexes, (B) antibodies were added to characterize the complexes with CDK/Cyclins and (C) antibodies
were added to detect the presence of pRB-E2F complexes in Rb1+/+ and Rb1!G/!G extract.

Figure 4-3 The !G mutation disrupts the formation of pRb-E2F complexes
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To confirm the composition of the complexes observed in the Rb1!G/!G
fibroblasts, antibodies directed against cyclins and CDKs were utilized. As shown in
figure 4.3b, addition of antibodies to CDK2 and Cyclin E, but not to CDK4, shifts the
pocket protein-Cyclin/CDK-E2F/DP complexes. This suggests that in the Rb1!G/!G cells,
there are significantly more complexes between pocket proteins bound CDK2/Cyclin E
proteins. Since the shifted pRb-E2F complexes migrate similarly to the complexes with
bound CDK2/Cyclin E, we first shifted the CDK2/Cyclin E complexes using a CDK2
antibody, then added a pRb antibody to identify pRb-E2F complexes. As shown in figure
4.3c, extract generated from Rb1+/+ has a significant amount of pRb-E2F complexes,
however no pRb-E2F complexes were identified from the !G- fibroblasts. Taken
together, this further confirms the defect in E2F binding produced by the !G mutation.
Specifically the !G mutation disrupts complex formation between pRb and E2F
transcription factors leading to increased prevalence of p107 and p130 complexes and an
increase in complexes with CDK2/Cyclin E.
Given the disruption of pRB-E2F complexes in the Rb1!G/!G, we next sought to
investigate the regulation of E2F target gene expression in the Rb1!G/!G fibroblasts. As
shown in figure 4.4a, the RNA levels of five canonical E2F target genes are significantly
increased in the serum starved Rb1!G/!G cells. Furthermore, the deregulation of E2F
targets is similar to Rb1-/- cells, suggesting that Rb1!G/!G fibroblasts are completely
defective for regulating E2F target gene expression. E2F target genes were observed to be
upregulated at the protein level as well in !G-fibroblasts as shown in figure 4.4b. This
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fits with the inability of !G-pRb to interact with E2F3 and the lack of !G-pRb-E2F
complexes capable of binding the labeled E2F probe.

4.4.2

Rb1!G/!G mice maintain proliferative control
Given the deregulation of E2F target genes in the Rb1!G/!G fibroblasts, current

understanding of cell cycle progression would predict that the Rb1!G/!G fibroblasts would
display altered cell cycle control in a similar manner as the Rb1-/- cells. Shown in figure
4.5a-b, the Rb1-/- cells have an increased proportion of cells in S-phase in both
asynchronous (Fig 4.5a) and in serum starved (Fig. 4.5b) cell populations. Strikingly, the
Rb1!G/!G cells appear to maintain cell cycle control and have similar cell cycle
distributions as Rb1+/+ cells (Fig. 4.5a,b). Thereby, despite deregulated E2F target gene
expression the Rb1!G/!G cells are capable of maintaining the G1 checkpoint and prevent
the ectopic S phase entry that is observed in Rb1-/- cells.
To investigate cell cycle control in other cellular contexts, the Rb1+/+ and
Rb1!G/!G fibroblasts were virally transduced with p16INK4A or p27KIP1 to induce an acute
arrest of asynchronous cells. In a similar manner to serum starvation, the Rb1!G/!G
fibroblasts respond to the ectopic expression of p16INK4A or p27KIP1 and arrest to a similar
extent as Rb1+/+ cells. In contrast Rb1-/- cells have a well-described defect in their ability
to respond to the expression of ectopic CDK inhibitors (18). The !G-pRb mutation
causes a clear defect in the interaction with E2F transcription factors that results in the
deregulation of E2F target genes, but this does not translate into discrete cell cycle
defects in Rb1!G/!G fibroblasts, as other mechanisms appear to exist to prevent ectopic Sphase entry.
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Figure 4-4 Deregulation of E2F target gene expression in Rb1!G/!G fibroblasts
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In addition to the cell cycle defects observed in Rb1-/- fibroblasts, the mice also
have severe defects in development that leads to embryonic lethality around E13.5. We
therefore investigated the development of the Rb1!G/!G to characterize the role of E2F
regulation in multiple developmental contexts. Despite the deregulated E2F target gene
expression observed in cell culture, live Rb1!G/!G mice were obtained after birth (Fig.
4.6a). Viable Rb1!G/!G mice have been observed into adulthood that are indistinguishable
from wild-type litter-mates (Fig. 4.6b). We next isolated embryos at distinct
developmental stages to characterize the viability of the Rb1!G/!G mice. As shown in
figure 4.6c, Rb1!G/!G embryos were obtained at expected Mendelian ratios up until birth.
Targeted disruption of pRB in the intestine leads to inappropriate proliferation of the
differentiated villi of the epithelium (26). We thus investigated the incorporation of BrdU
into the intestinal epithelium of adult Rb1!G/!G mice. As shown in figure 4.6d and
quantified in figure 4.6e, there appears to be no ectopic cell cycle entry in the villi of
Rb1!G/!G mice or altered proliferation of the crypt cells. This suggests, along with the
viability of Rb1!G/!G animals, that proliferative control is largely maintained in the
Rb1!G/!G mice.
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Figure 4-5 The Rb1!G/!G fibroblasts maintain proliferative control.
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However, approximately half of the neonatal Rb1!G/!G mice were found dead
shortly after birth (Fig. 4.6c) and some neonatal mice were observed in severe respiratory
distress. Given that Rb1-/- mice with rescued placenta also die shortly after birth we
wanted to investigate if a similar phenotype was occurring in the Rb1!G/!G mice. Rb1-/embryos have a defects in skeletal muscle development and their diaphragms that lead to
severe respiratory compromise (14). In the Rb1!G/!G animals there also appears to be a
defect in their diaphragm development that is characterized by inappropriate
differentiation and cell death (Fig. 4.6f). Furthermore, neonatal Rb1!G/!G mice appear to
have a thickened and abnormal development of the epithelial lining of the lung, as shown
in figure 4.6f, that resemble the neuroendocrine hyperplasia reported in lungs of chimeric
Rb1-/- animals (27). It is not clear how the defects in muscle and lung development
contribute to the neonatal lethality of a fraction of Rb1!G/!G animals. The survival of
Rb1!G/!G at expected ratios until birth and survival of some animals suggests that the
severe proliferative defects in the placenta that lead to the embryonic lethality of Rb1-/mice are not occurring in the Rb1!G/!G mice. Nevertheless, the lung and muscle
abnormalities suggest that in some contexts deregulated E2F activity is sufficient to lead
to partially penetrant developmental dysfunction that warrants further investigation.
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Figure 4-6 The majority of Rb1!G/!G animals are viable with maintained
proliferative control
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4.4.3

p27 functions in an overlapping manner to control
proliferation in the absence of E2F regulation by pRb
Given previous findings that pRb is capable of regulating distinct overlapping

pathways to maintain proliferative control, we next sought to investigate the contribution
of these pathways in the Rb1!G/!G mice. To disrupt the ‘specific’ interaction between pRb
and E2F1 we crossed the Rb1!G/+ mice with E2f1-/- animals. pRb can also regulate the
levels of p27 indirectly through the interaction with Cdh1 and Skp2 independently of
E2Fs. To abrogate this pathway of cell cycle control we crossed the Rb1!G/+ mice with
Cdkn1b-/- mice that lack the p27 protein. As shown in figure 4.7a, viable Rb1!G/!G E2f1-/and Rb1!G/!G Cdkn1b-/- were obtained at less than expected frequencies but consistent
with neonatal lethality of the Rb1!G/!G animals. However, as shown in figure 4.8a,
Rb1!G/!G E2f1-/- fibroblasts maintain proliferative control in response to serum starvation.
This suggests that mechanisms exist beyond E2F regulation to control proliferation as the
introduction of the !G mutation into E2f1-/- mice effectively disrupts both the general and
specific E2F binding sites in pRB. In contrast, proliferative control is disrupted in the
Rb1!G/!G Cdkn1b-/- fibroblasts with increased cells in S-phase and G2/M suggesting a
defective G1 arrest of the cells (Fig 4.8a). This suggests that, at least in some contexts, the
proliferative control in Rb1!G/!G cells is mediated by the activity of p27.
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Figure 4-7 Combination of the !G mutation with E2F1 or p27 deficiency does not
alter the viability of Rb1!G/!G mice
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We have followed the Rb1!G/!G mice to investigate tumor formation in these
animals and have yet to identify animals with any morbidity or tumors with the oldest
Rb1!G/!G over 1.5 years of age. In contrast Rb1+/- animals develop completely penetrant
pituitary tumors within the first year of life (28). Cdkn1b-/- mice develop pituitary and
thyroid tumors, but with a low penetrance and typically later in life after one year of age
(20). However, the incidence of tumors is significantly increased when combined with
Rb1 disruption with a mean age of death 178 days for Rb1+/- Cdkn1b-/- animals (21).
Given that the Rb1!G/!G Cdkn1b-/- compound mutant fibroblasts displayed a defect in
proliferative control we next sought to investigate tumor formation in animals carrying
the !G-mutation along with p27 deficiency. As shown in figure 4.8b, the Rb1!G/!G
Cdkn1b-/- appear to rapidly develop pituitary tumors with similar kinetics as Rb1+/Cdkn1b-/- animals, with the mean tumor free survival of these animals at 197 days (Fig.
4.8b). Furthermore, mice with Rb1!G/+ Cdkn1b-/- and Rb1!G/!G Cdkn1b+/- genotypes also
develop pituitary tumors. Importantly, no Rb1!G/!G E2f1-/- animals have developed
tumors or other signs of morbidity suggesting that the ‘general site’ and p27 regulation
have a critical synergistic role in blocking pituitary tumorigenesis.
As shown in figure 4.8c, the pituitary glands of Rb1+/+ and Rb1!G/!G are small
structures located at the base of the brain that contain a regular arrangement of cells with
a well organized vasculature (fig. 4.8d). In stark contrast, the pituitary tumors isolated
from the !G/p27 deficient animals are grossly enlarged hemorrhagic structures that

162

163

A
80
70

Percent

60

*

50

*

40

Rb1+/+ E2F1+/+ Cdkn1b+/+
WT
Rb1!G/!G E2F1+/+ Cdkn1b+/+
g/g

30

!G/!G E2F1-/- Cdkn1b+/+
Rb1
g/g
e2f1-/-

20

!G/!G E2F1+/+ Cdkn1b-/Rb1
g/g
p27-/-

*

10
0
G1
G1

SS

G2/M
G2/M

B

Rb1+/+ Cdkn1b+/+
Rb1!G/!G Cdkn1b+/+
Rb1!G/!G Cdkn1b+/Rb1!G/+ Cdkn1b-/Rb1!G/!G Cdkn1b-/-

C

Rb1+/+ Cdkn1b+/+

Rb1!G/!G Cdkn1b+/+Rb1!G/!G Cdkn1b-/- Rb1!G/!G Cdkn1b+/- Rb1!G/+ Cdkn1b-/-

Pituitary
Gland

D

Rb1+/+ Cdkn1b+/+

Rb1!G/!G Cdkn1b-/-

Rb1!G/!G Cdkn1b+/-

Rb1!G/+ Cdkn1b-/-

(A) Cell cycle distributions of serum starved fibroblasts of indicated genotypes as determined by BrdU
incorporation and DNA content detected by flow cytometry. All bars represent the mean of three independent
samples and error bars represent one standard deviation from the mean. The asterisks indicate a statistically
significant difference (Students T-test; P<0.05) (B) Kaplan-Meier survival proportions shown for mice of
indicated genotypes. A significant difference between the survival of the indicated genotypes was identified
(Log-rank Test; P<0.0001) (C) Gross photographs of normal pituitary gland morphology in one-year-old
Rb1+/+Cdkn1b+/+ and Rb1!G/!G Cdkn1b+/+ animals. Gross photographs of pituitary tumor morphology from
mice of indicated genotypes. (D) Hematoxylin and eosin staining of axial sections from pituitary tumors of
indicated genotypes and sections of control pituitary gland from a Rb1+/+Cdkn1b+/+mouse.

Figure 4-8 Disruption of E2F regulation and p27 deficiency results in altered
proliferative control and pituitary formation
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impinge upon the base of the brain (Fig 4.8c and d). The animals were observed to go
through a rapid decline, characterized by significant weight loss and lethargy. Further,
some animals displayed signs of neurological dysfunction including hemi-paralysis and
an intracranial hemorrhage was observed upon necropsy of multiple animals.
Taken together these results suggest that deregulation of E2F signaling is not
sufficient to allow ectopic proliferation and tumorigenesis in mice. The preliminary
evidence presented here suggests that in the absence of E2F regulation by pRb, p27
functions to maintain proliferative control and block tumorigenesis. This is highlighted
by the rapid development of tumors in mice that simultaneously disrupt both E2F
regulation and p27. Thereby, pRb is capable of engaging multiple cellular pathways to
prevent ectopic S-phase entry and provide a robust barrier to tumorigenesis.

4.5

Discussion

While current understanding typically highlights the role of pRb-E2F interactions
in the regulation of proliferative control, our work highlights the importance of the
multiple overlapping mechanisms of cell cycle arrest mediated by pRb. As shown in
figure 4.9, pRb is capable of forming multiple interchangable complexes in the G1 phase
of the cell cycle to negatively regulate entry into S-phase. Specifically, pRb is capable of
interacting with the transactivation domain of E2F transcription factors to restrict the
activation of S-phase target genes. This regulation is mediated by the ‘general’
interaction between pRb and E2Fs and is disrupted by CDK phosphorylation. This site is
abrogated by the !G mutation, which results in the deregulation of E2F target gene
expression. Additionally the ‘specific site’ can form a unique interaction with E2F1
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independently of the ‘general site’ and was disrupted by crossing the mice to E2f1-/animals. Lastly pRb is capable of interacting with components of two ubiquitin ligase
complexes Cdh1 and Skp2 to promote the degradation of Skp2 and protect p27 from
degradation. This pathway was abrogated in Cdkn1b-/-, as these animals do not express
p27. As predicted from earlier work in chapter 3 the overall cell cycle control mediated
by pRb is not regulated solely by E2F regulation of the ‘general site’, as other binding
interfaces on pRb can function in the !G-mice to maintain proliferative control. We find
that regulation of p27 has a critical function in maintaining proliferative control and
tumor suppression, as combined disruption of the ‘general site’ along with p27 results in
deregulated proliferation and tumorigenesis. In contrast, combined disruption of E2F1
and the ‘general site’ did not appear to alter proliferative control or tumor suppression. In
contrast to Rb1-/- mice, the Rb1!G/!G Cdkn1b-/- were viable and born at expected ratios.
This suggests that the placental dysfunction that leads to the embryonic lethality of the
Rb1-/- embryos does not occur in the Rb1!G/!G Cdkn1b-/- embryos. It is conceivable that
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pRb is capable of forming at least three distinct interchangeable complexes to regulate proliferation.
Complete genetic disruption of the Rb1 gene in Rb1-/- animals disrupts all three aspects of growth control by
pRb. In Rb1!G/!G animals E2F activity is deregulated but ectopic S-phase entry is prevented by the ability of
pRb to stabilize p27 through a direct interaction between Cdh1 and Skp2. Rb1!G/!G Cdkn1b-/- animals disrupt
both these elements of proliferative control and as appear to have deregulated proliferative control and
rapidly develop tumors. In contrast combination of E2F1 disruption with the !G mutation does not lead to
drastic disruption of proliferative control or induce tumorigenesis.

Figure 4-9 Model of pRb proliferative control
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the remaining proliferative control is mediated by the maintained regulation of E2F1
through the specific site. To address this possibility we are currently attempting to
generate Rb1!G/!G Cdkn1b-/- E2f1-/- animals to characterize the effect of abrogating all
three mechanisms of cell cycle control.
The importance of all the mechanisms of cell cycle control shown in figure 4.9 is
supported by previous work implicating the utilization of three distinct binding sites on
pRb to control proliferation. These sites were defined as the ‘general site’ to regulate E2F
dependent transcription, the ‘LXCXE site’ that indirectly regulates p27 levels, and the
‘specific site’, which forms a unique interaction with E2F1. Disruption of the ‘specific
site’ in this study by introducing the !G mutation into E2f1-/- background was not found
to alter proliferative control or tumor suppression. It has been suggested that the ‘specific
site’ functions predominately in the regulation of E2F1-induced apoptosis to regulate the
transcription of pro-apoptotic targets of E2F1 (8). E2F1 is capable of maintaining an
interaction with hyperphosphorylated pRb (ppRb) (8) and complexes between ppRb and
E2F1 have been identified at pro-apoptotic promoters (29). Presumably, this implicates
the E2F1 ‘specific site’ in the regulation of a distinct set of E2F target genes. This is
supported by the data from our current study, as E2F activity in fibroblasts is deregulated
to a similar extent as Rb1-/- cells, suggesting that the pRb-E2F1 ‘specific’ interaction has
a limited contribution to the regulation of canonical cell cycle target genes. Future studies
are investigating the ability of the ‘specific’ interaction to block apoptosis in the !Gmice and the effect this may have on tumorigenesis and sensitivity to DNA damage.
The noted defects in the lungs of Rb1!G/!G mice suggest that, in some contexts,
deregulated E2F expression is sufficient to induce abnormal development. This fits with
167

168

the observation that neuroendocrine hyperplasia noted in chimeric Rb1-/- animals is
suppressed by loss of E2F3 (27), suggesting that the correct differentiation of the lung
epithelium is dependent upon appropriate E2F regulation. However, the abnormalities in
lung structure do not worsen with age and the surviving Rb1!G/!G do not appear to have
respiratory difficulties, and no lung tumors have been observed. Further, a defect in
skeletal muscle is observed in both the Rb1!G/!G and the Rb1-/- mice that is characterized
by reduced differentiation and cell death of the muscle fibers. This likely contributes to
the embryonic lethality of the mice. Recent work has suggested that the defects in Rb1-/myocytes cannot be rescued with ectopic expression of p27, suggesting that the defect is
not due to an inability to appropriately exit the cell cycle, but rather the lack of Rb1
results in mitochondrial dysfunction that induces cell death through apoptosis and
autophagy (30). This suggests that while proliferative control is largely maintained in the
Rb1!G/!G mice, the deregulated E2F activity may cause tissue-specific alterations for nonproliferative reasons.
Recent studies have suggested that, contrary to expectations, many cell types are
capable of proliferating in the absence of the activator E2Fs 1-3 (26, 31, 32). However,
proliferation in the absence of E2F1-3 results in the activation of p53 and results in
apoptosis of the cells (31, 32). Previous to this work, E2F transcription factors were
thought to be largely required to initiate the entry into S-phase and was supported by the
embryonic lethality of E2F1-3 mice and proliferative defects in fibroblasts with
conditional inactivation of E2F1-3 (33, 34). However, more recent studies have suggested
that E2F1-3 have an essential role for sustaining proliferation but are dispensable for
entry into the S-phase of the cell cycle (26, 32). Our current work further extends the
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revision of the canonical model of E2F activity in that deregulation of E2F activity
appears to be insufficient to induce ectopic proliferation. This is highlighted by
proliferative control in the Rb1!G/!G mice and cells despite highly deregulated E2F target
gene expression. Therefore, while E2F regulation has a critical role in maintaining
proliferation of cells, pRb can stabilize p27 to maintain proliferative control in cells with
deregulated E2F target gene expression.
P27 functions as a cyclin-dependent kinase inhibitor to block the activity of
CDKs, which phosphorylate pRb and release bound E2Fs to drive S-phase entry. This
would suggest that p27 functions largely upstream of pRb to regulate proliferation. Our
current study suggests a role for p27 downstream of pRb that occurs independently of
E2F regulation. This is supported by the acceleration of tumorigenesis in Rb1+/- Cdkn1b-/animals (21), and the ability of ectopic expression of p27 to induce a partial arrest of Rb1/-

cells (35). The mechanism by which p27 regulates proliferation in the absence of pRb is

likely through modulation of CDKs, as down regulation of CDK activity is also sufficient
to arrest proliferation in the absence of pRb (36). The ability of p27 to regulate
proliferation in the absence of E2F regulation suggests that E2F regulation must be
combined with CDK activity to advance beyond the G1 phase of the cell cycle.
Disruption of the human RB1 gene results in the formation of highly penetrant
retinoblastoma early in life and occurs frequently during non-small cell lung carcinoma
development (37). The vast majority of patients with familial retinoblastoma carry
genetic alterations of the human RB1 gene that result in complete inactivation of the gene
through large-scale genomic rearrangements, mutations that alter splicing or frameshift
mutations to prevent the production of functional pRB protein (38). Relatively few
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missense mutations of RB1 are observed in human cancers and the few examples are
located in regions that likely disrupt the stability of the entire protein (39). This is in stark
contrast to the p53 tumor suppressor, which is typically inactivated in human cancer
through a number of distinct missense mutations that localize to the DNA binding
domain and other interfaces critical for its tumor suppressive properties (40). Our work
suggests that single missense mutations in pRb would be insufficient to disrupt
proliferative control as pRb is capable of engaging multiple mechanism to induce cell
cycle arrest that are mediated by distinct structural interfaces. Thereby, this provides a
molecular basis for the paucity of discrete loss of function missense RB1 mutations in
human cancer. Any point mutation of a surface exposed amino acid would likely be
unable to disrupt all of the distinct binding sites that contribute to cell cycle control by
pRb and tumor suppression.
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5

Discussion

5.1 Summary of findings
The retinoblastoma tumor suppressor protein was identified through close genetic
analysis of patients with familial retinoblastoma. However, the specific molecular role for
pRB in cancer and proliferative control is still unclear in many respects. Retention of
functional pRB in many types of cancer is not well described by current models of pRB.
Further, no mutations of pRB have been identified from human cancers that lead to
discrete binding defects. In this thesis I utilize various experimental systems to dissect the
functional roles of discrete binding sites in pRB to better understand their contribution to
proliferative control and tumor supression.
Contrary to current understanding, I find that the ability of pRB to regulate
proliferation extends beyond regulation of E2F transcriptional control. In chapter 4 we
describe a novel gene-targeted mouse model, which provides evidence for the importance
of p27 regulation by pRB and suggests that in the absence of E2F control, p27 can
function to maintain proliferative control. As described in chapter 3, these pathways are
controlled by distinct interaction surfaces on pRB, which suggests an explanation for the
lack of E2F-binding deficient pRB mutants in human cancer. These findings suggest that
complete pRB inactivation is required in human cancer to abrogate all mechanisms of
cell cycle control that are controlled by distinct binding sites.
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While cancers such as retinoblastoma and small cell lung cancer typically have
complete genetic disruption of RB1, the vast majority of human cancers maintain the
expression of functional pRB (1). These cancers bypass the ability of pRB to prevent
ectopic S-phase entry through the deregulation of CDK complexes, which in turn
maintain pRB in a hyperphosphorylated state. The selection for pRB maintenance in
many human cancers is not well understood but may involve a protection from apoptosis
(2). Current models of pRB function suggest that phosphorylated pRB is largely inactive
however, we show in chapter 2 that pRB in its hyperphosphorylated state is able to
maintain an interaction with E2F1 through the E2F1 ‘specific site’. Furthermore, the
‘specific’ interaction is capable of regulating the expression of the pro-apoptotic p73
promoter. This provides a potential mechanistic basis for the maintenance of pRB in
human tumors as a means to restrain the apoptotic activity of E2F1. Taken together this
thesis extends the current understanding of pRB function and provides experimental
evidence that supports a multifaceted role for pRB in proliferative control and
tumorigenesis.

5.2

An extended model for pRB function

This thesis provides experimental evidence for a refinement in the model of pRB in
proliferative control and tumor suppression. As depicted in figure 5.1 this work highlights
the ability of the discrete binding interfaces to mediate the overall functionality of pRB.
Specifically, pRB is capable of forming a series of interchangeable complexes in distinct
phases of the cell cycle. pRB can interact with E2F/DP through the ‘general site’ to block
the transactivation domain of E2Fs (3). Further these complexes can form at E2F target
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genes and recruit CRFs to actively repress E2F target gene expression(4). pRB can also
form complexes with E2F1 through the specific site of pRB and the marked box domain
of E2F1(5). As described in chapter 2 these two E2F binding sites are regulated in a
distinct manner by phosphorylation. The ‘general site’ is disrupted by phosphorylation
while the ‘specific site’ appears to be resistant to disruption by phosphorylation.
Complexes between the ‘specific site’ and E2F1 retain the ability to regulate E2F1
specific targets that include p73 and may function to attenuate E2F1 induced apoptosis.
These data provide a structural basis for the observed complexes between pRB and E2F1
in S-phase (6) and between phosphorylated pRB and E2F1 following DNA damage at
pro-apoptotic promoters (7).
In addition to the interaction with E2Fs, pRB is capable of regulating p27 stability
through an interaction with two ubiquitin ligase complexes that is dependent upon the
LXCXE binding cleft (Fig. 5.1) (8, 9). As described in chapter 3 with the use of the
!CRF mutant of pRB and in chapter 4 with the use of Cdkn1b-/- mice we find that the
regulation of p27 functions in a redundant manner to control proliferation in the absence
of E2F regulation. Disruption of both the regulation of E2Fs and p27 by pRB in the !G!CRF-pRB reduces the arrest of Saos-2 cells (chapter 3) and the Rb1!G/!GCdkn1b-/animals results in a loss of proliferative control and tumor formation in the mice (chapter
4). This suggests a model for pRB function at the G1-S transition that more closely
resembles a network rather than the conventional linear pathway (Fig. 1.4). Multiple
binding sites appear to contribute to the overall function of pRB as a barrier to
tumorigenesis.
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5.3

Therapeutic potential of the ‘specific site’

Given that the majority of human cancers express pRB that is phosphorylated by
CDKs (10), our work suggests that ppRB-E2F1 complexes may exist in most human
cancers. The ‘specific site’ appears to have a critical role in regulating E2F1-induced
apoptosis (5) and complexes between phosphorylated pRB and E2F1 have been localized
to apoptotic promoters in response to DNA damage (7). Our data in chapter 2 suggests
that the complexes between phosphorylated pRB and E2F1 are likely mediated by the
‘specific site’ and thus implicates this site in the regulation of pro-apoptotic promoters
following DNA damage. DNA damage-based therapies remain the mainstay of
chemotherapy and function by rapidly killing proliferating cancer cells (11). The
majority of human cancers have mutations that abrogate p53 (12) and as such the
homologous p73 protein mediates apoptosis in cancer cells (13). In turn p73 is activated
primarily by E2F1, as loss of E2F1 significantly impairs the p73 response to DNA
damage (14). As the ‘specific site’ is able to regulate the activation of p73 by E2F1 and
this interaction is likely maintained in most human cancers, this may provide a
mechanism for cancer cells to attenuate the response to DNA damage.
A small molecule inhibitor designed to disrupt the interface between E2F1 and the
‘specific site’ could, in combination with conventional DNA damage-based
chemotherapies, significantly increase the efficacy of cancer treatment. Given that the
‘specific site’ is independent of the ‘general E2F site’, the small molecule could be
designed to only disrupt E2F1 when bound at the ‘specific site’. Since the ‘specific site’
does not appear to have a major role in proliferative control (chapter 3), the drug would
not likely interfere with proliferative control as the ‘general site’ could maintain
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interaction with E2F1 to block ectopic proliferation. However, in cancer cells with pRB
maintained in a hyperphosphorylated state, our work suggests that the ‘general site’
would be largely ineffective at regulating E2F1, which would be free to induce
expression of p73 and other apoptotic targets in response to the DNA damage-based
therapy.
A fluorescence resonance energy transfer (FRET) system could be used to screen
molecular libraries for small molecule inhibitors of the ‘specific site’. FRET paired
proteins CFP and YFP have been cloned onto fragments of pRB and E2F to generate a
robust assay to facilitate screening of these compounds. Once a molecule has been
developed the Rb1!G/!G Cdkn1b-/- mice would provide an ideal system to study the
effectiveness of potential molecules in the treatment of cancer. These mice mimic the
inactivation of pRB in the majority of human cancers as they disrupt E2F and p27
regulation but likely maintain the ability of ppRB to interact with E2F1. Therefore, the
therapeutic utility of releasing E2F1 from the ‘specific site’ could be studied in the
Rb1!G/!G Cdkn1b-/- animals. Successful inhibitors of the ‘specific site’ would be expected
to potentiate cell death after treatment with chemotherapy.
In addition to providing a potential novel means to target cancer cells, pRB may
also provide a prognostic marker in human cancers. Contrary to expectations, some
studies have reported that pRB expression is inversely correlated with survival in patients
with ovarian cancer (15). Specifically, patients with elevated levels of pRB expression
had a significantly worse prognosis compared with patients that lack expression of pRB.
The patients were from a clinical study comparing the use of cisplatin and paclitaxel
versus carboplatin and paclitaxel chemotherapy regimes, which are all designed to induce
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DNA damage and cell death in malignant cells (16). It is possible that patients with
maintained pRB expression block the activation of E2F1 to attenuate the effectiveness of
DNA damage based therapy.
Another clinical scenario is in lung cancer where almost all cases of small cell
lung cancer (SCLC) have complete disruption of pRB, while non-small cell lung cancers
(NSCLC) maintain pRB expression (10). SCLC patients have a much better response to
chemotherapy and tend to have a higher rate of apoptosis than NSCLC patients (17).
These observations warrant further investigation into the role that maintained pRB
expression might have on the regulation of E2F1 and apoptotic targets. Conceivably, the
lack of pRB expression could provide a means to stratify patients that may respond best
to chemotherapy. NSCLC tumors that do not express pRB respond more effectively to
chemotherapy than the majority of cancers that maintain pRB expression (18). Therefore,
while chemotherapy is not effective in the majority of NSCLC patients it is conceivable
that chemotherapy would be an effective treatment for tumors that lack pRB expression
(19). The majority of patients, which maintain pRB expression, would be potential
candidates for therapies directed at the disruption of the ‘specific site’. Since p53
mutations occur in up to 90% of NSCLCs the majority of apoptosis is likely induced by
p73 (13). Given the strong induction of p73 by E2F1 (14) it suggests that therapies
targeted to potentiate E2F1 activity may prove to be effective means to increase the
chemosensitivity of this cancer.
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5.4 Proliferative control in the absence of E2F and p27
regulation
As shown in chapter 4 the Rb1!G/!G Cdkn1b-/- mice rapidly develop tumors with a
similar incidence to the Rb1+/- Cdkn1b-/- animals, however in contrast to Rb1-/- animals,
these mice are largely viable. The defect in Rb1-/- mice most closely associated with
proliferative control is the placental defect in which ectopic proliferation of the placental
trophoblast cells results in inadequate development and embryonic lethality of the mice
(20, 21). Given that the Rb1!G/!G Cdkn1b-/- mice are born at the expected Mendelian
ratios, this suggests that proliferative control in the placenta is largely maintained.
However, the tumorigenesis and altered cell cycle kinetics observed in culture suggests
that, in many contexts, proliferation is disrupted in these animals. As described in chapter
3 the ‘specific site’ can also contribute to proliferative control in the absence of the
‘general site’ and p27 regulation through the ‘LXCXE’ binding cleft. Therefore, the lack
of placental defects may be due to the ability of the ‘specific site’ to maintain
proliferative control and is currently being assessed through the generation of Rb1!G/!G
Cdkn1b-/- E2f1-/- mice.
It is also possible that additional pathways exist outside of E2F1 regulation
through the ‘specific site’ to maintain cell cycle control. In chapter 3 we utilized the
!CRF mutant to disrupt the LXCXE binding cleft in pRB and the interaction with Cdh1
to prevent the stabilization of p27. However, in our gene-targeted mouse model we
utilized the direct disruption of p27 to abrogate this pathway. It is possible that the
LXCXE binding cleft may function through other means to ensure appropriate
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proliferative control. pRB is thought to recruit chromatin remodeling enzymes through
this binding site to E2F-target promoters to produce a closed chromatin landscape to
actively repress the expression of these genes (4). Therefore, it is expected that in the
absence of E2F binding chromatin remodeling factors will not be recruited to E2F target
genes in Rb1!G/!G animals. This is supported by preliminary data that suggests that the
Rb1!G/!G mice share similar defects to the Rb1!L/!L animals including a hyperplasia of the
mammary ductal epithelium and a defective response to TGF-!(Data not shown).
However, condensin and cohesion complexes have recently been shown to interact with
pRB at the LXCXE binding cleft (22, 23). Cohesin and condensin complexes have been
implicated in the direct transcriptional control of target genes involved in proliferation
and differentiation (24). It is possible that pRB participates in these complexes with
condensin and cohesin as a means to regulate proliferation in the Rb1!G/!G mice and
warrants further investigation.

5.5

Perspectives

The work in this thesis has extended our understanding of the role of pRB in
proliferative control and tumor suppression. Using a combination of in vitro interaction
assays, cell culture experiments and mouse models, we have refined the model of pRB
function. However, many aspects of pRB’s function remain unclear. While both the
‘general’ and the ‘specific site’ appear to contribute to the regulation of E2F transcription
factors, current data suggests that the ‘specific site’ may regulate a subset of E2F1
specific promoters. However, there is currently little experimental data that describes the
ability of the ‘general’ or the ‘specific site’ to regulate distinct E2F targets. The !G
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mouse model presented in chapter 4 allows for the disruption of only the ‘general site’ so
that the ‘specific site’ can be studied in isolation. An analogous mouse model that
disrupted the ‘specific site’ would allow for the ‘general site’ to be studied in isolation.
As outlined in chapter 2 multiple synthetic mutations were identified that disrupt
the interaction between pRB and E2F1 at the ‘specific site’. Further analysis suggests that
the F839A substitution would be an ideal candidate to selectively disrupt the interaction
between the ‘specific site’ and E2F1 (Data not shown). Development of a !S mouse
model in which the ‘specific site’ was disrupted would greatly enhance our understanding
of the molecular function of these sites. One potential application of these models is the
use of chromatin immunoprecipitation sequencing (ChIP-Seq) to identify targets of the
‘general’ and ‘specific sites’. The identification of targets would further our
understanding into the molecular function of these sites. Furthermore, the identification
of unique transcriptional targets for the ‘specific site’ would provide a potential role for
the persistent ppRB-E2F1 complexes beyond the G1 phase of the cell cycle.
The Rb1!G/!G mice will provide an ideal experimental system for future studies to
investigate the molecular role of E2F regulation by pRB. Specifically the differentiation
and development of specific tissues can be studied in greater detail. As described in
chapter 4 the Rb1!G/!G mice have significant defects in muscle and lungs that is
reminiscent of Rb1-/- animals. The lack of proliferative defects in the Rb1!G/!G mice
suggests that the defects may occur independently of cell cycle defects. However, this
warrants further investigation through the study of differentiation in Rb1!G/!G cells and
embryos. The muscle development can be studied through the differentiation of MEFs
into myoctyes through the expression of MyoD (25) Since Rb1-/- are defective in this
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differentiation the Rb1!G/!G fibroblasts can be utilized to assess the role of E2F regulation
in this process. In this way the !G mouse model will likely prove to be a valuable system
to investigate the contribution of E2F regulation in multiple developmental contexts
including muscle differentiation.
Previously, a gene-targeted mouse model has been created that introduces three
substitutions into the mouse Rb1 gene to selectively disrupt the interaction with proteins
at the LXCXE binding cleft (26). These substitutions are termed !L and this mouse
model has highlighted critical roles for the LXCXE binding cleft in response to TGF!, senesence and in the maintenance of genome stability (22, 27, 28). The !G mouse
model described in this thesis will further our understanding of the molecular basis for
the role of pRB in these pathways. As depicted in figure 1.4, the current model for
LXCXE function suggests that it is dependent upon the ‘general site’ to recruit pRB
complexes to E2F target genes. However, studies that suggest a role for the LXCXE cleft
in the regulation of pericentric heterochromatin and the maintenance of genomic stability
(22, 26) raise the question of how pRB is targeted to regions that may lack E2F binding
sites. By investigating the previously identified LXCXE dependent functions of pRB in
the !G mouse model the requirement for E2F binding can be explored. Furthermore, if
these pathways occur independently of E2F binding the models will afford the ability to
potentially identify the alternative means by which pRB is targeted to distinct genomic
loci.
Current understanding of pRB suggests that it functions as an adapter protein to
nucleate distinct protein complexes to maintain proliferative control and mediate other
cellular signaling. Since the binding sites of pRB mediate distinct complexes that can
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produce contrasting signals there is a need to study the role of these binding sites in
isolation. As such, this thesis has utilized multiple experimental models and developed a
series of novel systems to better understand the functionality of the distinct binding
interfaces of the retinoblastoma tumor suppressor protein.
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An overlapping kinase and phosphatase docking site
regulates activity of the retinoblastoma protein
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Alexander Hirschi1, Matthew Cecchini2, Rachel C Steinhardt3, Michael R Schamber3, Frederick A Dick2 & Seth M Rubin3
The phosphorylation state and corresponding activity of the retinoblastoma tumor suppressor protein (Rb) are modulated by
a balance of kinase and phosphatase activities. Here we characterize the association of Rb with the catalytic subunit of protein
phosphatase 1 (PP1c). A crystal structure identifies an enzyme docking site in the Rb C-terminal domain that is required for
efficient PP1c activity toward Rb. The phosphatase docking site overlaps with the known docking site for cyclin-dependent kinase
(Cdk), and PP1 competition with Cdk-cyclins for Rb binding is sufficient to retain Rb activity and block cell-cycle advancement.
These results provide the first detailed molecular insights into Rb activation and establish a novel mechanism for Rb regulation
in which kinase and phosphatase compete for substrate docking.
The retinoblastoma tumor suppressor protein (Rb) regulates the
cell cycle through its capacity to associate with and influence the
function of a number of cellular proteins. In the best-characterized
example, Rb binds and inhibits E2F transcription factors to coordinate
the initiation of S phase with mitogenic signaling1,2. Rb activity—
namely, its competency to bind E2F—is regulated by phosphorylation
in a cell cycle–dependent manner. In G0 and early G1, Rb is active
and modified at relatively few phosphorylation sites. In this hypophosphorylated state, Rb sequesters E2F and recruits transcriptional
corepressors and chromatin-modifying enzymes to E2F-responsive
promoters to block transcription1,3–6. Hyperphosphorylation of Rb
by cyclin-dependent kinases (Cdks) from late G1 until mitosis inactivates Rb by dissociating these factors and results in the expression of
genes required for DNA synthesis and cell-cycle progression1,7,8. The
enzyme protein phosphatase 1 (PP1), which is required for mitotic
exit and is responsible for reversing the phosphorylation of many
Cdk substrates, dephosphorylates Rb beginning in anaphase9–11.
PP1-dependent Rb dephosphorylation has also been observed during
S and G2 in response to hypoxia and DNA damage, suggesting that it
is also responsible for Rb activation under these conditions12,13. The
importance of phosphorylation for regulating Rb activity as a tumor
suppressor is underscored by the fact that genes encoding cyclin D
and p16 are frequently mutated in cancers, leading to constitutive
Rb hyperphosphorylation14,15.
Mechanisms for regulating Rb phosphorylation have focused on the
modulation of Cdk activity1,2,16. Although levels of Rb phosphorylation in the cell cycle generally coincide with levels of Cdk activity,
there are circumstances, such as during mitotic exit and after DNA
damage, in which Rb must be actively dephosphorylated and maintained in a hypophosphorylated state. In fact, several cancer lines have

been shown to be defective in activating Rb by dephosphorylation17.
Therefore, an important mechanistic question remains regarding how
phosphatase activity opposes kinase activity to control Rb phosphorylation. A stable PP1–Rb complex has been observed that is coincident
with the timing of dephosphorylation in mitosis18. Nevertheless, compared to Cdks, much less is known regarding how PP1 recognizes Rb
and how Rb dephosphorylation may be regulated.
In cells, PP1 activity typically arises from a complex containing the
catalytic subunit (PP1c) and a variable regulatory subunit; the latter
confers substrate specificity and enhances activity19. There are three
mammalian isoforms of PP1c; the isoforms all contain the highly
conserved catalytic domain and only differ in their unstructured
N and C termini19,20. Nearly all regulatory subunits and many inhibitors contain a consensus Arg-Val-x-Phe (RVxF) sequence, which
binds PP1c at a site distinct from the catalytic site19–21. Endogenous
Rb–PP1 complexes copurify with other proteins, and an interaction
between Rb and the myosin phosphatase-targeting subunit has been
reported22,23; these observations suggest the existence of a regulatory
subunit for Rb dephosphorylation. In contrast, there have been several
reports of a direct, functional complex between Rb and all three PP1c
isoforms without the requirement of a targeting subunit24,25. Thus, the
mechanism of Rb-specific PP1 activity remains unclear.
Rb contains two structured domains known as the N-terminal and
pocket domains as well as a C-terminal domain (RbC) of ~150 residues (Fig. 1a). RbC is necessary and sufficient for observation of an
Rb–PP1c complex in cell extracts for all three PP1c isoforms24,25. RbC
is intrinsically disordered but adopts structure upon binding E2FDP heterodimers26 (Supplementary Fig. 1). Other proteins that have
been shown to associate with RbC include cyclins, Skp2, c-Abl and
MDM2 (refs. 27–30). In the case of cyclin A (CycA), a crystal structure
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RESULTS
Rb870–882 is necessary and sufficient for PP1c association
To determine the precise sequence requirements for RbC-PP1c binding, we applied isothermal titration calorimetry (ITC) to quantitate
binding affinity. We titrated recombinant, purified Rb proteins into
recombinant PP1c (A-isoform), and we calculated dissociation constants from the resulting isotherms (Fig. 1). We first determined that
Rb55–928, which contains all of the conserved Rb domains and phosphoacceptor sites, binds PP1c with Kd = 3.9 o 0.2 MM (Fig. 1b,c). This
value is typical for enzyme-substrate binding interactions and is similar to that previously observed between an RbC peptide and CycA31.
We next made a series of truncation mutants and tested the affinity
of these mutants for PP1c by calorimetry (Fig. 1c and Supplementary
Fig. 2). Rb771–928 and Rb866–928 bind PP1c with similar affinity to
that of full-length Rb, which is consistent with previous reports
that RbC is sufficient for the association and phosphorylation is not
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required24,25,33. Titration of Rb889–928 into PP1c results in no detectable heat signal, indicating that the conserved residue sequence
between 866 and 889 is required for binding. Using a synthetic peptide,
we found that Rb870–882 binds PP1c with comparable affinity (Kd =
1.2 o 0.4 MM) to that of full-length Rb, confirming that Rb870–882 is
necessary and sufficient for PP1c association and likely contains all of
the significant interacting residues. This conserved sequence contains
the CycA docking site and a Lys-Leu-Arg-Phe (KLRF) sequence that
resembles the consensus RVxF motif found in PP1 regulatory subunits
(Supplementary Fig. 1).
Crystal structure of Rb870–882-PP1c
We next crystallized and solved the structure of a complex of the
A-isoform of PP1c with an Rb870–882 peptide (Table 1, Supplementary
Methods and Supplementary Fig. 3). The structure of PP1c in the
complex is essentially identical to that observed in both the PP1c–
microcystin and PP1c–tungstate complexes33,34. The Rb peptide binds
PP1c in an extended conformation at the hydrophobic interface of
the core B-sandwich subdomain opposite the catalytic site (Fig. 2a).
Rb binding is mediated both by main chain hydrogen bonding and
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reveals that a short Rb868–878 peptide docks to the structured CycA
domain in an extended conformation31. This sequence contains the
canonical Arg-x-Leu (RxL) sequence motif that targets Cdk-cyclins to
Rb and other substrates for efficient phosphorylation27,32. At present,
little is known about whether these RbC binding partners are capable
of interacting with Rb simultaneously or competitively, leaving their
regulatory impact on Rb uncharacterized.
We examine here the RbC-PP1c association in molecular detail to
understand the mechanism of Rb activation by dephosphorylation.
We find that human PP1c uses its regulatory subunit-binding cleft to
dock with an RVxF-like motif in RbC. The PP1c binding sequence
overlaps with the previously identified RxL cyclin binding site, and
the association of Rb with PP1c and Cdk-cyclin is exclusive. These
results reveal an efficient regulatory mechanism, generally applicable
in cell signaling, in which phosphatase and kinase activities affect
phosphorylation state not only through catalysis but also through
restricting access to their target substrate.

a

Se

Figure 1 Rb880–892 is necessary and sufficient for PP1c association.
(a) Domain structure of Rb with the location of the conserved Cdk
consensus phosphorylation sites. (b) Isothermal titration calorimetry (ITC)
data for titration of Rb55–928 into PP1c. (c) Results from ITC experiments
as shown in b but with RbC truncation mutants. Sample ITC data from
each experiment are shown in Supplementary Figure 2.
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Figure 2 Structure of the Rb870–882–PP1c complex. (a) RbC (brown) binds in an extended conformation and extends sheet 1 of the PP1c B-sandwich domain
(cyan). Purple spheres, Mn2+ ions at the distant PP1c catalytic site. (b) Close-up view of the Rb870–882–PP1c interface. The main chain hydrogen bonding
interactions between the RbC peptide (light brown) and PP1c (cyan) are shown. (c) Hydrophobic side chain interactions between Rb870–882 and PP1c.
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Figure 3 The RbC KLRF docking sequence is required for efficient dephosphorylation by PP1c. (a) RbC constructs used as substrates in the
phosphatase assays. (b) PP1c phosphatase assay using 5 MM 32P-labeled phosRb771–928 and phosRb771–874 and 10 nM PP1c. Quenched aliquots
removed from the reaction at the indicated time point are visualized with phosphorimaging. (c) Plot of band intensities in b as a function of reaction
time. (d) Plot of initial reaction rate as a function of substrate concentration for dephosphorylation of phosRb 771–928 and phosRb771–874. Fit of
the data to a simple steady-state model indicates similar apparent kcat values; however, the apparent KM for phosRb771–874 is greater. Error bars,
fitting error for initial rate calculation from reaction time course data. (e) Analysis of docking-site mutations in the phosphatase assay described in
b and c. phosRb771–928 with the indicated mutation was used as a substrate at a concentration of 1 MM with 10 nM PP1c. (f) Analysis of docking-site
mutations in a Cdk kinase assay; 2 MM of the indicated Rb771–928 substrate was phosphorylated with Cdk2-CycA in the presence of E2F1-DP1.

hydrophobic side chain interactions (Fig. 2b,c). Arg876–Asp878 of
Rb form a short B-strand that adds to sheet 1 of the PP1c B-sandwich
subdomain. The Rb B-strand makes hydrogen bonding interactions
with the edge strand of the sheet that are typical of parallel strandstrand interactions.
The other significant interactions between the Rb peptide and PP1c
are made by the highly conserved hydrophobic side chains of Leu875
and Phe877 (Fig. 2c and Supplementary Fig. 1). Each inserts into
a pocket within the hydrophobic core of the B-sandwich subdomain
of PP1c. The PP1c B-sandwich structure and the specific side chains
that contact RbC are conserved in all three mammalian isoforms of
the enzyme (Supplementary Fig. 4). Thus, our structural data are
consistent with and explain the previous observation that all of the
PP1c isoforms bind Rb25. Furthermore, the observation that RbC
contacts PP1c at a site that is distinct from the phosphatase active site
explains the observation that catalytic activity of PP1c is not required
for Rb-PP1 association35.
The location of the Rb peptide binding site in PP1c and the molecular interactions stabilizing the complex are nearly identical to those
observed between PP1c and the RVxF motif of two PP1 targeting
subunits20,21. In the structure of the myosin phosphatase subunit 1
(MYPT1) bound to PP1c (isoform D) (Supplementary Fig. 5), Lys37–
Asp39 of MYPT1 add to the PP1c sandwich domain as a parallel
B-strand, and Val36 and Phe38 of MYPT1 insert into the same hydrophobic pockets of PP1c as observed here for Leu875 and Phe877 of
Rb20. Notably, the occurrence of leucine in RVxF motifs is extremely
rare, and mutation of the canonical valine to leucine sometimes
abolishes docking motif binding36. However, the similarity of contacts
by RbC and MYPT1 with PP1 shows that the KLRF sequence at
residues 874–877 of Rb functions as an RVxF motif.
It is noteworthy that Leu875 and Phe877 in RbC also bind to
hydrophobic pockets in CycA (Supplementary Figs. 1 and 5)31.
Leu875 is the leucine in the Rb RxL motif that is required for its
phosphorylation27,31,32. Phe877 is buried along with Leu875 in the
NATURE STRUCTURAL & MOLECULAR BIOLOGY

VOLUME 17

RbC-Cdk2-CycA structure, and both appear critical for stabilizing
the observed docking interaction between kinase and substrate31. We
found that mutation of these hydrophobic residues results in a loss
of RbC affinity for PP1c and Cdk2-CycA (Supplementary Methods
and Supplementary Fig. 2). These experiments verify that Leu875
and Phe877 are part of an enzyme-docking site in RbC required for
association with both enzymes.
The Rb paralogs p107 and p130 also contain RxL sequences that
are critical for binding to Cdk2-CycA31,32. However, unlike Rb, the
phenylalanine in both the p107 and p130 docking motifs directly follows the leucine (Arg-Arg-Leu-Phe (RRLF)). We found that the CycA
binding motifs in both pocket proteins (p107655–667 and p130677–689)
do not also bind PP1c (Supplementary Fig. 2). This result is
consistent with the crystal structure, which reveals that leucine
forms critical contacts with PP1c in the −2 position (relative to
the phenylalanine).
PP1c docking is required for efficient RbC dephosphorylation
To examine the effects of the Rb-PP1c association on Rb-directed PP1
phosphatase activity, we developed an assay to measure Rb dephosphorylation rates. We quantitatively phosphorylated two RbC constructs, both containing seven Cdk consensus sites (Fig. 3a), with 32P.
After mixing substrate with phosphatase, signal intensity remained at
longer time points in phosphorylated Rb771–874 (phosRb771–874) compared to phosRb771–928 (Fig. 3b), indicating that deletion of the PP1c
docking site in RbC results in a loss of dephosphorylation efficiency.
Quantification of the signal indicates that the first-order rate constant
for dephosphorylation of phosRb771–874 (kdephos = 0.027 o 0.002 min−1)
is approximately eight times smaller than for phosRb771–928 (kdephos =
0.20 o 0.01 min−1) (Fig. 3c). We also found that a short peptide containing the KLRF sequence inhibits phosRb771–928 dephosphorylation
when added to the assay, further confirming that the docking site
permits more efficient substrate processing (Supplementary Fig. 6).
Analogous phosphatase assays with mutant phosRbC fragments
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a first-order rate constant similar to that of wild type. This observation follows previous findings that Cdk2-CycA is capable of docking
to both K/RxLxF (Rb-like) or K/RxLF (p107-like) sequences31. Our
kinetic studies of docking-site mutants show that both PP1c and
Cdk-cyclin utilize an overlapping docking site in Rb and indicate
that the R876F F877R mutant is defective as a PP1 substrate but not
as a Cdk substrate.
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Figure 4 PP1c inhibits Cdk2-CycA activity toward RbC. Phosphorylation
of 2 MM Rb771–928 or Rb771–874 with 75 nM Cdk2-CycA in the absence
and presence of a saturating concentration of PP1c–microcystin (15 MM).

that contain only one pair of phosphorylated sites show that dephosphorylation occurs at all of the sites with kinetics that are sensitive to
the presence of the PP1c docking site (Supplementary Fig. 7).
We performed phosphatase assays at different substrate concentrations to determine apparent steady-state kinetic parameters for
dephosphorylation of the multiple RbC sites (Fig. 3d). The apparent
kcat for dephosphorylation of phosRb771–874 (kcat = 140 o 20 min−1)
and of phosRb771–928 (kcat = 160 o 20 min−1) are similar. However,
the apparent KM for phosRb771–874 (KM = 30 o 10 MM) is greater than
the apparent KM of phosRb771–928 (KM = 6 o 3 MM). These results
are consistent with the RbC KLRF docking sequence enhancing
dephosphorylation by enabling PP1c to capture substrate and form
an enzyme–substrate complex.
We next examined how mutations in the overlapping PP1c and
Cdk-cyclin docking site affect enzyme activity toward Rb. In the
phosphatase assay, dephosphorylation of Rb 771–928 that contains
an F877A mutation (kdephos = 0.071 o 0.004 min−1) is slower than
wild type (kdephos = 0.29 o 0.03 min−1) (Fig. 3e). Switching the position of the phenylalanine and arginine (R876F F877R) in Rb771–928,
which creates a docking sequence that more resembles P107 and
P130, also results in a smaller first-order rate constant in the assay
(kdephos = 0.067 o 0.006 min−1).
To test these mutants in a kinase assay, we prepared complexes
of RbC and E2F1-DP1 to mimic the physiological, active Rb substrate. In binding assays, the presence of E2F1-DP1 does not affect
appreciably the affinity of either PP1c or Cdk2-CycA for RbC
(Supplementary Fig. 2), indicating that the E2F-DP binding site in
RbC does not overlap with the common enzyme-docking site. The
first-order rate constant characterizing phosphorylation of wild-type
RbC (kphos = 0.023 o 0.001 min−1) is greater than that for the F877A
mutant (kphos = 0.011 o 0.001 min−1) (Fig. 3f). This measured kinetic
difference is consistent with the Lys-x-Leu-x-Phe (KxLxF) motif
at 873–877 in Rb being required for phosphorylation by Cdk2CycA27. The R876F F877R mutant (kphos = 0.024 o 0.001 min−1) has
1054
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PP1 inhibits Cdk2-CycA activity toward Rb
Considering that both kinase and phosphatase cannot bind the
required docking site together, we hypothesized that each enzyme
would act as an inhibitor of the other by occluding the site. We first
tested whether inactive PP1c could inhibit the phosphorylation
of RbC by Cdk2-CycA in the kinase assay (Fig. 4). In the absence
of PP1c, the first-order rate constant for Rb771–928 phosphorylation (kphos = 0.0185 o 0.0001 min−1) was 11 times greater than that
for Rb771–874 phosphorylation (kphos = 0.0017 o 0.0001 min−1).
We then carried out kinase reactions in the presence of saturating quantities of PP1c that was irreversibly inhibited at its catalytic
site with microcystin (Fig. 4). The presence of PP1c–microcystin
reduces the rate constant for Rb771–928 phosphorylation (kphos =
0.0051 o 0.0001 min−1) such that it is more similar to the rate constant for Rb771–874 phosphorylation. By contrast, PP1c–microcystin
has little effect on Rb771–874 phosphorylation (kphos = 0.0013 o 0.0001
min−1). Thus, our data indicate that PP1c directly inhibits RbC phosphorylation by Cdk2-CycA and that inhibition is independent of
phosphatase activity and dependent on the presence of the KLRF
docking site. We have also found, using the phosphatase assay,
that Cdk2-CycA inhibits RbC-directed PP1c phosphatase activity
(Supplementary Fig. 8).
Inhibition of Cdk access to Rb blocks cell-cycle progression
Having established that Cdk and PP1c compete for Rb access, we
investigated the functional importance of this competition in the
context of cell-cycle regulation. The human osteosarcoma cell line
Saos-2 is deficient for Rb, and Rb re-expression leads to a strong G1
arrest37. Coexpression of Cdk2-CycA abrogates this arrest through
phosphorylation and inactivation of Rb38,39. We used this model system to observe the effect of PP1 on Cdk regulation of Rb (Fig. 5a).
We found that the Rb-induced arrest was overcome by Cdk2-CycA
expression, and it could be largely recovered by expressing PP1c.
Notably, coexpression of a catalytically inactive mutant of PP1c (PP1c
H248K) also resulted in a restoration of G1 arrest. Omission of Rb
from these assays abrogated the PP1c-dependent cell-cycle block,
confirming that Rb is the relevant target of enzyme competition. In
Figure 5b, the expression levels of PP1c were titrated and reveal that
catalytically inactive enzyme is as potent as wild type in blocking cellcycle advancement under conditions in which Rb expression has been
reduced. Based on these cell-cycle control data, we conclude that the
competition for substrate access between Cdk2-CycA and PP1c on
Rb offers an efficient means to control cell proliferation beyond the
catalytic regulation of phosphorylation.
We next confirmed that PP1c inhibits phosphorylation of Rb in
cells, as in our kinetic analyses, in a manner that is independent of
catalytic activity. We used C33A cells to test whether exogenously
introduced PP1c could compete with Cdks and block Rb phosphorylation regardless of cell-cycle position effects on enzyme activity
(Fig. 5c). Ectopically expressed Rb becomes phosphorylated in C33A
cells. Expression of a dominant negative Cdk2 controls for inhibition
of Rb phosphorylation in our analysis, and coexpression of Rb with
Cdk2-CycA shows the maximum extent of Rb hyperphosphorylation.
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As predicted, expression of PP1c or catalytically dead PP1c H248K
inhibited Rb phosphorylation levels in a dose-dependent manner.
Our kinetic data indicate that the Rb R876F F877R mutant is a poor
PP1 substrate but a good Cdk substrate. We used this mutation to
study the importance of the docking site for dephosphorylation and
Rb activation in cell-based assays. First, we transfected wild-type Rb
and Rb R876F F877R into C33A cells with and without also transfecting PP1c (Fig. 5d). Coexpression of PP1c reduces the observed
phosphorylation of wild-type Rb (migrates as a faster, single band),
whereas the mutant Rb R876F F877R is unaffected by phosphatase
expression. This observation suggests that the docking interaction
observed in our crystal structure is required in cells for efficient Rb
dephosphorylation by PP1.
We also tested the Rb R876F F877R mutant in the Saos-2 cell-cycle
arrest assay. Expression of Rb R876F F877R in Saos-2 cells gives a
less robust arrest in G1 compared to wild type, consistent with the
idea that Rb activation requires docking-dependent PP1c dephosphorylation that is defective in this mutant (Fig. 5e). Cdk2-CycA

expression still inactivates Rb R876F F877R as expected because the
kinase-docking site remains intact. We also find that, under conditions in which Rb and kinase are expressed, coexpression of PP1c
is sufficient to restore the activity of wild-type Rb but is unable to
reactivate phosphorylated Rb R876F F877R (Fig. 5f). Taken together,
these data highlight a critical role for the KLRF docking site in the
regulation of Rb activity.

NATURE STRUCTURAL & MOLECULAR BIOLOGY

VOLUME 17

NUMBER 9

IP:Rb

IP:lgG

IP:Rb

IP:lgG

Saos-2

Stable Rb–PP1 complexes are coincident with Rb activation
The competition for access to Rb between PP1c and Cdk-cyclin suggests that Rb and PP1c are in a complex at times when Rb is activated
by dephosphorylation. To investigate the relevance of this mechanism
of cell-cycle regulation under endogenous conditions, we examined
the abundance of Rb–PP1c complexes in CV-1 cells during mitotic exit
and transfected Saos-2 cells that arrest in a PP1-dependent manner
in early G1 (Fig. 6). We used CV-1 cells because synchronization
experiments have shown that PP1 and Rb associate selectively in late
mitosis, coincident with Rb dephosphorylation and activation in these
cells18. We first compared the relative level of
the endogenous proteins in CV-1 cells with
a
b
Recombinant
the level of transfected proteins in Saos-2 cells
Mitotic CV-1 Recombinant
Saos-2
standards (pmol)
standards (pmol)
by applying recombinant standards (Fig. 6a).
0.1 0.2 0.4
0.1 0.2 0.4
We found that the molar quantities of Rb in
Rb
WB: Rb
extracts from CV-1 and Saos-2 transfected
Rb
GST-Rb379–928
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GST-Rb379–928
cells were equivalent. Considering that the
Rb quantity 0.8
0.8
(pmol)
Rb quantity
1.5
1.1
majority of Saos-2 cells are transfected in our
Myc-PP1c
(pmol)
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WB: PP1c
PP1c
experiments, the Rb expression level in the
WB: PP1c
PP1c
Saos-2 cells is no more than 2 times higher.
PP1c quantity 0.3
0.8
PP1c quantity
0.03
0.3
(pmol)
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The levels of PP1c in mitotic CV-1 cells were
Rb bound by PP1c
2%
27%
a little less than half as much as those of Rb,
Figure 6 Abundant Rb–PP1c complexes during PP1c-dependent growth arrest. (a) Saos-2 cells
whereas the total levels of endogenous and
were transfected as in Figure 5a to generate a PP1c-dependent arrest in early G1. CV-1 cells
exogenously introduced PP1c in arrested
were released form an S-phase block, and mitotic cells were isolated by a mitotic shakeoff 16 h
Saos-2 cells were approximately equivalent to
later. Extracts were analyzed by SDS-PAGE and western blotting (WB) to quantitate Rb and PP1c
those of Rb. These observations indicate that
levels. Quantities of Rb and PP1c were determined by band intensities relative to a standard curve
our transfection-based assay system closely
generated using recombinant proteins. The quantities are listed below each respective gel lane.
mimics the levels of endogenous proteins
(b) Rb was immunoprecipitated from extracts prepared as in a, and the quantities of Rb and
under conditions where Rb is activated.
associated PP1c were determined as above.
Mitotic CV-1
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Percent G1

Figure 5 PP1c inhibits Cdk inactivation of Rb independently of phosphatase activity. (a) Saos-2 cells were
80
transfected with expression plasmids corresponding to the indicated proteins. The H248K form of PP1 is
75
a catalytically inactive mutant. The percentage of cells in G1 is indicated for each. Error bars, s.d. from the
mean from at least four experiments. (b) Saos-2 cells were again transfected with Cdk2-CycA, and Rb expression
70
plasmids and cell-cycle position was analyzed by flow cytometry. The levels of expression plasmid for PP1 and the
65
H248K mutant were titrated to compare their relative effect on an Rb-dependent arrest. (c) C33A cells were
1
2
0
3
4
transfected with the expression plasmids corresponding to the indicated proteins. Rb and phosphoserine 807/811-Rb
pcDNA3.1-PP1c (g)
were detected by western blotting (WB). phosRb and Rb, relative migration positions of hyper- and hypophosphorylated Rb,
respectively. (d) C33A cells were transfected with the indicated proteins, and Rb was detected as in c. WT, wild type. (e) Saos-2 cells were transfected
with expression plasmids corresponding to the indicated proteins, and the analysis was conducted as in a. (f) Saos-2 cells were transfected with Rb, or
the indicated Rb mutant, and Cdk2-CycA expression plasmids as in b. Increasing quantities of PP1c were co-transfected to assess the sensitivity of the
Rb mutant to protection from phosphorylation and subsequent cell-cycle advancement out of the G1 phase.
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Table 1 X-ray data collection and structure model refinement
statistics
Rb870–882-PP1c
Data Collection
Space group

P41212

Cell dimensions
a, b, c (Å)

92.95, 92.95, 192.38

Resolution (Å)

83.6–3.2

(%)a

5.6 (20.6)

Rpim
I / SI

18.8 (4.6)

Completeness (%)

98.2 (97.8)

Redundancy

12.3

Refinement
Resolution (Å)

3.2

No. Reflections

13,588

Rwork / Rfree (%)

22.1 / 26.1

No. Atoms

4,798

© 2010 Nature America, Inc. All rights reserved.

Protein

4,792

Ligand/ion
Avg. B-factor

6
(Å2)

50.1

R.m.s. deviations
Bond lengths (Å)

0.004

Bond angles (°)

0.789

Values in parentheses correspond to the highest-resolution shell (3.4–3.2 Å).

= 3hkl [1/(N − 1)]1/2 3i |Ii(hkl) − I(hkl)| / 3hkl 3i Ii(hkl), where i indexes the ith measurement
of reflection hkl and N indicates the total number of times a given reflection is measured.
aR
pim

We next immunoprecipitated Rb complexes from CV-1 and transfected Saos-2 cells and immunoblotted for bound PP1c (Fig. 6b).
The amount of PP1 coprecipitated from arrested Saos-2 cells is ~30%
of the total amount of immunoprecipitated Rb, indicating that onethird of Rb molecules are bound to PP1c when cells are arrested in
a PP1-dependent manner. The amount of PP1c coprecipitated with
Rb in CV-1 cells is ~2%; however, given that the population of CV-1
cells is actively progressing through mitosis and the limitations of
synchronization by shakeoff, this measurement likely underestimates
the quantity of Rb–PP1c complex that exists in a cell at the instant of
Rb activation. Taken together, these experiments suggest that PP1 can
form stable, abundant complexes with Rb at endogenous expression
levels. These complexes attenuate the activity of Cdks by blocking
their access to Rb and regulate progression through the cell cycle.
DISCUSSION
Although much attention has been paid to the inactivation of Rb
by Cdk phosphorylation from G1 through mitosis, less is known
regarding how Rb is activated by PP1 dephosphorylation during
mitotic exit and following cellular stress. We have identified a short
sequence in RbC that binds to PP1c directly and is required for
efficient Rb-directed PP1 phosphatase activity. Our structural data
show that the molecular interactions stabilizing RbC–PP1c are
nearly identical to those observed between PP1c and its regulatory subunits. Whereas PP1c typically uses its hydrophobic binding cleft to recruit an additional subunit responsible for substrate
binding, here PP1c uses the cleft to recruit Rb substrate directly20,21.
Although uncommon, a direct interaction between PP1c and the
PP1 substrate Cdc25 has also been observed in Xenopus laevis
embryonic extracts40. Recent data indicate that PP1c dissociates from inhibitors following Cdk inactivation during mitosis 9.
The timing of this population of free PP1c is concurrent with the
requirement to dephosphorylate Rb through a direct interaction,
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and it would be interesting to explore whether other PP1 substrates
are dephosphorylated at mitotic exit without a targeting subunit.
The fact that the direct enzyme-substrate association is mediated
through the ‘RVxF’-binding cleft may explain why an Rb-targeting
regulatory subunit has not been identified and is not necessary for
Rb dephosphorylation25. Although the existence of such a subunit
cannot be ruled out, our data indicate that both Rb and a hypothetical
Rb-targeting subunit could not both occupy the RVxF-binding cleft
and that a different mode of Rb–PP1 holoenzyme assembly would be
required. However, considering that multiple phosphates in varying
sequence contexts must be hydrolyzed in Rb, it seems reasonable that
the Rb phosphatase would not use a targeting subunit to impart a high
degree of specificity. RbC closely mimics regulatory subunits in PP1
binding, and it is also tempting to speculate that Rb itself is a PP1
regulatory subunit, either sequestering nuclear PP1c from other activating subunits or regulating PP1c access to other substrates. Notably,
it has been reported that RbC can act as a noncompetitive inhibitor
of PP1c activity toward a generic substrate35.
Our data, together with previous results, indicate that PP1c and
Cdk2-CycA bind an overlapping docking site in RbC that is required
in each case for efficient enzymatic activity27,31. To our knowledge,
this observation is the first example of a PP1c-binding sequence
(RVxF or other) having an additional functional role that competes
with PP1 activity. As a result of their exclusive associations with substrate, we have shown that Cdk2-CycA and PP1c can each directly
inhibit the activity of the other enzyme toward Rb. This result reveals
a novel mechanism for the regulation of Rb phosphorylation state
in which kinase and phosphatase compete for access to substrate.
Given the conservation of the RxL binding cleft in cyclin paralogs, it
is assumed that the observed competition would exist between PP1
and all Cdk-cyclins that phosphorylate Rb. In contrast, the other Rb
family proteins p107 and p130 do not bind PP1c; this competitive
mechanism is unique to Rb.
Competition between kinase and phosphatase for controlling
the phosphorylation state of a common substrate has been established as an important mechanism in cell signaling, and a theoretical
framework has been crafted for how such competition can generate
critical signaling properties such as sensitivity, switch-like responses
and multiple steady-state outputs41–44. However, few experimental
observations of these properties have been reported. Our finding of
a Cdk-cyclin competition with PP1c for Rb as a substrate not only
provides a rare example of direct kinase-phosphatase competition but
also shows that competition can be for substrate docking as well as
catalysis. Notably, the presence of common kinase/phosphatase docking sites in mitogen-activated protein kinases has been observed 45,
suggesting that competition for substrate binding may have a more
general role in signal transduction.
In the context of Rb phosphorylation in cell-cycle control, signaling sensitivity and specificity are critical. From mitosis through G1,
the capacity of PP1c to inhibit Cdk-cyclin could facilitate efficient Rb
dephosphorylation in response to small changes in PP1c concentration and could prevent Rb from being promiscuously rephosphorylated by residual Cdk activity. The same holds true in response to
cellular stress and cell-cycle exit, and in fact, it has been shown that
Rb is dephosphorylated in response to DNA damage despite the presence of active Cdks13. These regulatory concepts that would serve to
activate Rb are supported by our cell-cycle arrest assays. Therefore,
our findings establish a biochemical mechanism through which Rb
phosphorylation and function can be tightly controlled in the cell by
directly competing kinase and phosphatase activities. Further study
is necessary to determine what mechanisms influence the outcome of
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the competition and how access of each enzyme to the docking site is
controlled. Considering the observation that the association between
Rb and PP1c is direct, the nuclear concentration of PP1c, free of inhibitors and other targeting subunits, is an intriguing possible factor.
METHODS
Methods and any associated references are available in the online
version of the paper at http://www.nature.com/nsmb/.
Accession codes. Protein Data Bank: Coordinates and structure
factors for the Rb870–882-PP1c complex have been deposited under
code 3N5U.

© 2010 Nature America, Inc. All rights reserved.

Note: Supplementary information is available on the Nature Structural  Molecular
Biology website.
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Protein expression and purification. Recombinant PP1c (A isoform) was
expressed in E. coli using a tac promoter; 2 mM MnCl2 was added to the media
upon induction. Purification was best achieved using a salt-dependent PP1cinhibitor-2 association46. Full-length, human inhibitor-2 was expressed with
an N-terminal hexahistidine tag in E. coli. Following cell lysis with 6 M urea,
inhibitor-2 was bound to nickel sepharose beads and exchanged to a buffer containing 20 mM Tris, 50 mM NaCl, 15 mM imidazole, 0.4 mM MnCl2, 0.2 mM
TCEP and 0.1 mM PMSF (pH 8.0). Cells expressing PP1c were lysed in this same
buffer, the cleared lysate was passed over the immobilized inhibitor-2 and PP1c was
eluted with lysis buffer containing 1 M NaCl. For crystallography, PP1c was further
purified with a Superdex75 column (GE Healthcare) equilibrated in 20 mM Tris,
500 mM NaCl, 2 mM DTT, 0.4 mM MnCl2 (pH 8.0). RbC, Rb55–928, E2F1-DP1
(RbC binding domains) and Cdk2-CycA protein constructs were expressed and
purified as described previously26,47,48. The Rb constructs in both the calorimetry
and kinetic experiments had N-terminal hexahistidine tags left intact. Cdk activating
kinase from Saccharomyces cervisiae (Cak) was expressed as a GST fusion protein in
E. coli and purified with glutathione sepharose affinity chromatography.
Isothermal titration calorimetry. ITC experiments were performed with a
VP-ITC instrument (MicroCal). Typically, 0.5–1 mM of each RbC construct or
synthetic RbC peptide was titrated into a 25–50 MM solution of PP1c.
Experiments were carried out at 25 °C in a buffer containing 25 mM Tris, 100 mM
NaCl and 1 mM DTT (pH 8.0). Each reported binding constant is the average
from 2 or 3 experiments, and the reported error is the s.d. of the Kd from
these measurements.
Crystallization and structure determination. Purified PP1c was concentrated
to 10 mg ml−1 after the Superdex75 column and synthetic Rb870–882 peptide
(Biopeptide Co., Inc.) was added in a 3:1 molar ratio. Crystals were grown using
the hanging-drop vapor diffusion method at room temperature (22 °C) . The crystallization buffer contained 100 mM HEPES, 200 mM MgCl2 and 18% (w/v) PEG
4000 (pH 7.5) and was mixed in a 1:1 ratio with protein solution. Crystals grew with
a needle morphology to dimensions of approximately 50 Mm × 50 Mm × 500 Mm.
Crystals were harvested by transferring to a solution containing 100 mM HEPES,
200 mM MgCl2, 20% (w/v) PEG 4000 and 20% (v/v) glycerol (pH 7.5) and flash
freezing in liquid nitrogen. A molecular replacement solution was obtained
using the PP1c–microcystin crystal structure (PDB 1FJM) as a search model34.
Further details regarding model building and refinement can be found in
Supplementary Methods.
Phosphatase and kinase assays. Purified Cdk2-CycA was first activated by phosphorylation in a reaction containing 10% (w/w) GST-Cak, 10 mM MgCl2 and
5 mM ATP. To prepare for the phosphatase assays, 1 mg of RbC was incubated
with 0.25 mg of activated Cdk2-CycA for 1 h at room temperature in a buffer
containing 50 mM HEPES, 100 mM NaCl, 10 mM MgCl2, 1 mM ATP and 5 MCi
of 32P-labeled ATP (pH 7.5). These reaction conditions give nearly quantitative
phosphorylation of Cdk consensus sites in RbC48. Reactions were quenched by
addition of 8 M urea, and phosRbC was isolated with a nickel-nitrilotriacetic
acid spin column (Qiagen). Phosphatase reactions were carried out at room
temperature in a buffer containing 50 mM HEPES, 100 mM NaCl and 2 mM
MnCl2 (pH 7.5). Reactions were initiated by addition of enzyme. Aliquots were
removed at the indicated time point and quenched by mixing with SDS-PAGE
loading buffer.
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For the phosphatase steady-state analysis, dephosphorylation assays were carried out at varying substrate concentrations. The initial rate at each concentration was determined from a linear fit of band intensities of the first 3 or 4 time
points, and the corresponding fitting errors were assigned as the error of each rate
measurement. Initial rates were fit as a function of substrate concentration with a
simple Michaelis-Menten model to calculate the effective KM and kcat.
For kinase assays, 75 nM activated (phosphorylated with CAK) Cdk2-CycA,
20 MM E2F1-DP1 and 2 MM RbC substrates were mixed in a reaction at
room temperature containing the kinase buffer described above and 20 MCi
of 32P-labeled ATP (pH 7.5). In kinase reactions with PP1c, PP1c was first
inactivated by mixing in a 1:3 molar ratio with L,R-microcystin. An additional
25 MM microcystin was present in the competition reactions to ensure no residual
PP1c activity (the IC50 for microcystin is ~1 nM). Phosphorimaging was done
with a Typhoon Trio gel scanner (Amersham) and data was analyzed with the
ImageQuant software package (Molecular Dynamics). Kinetic data were fit with
a first-order rate law using Kaleidagraph (Synergy Software). The reported error
of each kinetic parameter is the fitting error.
Cell-cycle arrest experiments. We transfected 1 × 106 proliferating Saos-2 cells
with 0.75 Mg of CMV-Rb (0.5 Mg in Fig. 5b), 1 Mg of CMV-CD20 (used to mark
transfected cells in flow cytometry analysis) and 6 Mg of CMV-bGal, using Fugene 6
(Roche). Where indicated, 1 Mg of CMV-HA-cdk2, 1 Mg of CMV-CycA and
4 Mg of CMV-myc-PP1c were added, and the appropriate amount of CMV-bGal
was omitted to maintain uniform DNA concentrations. We analyzed cells 3 d
following transfection by flow cytometry as described previously49.
C33A cells were transfected with 10 Mg of CMV-Rb, 2.5 Mg of CMV-HAcdk2, 2.5 Mg of CMV CycA and 2.5 to 10 Mg of CMV-myc-PP1c; CMV-BGal
was included where necessary to obtain a final quantity of 25 Mg. Transfections
were performed by Ca2PO4 precipitation. Cells were harvested after 2 d, and
nuclear lystates were prepared for SDS-PAGE and western blotting as described50.
Rb was detected with monoclonal antibody G3-245 (BD Pharmingen) and antiphosphoserine 807/811 antibodies from Cell Signaling.
For immunoprecipitation experiments, extracts were prepared as described
above from Saos-2 cells transfected with Fugene HD (Roche). CV-1 cells were
isolated by mitotic shakeoff from cultures that were first blocked in S phase with
2.5 mg ml−1 aphidicolin for 24 h then released for 16 h to enrich for mitotic
cells. Immunoprecipitations were carried out using monoclonal antibody Rb4.1
(Developmental Studies Hybridoma Bank, University of Iowa) against Rb.
Extracts and immunoprecipitated proteins were analyzed by SDS-PAGE alongside recombinant PP1c and GST-Rb380–928 controls. Rb and PP1 were detected
on western blots by Rb4.1 and sc-7482 (Santa Cruz), respectively. Standard
curves to determine protein quantities were generated by using ImageJ software
(US National Institutes of Health) to quantitate band intensities.
46. Zhang, Z., Zhao, S., Zirattu, S.D., Bai, G. & Lee, E.Y. Expression of recombinant
inhibitor-2 in E. coli and its utilization for the affinity chromatography of protein
phosphatase-1. Arch. Biochem. Biophys. 308, 37–41 (1994).
47. Russo, A.A. Purification and reconstitution of cyclin-dependent kinase 2 in four
states of activity. Methods Enzymol. 283, 3–12 (1997).
48. Burke, J.R., Deshong, A.J., Pelton, J.G. & Rubin, S.M. Phosphorylation-induced
conformational changes in the retinoblastoma protein inhibit E2F transactivation
domain binding. J. Biol. Chem. 285, 16286–16293 (2010).
49. van den Heuvel, S. & Harlow, E. Distinct roles for cyclin-dependent kinases in cell
cycle control. Science 262, 2050–2054 (1993).
50. Seifried, L.A. et al. pRB-E2F1 complexes are resistant to adenovirus E1A-mediated
disruption. J. Virol. 82, 4511–4520 (2008).
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Appendix B: List of plasmids

Name

Genes
Encoded

Mutations

Obtained/Constructed Res

Stock
Number

pscodonGST-p107C

GST,
p107(9701069)

N/A

M. Cecchini

AMP

609

pscodonGST-p130C

GST, p130
(10401139)

N/A

M. Cecchini

AMP

610

pscodon"LCRF
RBLP

GST,
RBLP

Y756W

M. Cecchini

AMP

611

pscodon"G-"LCRFRBLP

GST,
RBLP

S463A, E464A,
R544A, K548A,
K652A, R656A,
L660A, T664A,
R668A, K873A,
K874A, Y756W

M. Cecchini

AMP

612

pscodon"Gn-"LCRFRBLP

GST,
RBLP

R467E, K548E
Y756W

M. Cecchini

AMP

613

CMV-pRB"Sn

pRB

F839A

M. Cecchini

AMP

614

CMV-pRB"Gn-"Sn

pRB

R467E, K548E,
F839A

M. Cecchini

AMP

615

CMV-pRB"Gn-"LCRFpRB

pRB

R467E, K548E
Y756W

M. Cecchini

AMP

616

CMV-pRB"Gn-"SpRB

pRB

R467E, K548E
M851A, V852A

M. Cecchini

AMP

617

CMV-"Gn"LCRF-"S-

pRB

R467E, K548E
M851A, V852A,

M. Cecchini

AMP

618

198

199

pRB

Y756W

pflag-CMVSkp2

Flag-Skp2

N/A

L. Zhu

AMP

619

Myc-PP1

Myc-PP1

N/A

T. Pawson

AMP

620

Myc-PP1H248K

Myc-PP1

H248K

M.Cecchini

AMP

621

CMV-pRBR876FF877R

pRB

R876F, F877R

M.Cecchini

AMP

622

CMV-p27

p27

N/A

L. Zhu

AMP

623

CMV-p27
T127D

p27

T127D

L. Zhu

AMP

624

CMVE2F1-Danio

E2F1

272-282 in
human E2F1
replaces with
Danio rerio

F. Dick

AMP

625

CMVE2F1-Fugu

E2F1

272-282 in
human E2F1
replaces with
Fugu rubripes

F. Dick

AMP

626

pFAD 307
(E2F3P329V)

E2F3

P329V

F. Dick

AMP

627

pFAD 309
(E2F1Gallus)

E2F1

272-282 in
human E2F1
replaces with
Gallus gallus

F. Dick

AMP

629

pFAD 308
(E2F1V276P)

E2F1

V276P

F. Dick

AMP

628

CMVE2F1V276A

E2F1

V276A

M. Cecchini

AMP

630

CMVE2F3-

E2F3

P329A

M. Cecchini

AMP

631

199

200

P329A
CMVE2F2P280V

E2F2

P280V

M. Cecchini

AMP

632

pRB-G
Targeting
Vector

Rb1

N/A

M. Cecchini

AMP

633

pBAC
252C16

Rb1

N/A

TCAG

Chlor

552

pscodonRBLP

GST,
RBLP

N/A

Fred Dick

AMP

519

pGEX-RBC

GST, RBC

N/A

Fred Dick

AMP

242

pFAD300

E2F1

N/A

Fred Dick

AMP

539

CMV-HAE2F1

E2F1

N/A

Fred Dick

AMP

399

CMV-HAE2F2

E2F2

N/A

J. Lees

AMP

319

CMV-HAE2F3

E2F3

N/A

J. Lees

AMP

320

CMV-HAE2F4

E2F4

N/A

J. Lees

AMP

318

CMVCDK2

CDK2

N/A

s. van den Heuvel

AMP

345

CMVCDK4

CDK4

N/A

s. van den Heuvel

AMP

101

CMV-DNCDK2

DN-CDK2

N/A

s. van den Heuvel

AMP

342

CMVCyclin D

Cyclin D

N/A

P. Sicinski

AMP

96

CMVCyclin E

Cyclin E

N/A

J. Zhou

AMP

353

p73-Luc

Luciferase

N/A

C. Prives

AMP

496
200

201

pFAD102

pRB

N/A

Fred Dick

AMP

39

pFAD101

pRB

N/A

Fred Dick

AMP

37

CMV-TAg

Tag

N/A

B. Kennedy

AMP

98

CMV-!-Gal

!-gal

N/A

S. Salama

AMP

42

CMV-CD20 CD20

N/A

M. Classon

AMP

27

pE2F4BLuc

Luciferase

N/A

F. Dick

AMP

138

p107(-280)Luc

Luciferase

N/A

M. Classon

AMP

329

pBB14

GFP

N/A

KAN

348

CMV-MycCdh1

Cdh1

N/A

N. Dyson

AMP

520

pUC19-RBR467EK548E

RB

R467E, K548E

M. Cecchini

AMP

560

pscodonRBLP
R467EK548E

RBLP

R467E, K548E

M. Cecchini

AMP

561

CMV-RBR467EK548E

RB

R467E, K548E

M. Cecchini

AMP

562

pUC19-RBK530DK548E

RB

K530D, K548E

M. Cecchini

AMP

563

pscodonRBLP
K530DK548E

RBLP

K530D, K548E

M. Cecchini

AMP

564

CMV-RBK530DK548E

RB

K530D, K548E

M. Cecchini

AMP

565
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202

pscodonRBLP
R467EK530DK548E

RBLP

R467E, K530D
K548E

M. Cecchini

AMP

566

pUC19-RBR467EK548E-"S

RB

R467E, K548E,
M851A, V852A

M. Cecchini

AMP

567

pscodonRBLPR467EK548E-"S

RBLP

R467E, K548E,
M851A, V852A

M. Cecchini

AMP

568

pUC19-RBK530DK548E-"S

RB

K530D, K548E,
M851A, V852A

M. Cecchini

AMP

569

pscodonRBLPK530DK548E-"S

RBLP

K530D, K548E,
M851A, V852A

M. Cecchini

AMP

570

CMVE2F1D277C

E2F1

D277C

M. Cecchini

AMP

571

pBABE

Puro

N/A

R. Hurford

AMP,
Puro

28

pBABEp16fl

p16, puro

N/A

J. Bruce

AMP,
Puro

386

pBABE-p27

p17, puro

N/A

J. Bruce

AMP,
Puro

390

202
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Appendix C: PCR conditions
PCR Conditions Rb1-!G
Master Mix per reaction
• 0.5µL MgCl2
• 2µL 2mM dNTPs
• 2µL 10X PCR Buffer
• 1µL 20uM LoxP-N-F
• 1µL 20µM LoxP-N-R
• 13.5 µL Water
• 0.5µL Taq
•

+ 2µL DNA sample

Reaction Conditions
•

MCGENO
1. 94°C 2:00
2. 94°C 0:45
3. 60°C 0:45
4. 72°C 0:45
5. Go to Step #2, 35 times
6. 72°C 7:00
7. 4°C Forever

Interpretation of results
WT~250 b.p.
"G~ 330 b.p.
Primers
LOXP-N-F: ctgcaatctgcgcattttta
LOXP-N-R: cgatgctgcaggcctataat

203
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PCR Conditions Cdkn1b (p27)
Master Mix per reaction
• 0.5 µL MgCl2
• 2 µL dNTPs2 µL 10X PCR Buffer
• 0.5µL 20µM N1
• 2µL 20µM K3
• 2µL 20µM K5
• 8.5 µL Water
• 0.5µL Taq
•

+ 2µL DNA sample

Reaction Conditions
.

P27G
1. 94°C
2:00
2. 94°C
0:45
3. 60°C
0:45
4. 72°C
2:00
5. Go to Step #2, 35 times
6. 72°C
7:00
7. 4°C
Forever

Interpretation of results
KO~600 b.p.
WT~ 1200 b.p.
Primer
K3: TGGAACCCTGTGCCATCTCTAT
K5: GAGCAGACGCCCAAGAAGC
N1: CCTTCTATGGCCTTCTTGACG
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Appendix D: Antibody list
Antibody
Name

Protein
recognized

Species

Supplier

Application*

3F10

HA-Epitope

Rat

Roche

WB

KH20

E2F1

Mouse

Santa Cruz

WB

PG37

E2F3

Mouse

Upstate

WB, IP

9E10

Myc-Epitope

Mouse

Hybridoma

WB, IP

G3-245

pRB

Mouse

BD pharmingen

WB

12CA5

HA-Epitope

Mouse

Hybridoma

WB, IP

PAb419

T-Ag

Mouse

Santa Cruz

WB

C36

pRB

Mouse

Hybridoma

WB

sc-7164

Skp2

Rabbit

Santa Cruz

WB

sc-6298

HDAC

Goat

Santa Cruz

WB

sc- 8272

RbAp46

Goat

Santa Cruz

WB

LY11

RBP1

Mouse

Hybridoma

WB

21C9

pRB

Mouse

Sibylle
Mittnacht

ES

C-22

CDK4

Rabbit

Santa Cruz

ES

AN4.3

CDK2

Mouse

Upstate

ES

M-20

Cyclin E

Rabbit

Santa Cruz

ES

C-18

p107

Rabbit

Santa Cruz

WB, ES

C-20

p130

Rabbit

Santa Cruz

WB, ES

141.2

MCM7

Mouse

Santa Cruz

WB

pc10

PCNA

Mouse

Santa Cruz

WB

A2066

Actin

Rabbit

Sigma

WB

205
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Rb4.1

pRB

Mouse

Hybridoma

WB, IP

PP1

sc-7482

Mouse

Santa Cruz

WB, IP

9308

Phospho-Rb
(Ser807/811)

Rabbit

Cell Signaling

WB

347580

BrdU

Mouse

BD-Bioscience

IF, FC

347673

CD20

Mouse

BD-Bioscience

FC

*WB: Western Blot, IP: Immunoprecipitation, IF: Immunofluorescence,
ES: Electromobility shift, FC: Flow Cytometry
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Appendix E: Permission Biochemical Journal
Data presented in chapter 2 is published in Biochemical Journal
Cecchini, M. J., and Dick, F. A. (2011) The biochemical basis of CDK phosphorylation
independent regulation of E2F1 by the retinoblastoma protein, Biochem J 434, 297-308.
See following page for the permission from Biochemical Journal.
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Appendix F: Permission Nature Structural and Molecular
Biology
Data presented in Appendix 1 is published in Nature Structural and Molecular Biology
Hirschi, A., Cecchini, M., Steinhardt, R. C., Schamber, M. R., Dick, F. A., and Rubin, S. M.
(2010) An overlapping kinase and phosphatase docking site regulates activity of the
retinoblastoma protein, Nat Struct Mol Biol 17, 1051-1057.
See following page for the Nature publishing group’s policy on permissions for including
published material in a thesis.
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